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Abstract (670 words) 
Research related to drug polymorphism is an important aspect in drug product 
development since the properties of a formulated product, such as its stability and 
bioavailability, are often directly related to the physicochemical properties of the existing 
polymorph in the formulation. Olanzapine (OLZ) belongs to a new generation of 
benzodiazepines for the treatment of schizophrenia and other related psychoses and may exist in 
several crystalline forms, including polymorphic anhydrates, hydrates and solvates. 
Consequently, the physical treatments and technological processes undergone by the drug may 
have an impact on its solid-state, which in turn may affect its performance in terms of 
dissolution rate, absorption and therapeutic activity and response. OLZ Form I is the form used 
in marketed tablets and the most stable form at room temperature.  
The work presented in this Thesis aimed to provide an in-depth understanding of the 
conversion of olanzapine polymorphic forms into hydrated forms when exposed to different 
processing conditions. To perform this study we used several techniques, such as a combination 
of thermal analysis (differential scanning calorimetry (DSC), thermogravimetry (TGA) and hot 
stage microscopy (HSM)) with spectroscopic (infrared spectroscopy – DRIFT; FTIR), 
diffraction analysis (XRPD) and surface measurements (contact angle and surface free energy). 
Dissolution performance and impact of polymorphism on the mechanical characteristic of solid 
dosage forms was also evaluated.  
At first, a thorough investigation of the solid state stability of olanzapine forms I and II 
was performed. Aspects such as the interaction with water and the conversion of both forms into 
different dihydrates were fully explored. This allowed the successful clarification of the higher 
hygroscopic nature and easier ability of olanzapine Form II to undergo hydrate formation. On 
the other hand, Form I showed to hydrate into the lowest soluble form of olanzapine - dihydrate 
D – when subjected to high RH environments.  The interaction of Form I with humidity and 
excipients was fully investigated. Form I was found to hydrate at different rates depending on 
the excipients in which it is formulated. Polymers such as polyethylene glycol (PEG) and 
hydroxypropyl cellulose (HPC) could induce hydrate transformation at lower relative humidity 
(75%), whereas PVP could avoid hydrate conversions at 93% RH. PEG, when physically mixed 
with olanzapine, showed to accelerate hydrate conversion, especially when the materials were 
subjected to a tableting process before storage. This study showed an interesting interplay 
between the polymer’s choice, load and chemistry that could further be used to maintain the 
stability of olanzapine in solid-dosage products. 
Transformations of olanzapine during processing, namely during the rapid expansion of 
supercritical solutions (RESS) and rapid expansion of supercritical solutions into aqueous 
solutions (RESSAS) processes were also taken into consideration. These technologies enabled 
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the production of nanoparticles and nanosuspensions of olanzapine, respectively. During the 
RESSAS process the selection of the right excipients was imperative to produce stable 
nanosuspensions before and after freeze drying the products. 
Microcrystalline cellulose and polymers (PEG, PVP and HPC) were used in the process 
of extrusion and spheronisation of olanzapine. The transformations which occur during 
processing (wet environments are involved) and during dissolution of the pellets were taken into 
consideration. During the extrusion process olanzapine showed to hydrate into a mixture of 
different hydrates when extruded in the presence of microcrystalline cellulose. The addition of 
polymers such as PVP and HPC to the formulation allowed olanzapine to remain anhydrous 
during processing and dissolution, which showed to significantly influence the dissolution of the 
drug. PEG, on the other hand, could not avoid the hydrate formation of olanzapine, having this 
transformation an impact on the physical and mechanical characteristics of the pellets, as well as 
an impact on the drug performance. The impact of the polymer content and molecular weight 
into olanzapine stabilization during wetting were also taken into consideration. 
In conclusion, the research carried out contributed to a better understanding of the 
complex characterization of solid state olanzapine and formulated products prepared by 
different technologies. In detail, it showed the impact of polymorphic/pseudopolymorphic 
changes on OLZ’s technological performance and dissolution, which highlighted the importance 
of this study during preformulation and formulation studies. 
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Resumo (803 palavras) 
O estudo do polimorfismo de fármacos é uma área científica importante no 
desenvolvimento de formas farmacêuticas sólidas, uma vez que as propriedades de um produto 
formulado, tais como estabilidade e biodisponibilidade, estão muitas vezes diretamente 
relacionadas com as propriedades físico-químicas dos polimorfos existentes na formulação. A 
olanzapina (OLZ) pertence a uma nova geração de benzodiazepínicos para o tratamento da 
esquizofrenia e outras psicoses relacionadas. Este fármaco pode existir em várias formas 
cristalinas, incluindo formas anidras, hidratadas e solvatadas. Por conseguinte, os tratamentos 
físicos e processos tecnológicos sofridos pelo fármaco podem ter um impacto na estabilidade da 
forma polimórfica escolhida para o produto final. Consequentemente, estes processamentos 
podem afetar o seu desempenho em termos de taxa de dissolução, absorção e, finalmente, 
atividade terapêutica. A olanzapina Forma I é a forma usada nos comprimidos existentes no 
mercado e é a forma polimórfica mais estável à temperatura ambiente. 
O trabalho apresentado nesta tese teve como objetivo obter uma compreensão 
aprofundada da conversão de formas polimórficas de olanzapina em formas hidratadas quando 
expostas a diferentes condições de processamento. Para tal, neste trabalho foram utilizadas 
diversas técnicas, tais como uma combinação de análise térmica (DSC, TGA, HSM) com 
espectroscópica (DRIFT; FTIR), análise de difração (XRPD) e energia de superfície (medições 
de ângulo de contacto e energia livre de superfície). Foi também avaliada a dissolução e o 
impacto do polimorfismo nas características mecânicas das formas farmacêuticas sólidas. 
Primeiramente foi realizada uma investigação completa sobre a estabilidade das formas 
cristalinas anidras I e II. Aspetos como o estudo da estabilidade das formas quando em presença 
de diferentes humidades relativas e caracterização dos hidratos formados foram explorados. Este 
estudo permitiu concluir que a Forma cristalina II é mais higroscópica, hidratando mais 
rapidamente e a menores humidades relativas do que a Forma I. A forma I, por outro lado, 
mostrou hidratar numa forma hidratada – dihidrato D – que apresenta uma velocidade de 
dissolução inferior às outras formas hidratadas da olanzapina, alertando para a necessidade de 
um armazenamento apropriado para este fármaco. Visto que os excipientes podem alterar as 
cinéticas de hidratação, estes podem fazer com que esta forma hidratada da olanzapina apareça a 
humidades mais reduzidas e com maior velocidade. Assim sendo, foram investigadas a 
interação da forma I com humidade e excipientes. Estando descrito que os excipientes 
poliméricos poderão ter maior impacto no processo de hidratação, 3 polímeros foram escolhidos 
para o estudo. A Forma I mostrou hidratar a velocidades diferentes, dependendo dos excipientes 
em que foi formulada. Polímeros, tais como PEG e HPC, mostraram induzir a transformação no 
hidrato D a uma humidade relativa baixa (75% RH), enquanto a PVP mostrou evitar quaisquer 
conversões, mesmo a humidades relativas de 93%. O PEG quando misturado fisicamente com 
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olanzapina, mostrou acelerar a conversão em hidrato, especialmente se estas misturas físicas 
tenham sido pressionadas (submetidas a um processo compactação) antes do armazenamento. 
Este estudo mostrou que deve ser feito um balanço quando é feita a escolha dos polímeros a 
serem usados no processo de formulação, nomeadamente tendo em conta a quantidade usada e a 
sua estrutura química, de forma a manter a estabilidade da olanzapina em formas farmacêuticas 
sólidas. 
As transformações da olanzapina durante o processo RESS / RESSAS foram igualmente 
estudadas. Estas tecnologias permitiram produzir nanopartículas e nanossuspensões de 
olanzapina, respetivamente. Durante o processo de RESSAS a seleção dos excipientes 
estabilizadores das suspensões formadas mostrou ser imperativa para produzir nanossuspensões 
estáveis antes e após o processo de secagem por congelação. 
A celulose microcristalina, bem como os diferentes polímeros utilizados neste trabalho 
(PVP, PEG, HPC) foram usados no processo de extrusão e esferonização da olanzapina. Foram 
estudadas as transformações que ocorreram durante o processamento (ambientes húmidos estão 
envolvidos) e durante a dissolução dos esferóides. Durante a extrusão a olanzapina mostrou 
hidratar numa mistura de diferentes hidratos apenas quando em presença da celulose 
microcristalina. A adição de polímeros à formulação, tais como o PVP e a HPC, permitiram a 
manutenção da olanzapina na sua forma anidra I tanto durante o processamento como durante a 
dissolução, o que mostrou influenciar de forma significativa a dissolução da mesma. O PEG, 
por outro lado, mostrou ser incapaz de estabilizar a olanzapina. Os hidratos formados durante o 
processo de extrusão mostraram afetar as características físicas e mecânicas dos pellets, bem 
como a dissolução do fármaco. Os diferentes polímeros usados, os seus pesos moleculares e as 
suas proporções nas formulações revelaram ter impacto na estabilização da olanzapina durante o 
processo de extrusão, nomeadamente durante a fase de malaxagem. 
Em conclusão, a investigação feita no âmbito desta Tese contribuiu para uma melhor 
compreensão da caracterização das alterações polimórficas e pseudopolimórficas da olanzapina 
durante o seu processamento e armazenamento. Permitiu ainda perceber em pormenor o 
impacto das alterações polimórficas e pseudopolimórficas na performance tecnológica e na 
dissolução da olanzapina, alertando para a importância do seu estudo nas fases de pré-
formulação e formulação. 
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Motivation and Objectives 
The studies on pre-formulation of drugs are part of the official requirements for the 
investigation and development of new drugs and new drug applications, since these studies 
assess the physicochemical properties and the biopharmaceutical performance of the APIs. 
Pharmaceutical companies have been paying special attention to research on phase 
transformations of the APIs because such transformations could lead to complications on the 
bioavailability, manufacturability and stability of the formulated product. Therefore, the study 
of polymorphic and pseudopolymorphic transformations of the drugs, alone or in the presence 
of excipients during processing and storage, has to be undertaken since an incomplete 
characterization of a drug substance can lead to problems on the manufacturability and 
bioavailability of the final product. 
 
The aim of this research was the production and characterization of different olanzapine 
crystal forms (polymorphs and pseudopolymorphs), assessing the stability of each crystal form 
during storage and processing, always with the clear objective of understanding the impact of 
processing on the technological properties, particularly on the dissolution rate of the drug. 
 
This goal was reached by: 
 Controlled production and characterization of defined polymorphic forms; 
 Understanding the polymorphic transitions to allow the anticipation of stability of 
each polymorph as a raw material or as a component of an extrudate; 
 Understanding the potential interactions between the API and the excipients, 
namely the stabilization effect that the excipient might have on the polymorph; 
 The identification of environmental conditions that affect the stability of 
polymorphs (e.g. humidity, in the air or in the excipients while being processed, 
and temperature, both room and processing temperatures on drying); 
 Study of the impact of particle size reduction techniques, namely SCF technology, 
on the technological properties and dissolution of olanzapine; 
 The identification of polymorphic forms at each moment of the manufacturing of 
extrudates and tablets, as well as the identification of the advantages / 
disadvantages on using a particular polymorph of the API on the preparation of an 
extrudate or tablet 
  
xxvi 
Thesis overview  
This thesis is divided into 8 chapters. Since olanzapine has a high capacity to interact 
with water molecules and form hydrates, firstly it was aimed to understand the role of water on 
the stability of olanzapine. Then we decided to mix olanzapine with certain excipients which are 
known to affect the water absorption capability of drugs when physically mixed or processed 
with them. Two pharmaceutical processes involving the utilization of water were studied, 
namely, rapid expansion of supercritical solutions into aqueous solutions and wet extrusion. 
Hence, the organization and objectives of each chapter can be briefly summarized, as follows: 
 
Chapter 1 – Describes the state of the art and provides the main concepts necessary to 
understand and discuss the work presented in the subsequent chapters;  
Chapter 2 – Summarizes the materials used, namely the API and excipients, throughout the 
thesis. The different technologies considered for producing and characterizing the different 
polymorphs of olanzapine and dosage forms are referred in this chapter, together with a short 
description of the characteristics of the equipments used. 
Chapter 3 – Provides a thorough investigation of the different olanzapine forms (anhydrates 
and hydrates) considered in the thesis. Differentiation on the physical stability of 2 anhydrous 
forms and their ability to form hydrates, as function of different relative humidity, is studied. 
Research question: Can anhydrous olanzapine hydrate in the presence of high humidity 
environments? What is the impact of the hydrate conversions on the dissolution performance of 
this drug?  
Chapter 4 – Explores the relative humidity conditions that could lead to the hydrate formation 
of olanzapine Form I (the most stable form) when physically mixed with different excipients (as 
powders or compacts) that present different crystallinities and moisture uptake abilities. 
Research question: May excipients have a role on hydrate conversion kinetics of olanzapine 
over storage? What is the impact of compaction of olanzapine and excipients on the 
pseudopolymorphic transformations of olanzapine? 
Chapter 5 – Gives an insight into the role of polymers on stabilization of olanzapine Form I 
(the most stable form) in aqueous environments.  
Research question:  How polymers may stabilize anhydrous olanzapine in aqueous suspensions?  
Chapter 6 – Provides an evaluation of the effect of particle size reduction of olanzapine by 
supercritical fluid (SCF) technology on the solid-state form of olanzapine.  
Research question: Can SCF technology reduce the particle size of olanzapine without affecting 
its crystal structure? Can SCF technology produce olanzapine particles with a submicron size 
and increased dissolution rate? What is the impact of excipients in the stabilization of submicron 
particles of OLZ? 
xxvii 
Chapter 7 – Identifies the impact of the extrusion/spheronisation process on the polymorphic 
transformation of olanzapine, with a special focus on the impact of those transformations on the 
mechanical properties of the final product (pellets).  
Research question: Can the process of extrusion lead to hydrate changes of olanzapine solid-
state form, with an impact on physical and mechanical properties of the extrudates? 
Chapter 8 – Explores how excipients used in extrusion/ spheronisation of wet masses of 
olanzapine can avoid pseudopolymorphic changes of olanzapine, with an impact on dissolution. 
Research question: May excipients have a role on the stabilization of olanzapine during wet 
extrusion? What is the impact of hydrate conversion on the final dissolution of olanzapine from 
the pellets? 
Chapter 9 – Presents the main conclusions and suggests future work. 
 
 
 
Hypothesis  
Polymorphic/pseudopolymorphic changes of olanzapine which occur during storage and 
processing with impact on drug’s performance can be identified, characterized and prevented. 
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Chapter 1 -  Introduction 
1.1 Introduction to solid-state properties of materials used in pharmacy 
The majority of drug entities are encountered in the solid state (1). A full 
characterization of the solid characteristics of an active pharmaceutical ingredient (API) is 
recognized as an essential part of pre-formulation research, in order for the quality of the 
manufacturing process, the drug’s performance and its bioavailability are maintained in its final 
dosage form (2). A solid state API can be classified based upon the order of its molecular 
packing into 2 major groups: the crystalline and the amorphous states. 
1.1.1 Amorphous State 
An amorphous structure has a short-range molecular order (3). The increased free 
volume, molecular mobility and the enthalpy of the amorphous state results in a structure with 
higher solubility, chemical reactivity and water vapor sorption when compared to the crystalline 
state (4). The higher solubility of an amorphous API, for example, is an advantage when rapid 
dissolution and absorption rates are required to obtain an increase of the bioavailability of the 
drug (5). However, the amorphous state is in a non-equilibrium state, thus an amorphous API 
may crystallize during storage or during a manufacturing process (6). The most used methods 
for large-scale production of amorphous materials at the moment are freeze-drying, spray-
drying and melt extrusion, being freeze-drying the most popular method, resulting from the easy 
control of operation parameters throughout the production of amorphous materials. Usually, 
excipients are added to the formulations to improve the stability of amorphous drug 
formulations (7). 
1.1.2 Crystalline state 
A crystalline state requires an ideal crystal, which is composed of atoms, ions or 
molecules arranged in a periodic 3-dimensionl pattern. The 3-dimensional array is called a 
lattice. The smallest periodic volume is defined as a unit cell (Figure 1.1). The unit cell has an 
orientation and shape defined by the translational vectors, a, b, and c and therefore has a definite 
volume, V, that contains the atoms and molecules necessary to form the crystal (8). 
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Figure 1.1 – Crystal unit cell and its dimensions. 
There are seven possible crystal systems (cubic, tetragonal, orthorhombic, 
rhombohedral, hexagonal, monoclinic, triclinic) which are described by the relationships 
between the axis lengths, a, b, and c, of the unit cell and between the angles, , , and γ of the 
unit cell (8, 9). For instance, if the three edge lengths are identical and all corner angles are 90º, 
then the crystal belongs to the cubic system. 
In any kind of repeating pattern, it is useful to have a convenient way of specifying the 
orientation elements relative to the unit cell. This is carried out by assigning to each element a 
set of integer numbers, known as Miller index. Miller indices are a notation for describing 
directions and labelling planes in lattices and crystals. The basis for determining the index is the 
unit cell (the smallest three-dimensional volume element from which the crystal can be 
constructed). Each face is designated with three integers, h, k and l,  which are the inverse of 
intersections of that face with the crystallographic axes a, b and c. Faces that are parallel to a 
crystal axis are given the Miller index of 0.  
The external shape of a crystal, also termed habit, form or morphology, is determined 
by its internal structural symmetry. In practice, crystal morphology is usually described in terms 
of length, width and thickness. Six basic crystal shapes have been reported and crystals having 
these shapes can occur in any of the seven systems (10). In the pharmaceutical area the 
classifications of crystal shapes adopted by either British Standard (BS 2955:1993) or the US 
Pharmacopoeia (monograph 776, Table 1.1) (11) are often used for routine microscopic studies 
of solid materials (12-14). 
The faces that can potentially develop into a crystal are determined by the symmetry 
properties of the underlying lattice, but the sizes of the faces that actually develop under specific 
conditions – and thus the overall shape of the crystal – are determined by the relative growth 
rate of the various faces. The slower the growth rate the larger the face.  
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Powders that have been milled may not present any evidence of the original shapes of 
the crystal, and the particles are likely to be irregularly shaped and have angular fragments (10).  
Table 1.1 – Classification of common crystal morphologies for pharmaceutical solids accepted by 
the US Pharmacopoeia. 
 
 
1.2 Polymorphism 
A crystalline substance has polymorphism (from Greek: poly-multiple, morfe-shape) 
when it can crystallize in different crystal packing arrangements and/or different conformations 
(15). Polymorphism in molecular crystals can be divided into two categories: conformational 
and packing polymorphism. In conformational polymorphism, the molecules are flexible and 
can adopt more than one conformation in the solid state (16).  Since pharmaceutical compounds 
generally contain flexible moieties in their molecular structures, there are numerous examples of 
conformational polymorphs. Two well-known examples of drugs that exhibit this type of 
conformational polymorphism are the antidepressant venlafaxine hydrochloride (17) and the 
antipsychotic olanzapine (18). Packing polymorphism emerge from different possible packing 
arrangements in the three dimensional space of conformational rigid molecules. Forms I and II 
of acetaminophen are the best known example of packing polymorphs (19, 20).  
Polymorphs have different relative intermolecular and/or inter atomic distances, or unit 
cells, resulting in different physical and chemical properties, as shown in Table 1.2 (21). 
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Table 1.2 – Properties that can be altered by choosing different polymorphic forms (21) 
Thermodynamic properties Kinetic properties 
- Melting and sublimation temperatures 
- Enthalpy, entropy and heat capacity 
- Free energy 
- Solubility 
- Dissolution rate 
- Rates of solid state reaction 
- Physical/chemical stability 
- Rate of nucleation/ crystal growth 
Packing Properties Surface properties 
- Molar volume and density 
- Refractive index 
- Particle morphology 
- Hygroscopicity 
- Color 
- Surface free energy 
- Interfacial tensions 
- Habit 
                                          Mechanical properties 
- Hardness 
- Compactibility and tableting 
- Cleavage 
- Tensile strength 
- Handling, flow  
- Blending 
 
The different properties of a polymorph can have an impact in the drug’s 
pharmaceutical properties such as bioavailability, processability and manufacturability. Some of 
the most important properties during drug discovery and development are solubility in water, 
dissolution and bioavailability. For a drug whose absorption into the body is only limited by its 
dissolution, differences in the apparent solubility of the various polymorphic forms are likely to 
affect the bioavailability of the drug (22). It is the goal of pre-formulation scientists to 
understand and characterize polymorphs of a pharmaceutical solid and select a form with the 
best combination of desired properties to proceed to the formulation stage (23). Furthermore, 
regulatory agencies declare that the understanding and controlling of the physical forms of a 
polymorphic drug substance have to be controlled, especially if drug bioavailability is affected 
by its polymorphism (24) (25). 
1.2.1 Polymorphic systems 
The term “polymorphic transition” refers to the interconversion between polymorphic 
forms. The stability relationship between a pair of polymorphs can be categorized as 
Monotropic or Enantiotropic, depending on their stability with respect to a range of 
temperatures and pressures. When one polymorph is stable at all temperatures and pressures 
below the melting point and all other polymorphs are unstable, the polymorphic system is 
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referred as Monotropic. If one of the polymorphs is stable (i.e., has lower free energy and 
solubility) over a certain temperature range and pressure while the other polymorph is stable 
over a different temperature range and pressure, then the two polymorphs are said to be 
Enantiotropes (Figure 1.2) (6, 26). Therefore, understanding thermodynamic and 
interconversion relationships between polymorphs is paramount to solid state characterization.  
 
 
Figure 1.2 – Free energy phase diagrams for Enantiotropic System (a) and Monotropic System (b) (6). 
The question that still needs to be addressed is why and how polymorphs do form. Like 
most chemical processes, crystallization in polymorphic systems is governed by a combination 
of thermodynamic and kinetic factors.   
1.2.2 Thermodynamics 
Systems tend to move toward a thermodynamically equilibrated state, i.e., in the 
polymorphic systems the metastable forms are eventually going to transform into the most 
stable state. Thermodynamics provides information about the relative thermodynamic stability 
between different polymorphic forms and the conditions and the direction in which a 
transformation can occur.  The main approaches used to assess thermodynamic stability 
relationships of polymorphs are based on thermodynamic rules (distinguishes between 
monotropic and enantiotropic systems) (26) and free energy change–temperature diagrams (also 
allows for calculation of the transition temperature) (27, 28).  
The relative thermodynamic stability of solids and the driving force for a transformation 
at constant temperature and pressure depends on the difference in Gibbs free energy (ΔG) 
between the different forms. When the difference is negative, the transformation may occur 
spontaneously and a change has the potential to continue to occur as long as the free energy of 
the system decreases, unless blocked by a kinetic barrier. If ΔG is equal to zero the system is at 
equilibrium with respect to the transformation and the Gibbs energy of the two phases is the 
same. In systems where the difference in Gibbs energy is positive then the transformation is not 
possible under the specific conditions 
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The thermodynamic conditions to either have equilibrium between phases or different 
transformations at constant pressure for a single component system that exists in both 
amorphous and crystalline states are shown in the Gibbs free energy plot (Figure 1.3). This 
diagram shows that polymorph C is more stable than A, since ΔG=GC−GA is lower than 0, thus 
allowing for a transformation from polymorph A to C. Amorphous or disordered solids of the 
same compound have a higher free energy than the crystalline states because of the higher 
enthalpy and entropy of the glass (28) . 
In the G versus T diagram, the intersection points show phases that coexist in 
equilibrium, crystal and liquid states corresponding to melting temperatures, crystalline states at 
transition temperatures, and both amorphous and supercooled liquid states at glass transition 
temperatures.  
 
 
Figure 1.3 – Gibbs free energy curves for a component system that presents crystalline and 
amorphous phase transitions. Monotropic systems (A and C), enantiotropic systems (A and B) with 
a transition temperature (Tt), and an amorphous and supercooled liquid with a glass transition 
temperature (Tg). Melting points (Tm), for the crystalline phases are represented by the intersection 
of the curves for the crystalline and liquid states (28). 
 
1.2.3 Kinetics 
Thermodynamic theory, as referred before, refers that crystallization must result in an 
overall decrease in the free energy of the system. This means that, in general, the crystal 
structures that appear will be those with the larger (negative) lattice (free) energies. However, 
the routes to the final stable state are dependent on the kinetics as well as other factors as shown 
below (29). 
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Figure 1.4 – Schematic representation of the reaction coordinate ρ for crystallization in a 
dimorphic system to show the activated barriers for the formation of polymorphs I and II. 
The traditional energy-reaction diagram (Figure 1.4) shows the kinetic factors involved 
in the nucleation process. This diagram represents G0 (the free energy per mole of a solute) in a 
supersaturated fluid which transforms by crystallization into one of two crystalline products, I or 
II, in which II is the more stable (GI>GII).  
A transition from the initial state G0 to state I or II will depend on the energy barrier 
and according to the reaction pathway in Figure 1.4, the height of the energy barrier for 
structure II (G*II – G0) is higher than that for B (G* I- G0). Since the rate of nucleation is 
related to the height of the energy barrier on the reaction path, I will nucleate at a faster rate than 
II (29).  
In general one can say that the probability of appearance of a particular Form I is given 
by equation ( Eq. 1.1) in which ∆G is the free energy for forming the polymorph i and R is 
the rate of the kinetic process associated with the formation of a crystal by molecular 
aggregation. Following the above argument one could equate the rate process with the rate of 
nucleation (J) of Form I. If all polymorphs have the same rates of nucleation, then their 
appearance probability would be restrained to the relative free energies of the possible crystal 
structures. 
 𝑷 (𝒊) = 𝒇(∆𝐆, 𝐑) Eq. 1.1 
According to the classical expression of Volmer (30), the rates of nucleation are related 
to various thermodynamic and physical properties of the system, such as, the bulk and surface 
free energies (γ), temperature (T), degree of supersaturation (σ) or solubility (hidden in the pre-
exponential factor A) which will not be the same for each structure but will correctly reflect the 
balance between changes in bulk and surface free energies during nucleation. This effect is 
shown in Equation 1.3 (2), which relates the rate of nucleation to the above parameters (ν is the 
molecular volume). 
Chapter 1 
9 
 𝑱 = 𝑨𝒏 𝒆𝒙𝒑 [−
𝟏𝟔𝝅𝜸𝟑𝒗𝟐
𝟑𝒌𝟑𝑻𝟑𝝈𝟐
] Eq 1.2 
Therefore, the tradeoff between kinetics and thermodynamics is not absolutely obvious. 
Figure 1.5 shows a schematic solubility diagram for a monotropic dimorphic system. It is noted 
that, for the occurrence given by solution compositions and temperatures that lie between the 
Form I and II solubility curves, only polymorph II can crystallize. Nevertheless, the outcome of 
an isothermal crystallization that follows the crystallization pathway indicated by the blue 
vector in Figure 1.5 is not so clear. In this case, the initial solution is now supersaturated with 
respect to both polymorphic structures, with thermodynamics favoring Form II (29). 
 
Figure 1.5 – Schematic solubility diagram for a dimorphic system (polymorphs I and II) showing a 
hypothetical crystallization pathway at constant temperature. 
In the 19
th
 century, authors working in the area of science of crystallization, observed 
that compounds could be obtained in more than one solid state form and a vast number of cases 
were documented about the fact that a metastable form of a compound tended to first crystallize 
prior to transformation into a more stable form. These observations led Ostwald in 1897 to 
propose the Law of Stages, where he stated that crystallization from melts and solutions yields 
an initial metastable form which is ultimately replaced by a stable form. This means that when a 
given compound leaves its initial metastable state it does not seek out the most stable state, but 
transforms instead into the nearest metastable one, that is, the one that can be reached without 
loss of free energy (28).  
Later, Stranski and Totomanov (31) provided an explanation for this phenomenon 
developed in terms of the kinetics of transformation. In this model, the determining factors are 
the relative rates of nucleation and crystal growth for the stable and metastable forms. The 
differences between the various parameters may be theoretically justified by the fact that, at a 
specific working temperature, the rate of nucleation is higher for the metastable product. This 
situation would cause the metastable phase to preferentially nucleate. In a distinct scenario, the 
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rates of nucleation may be more or less the same for the two forms, but if the metastable phase 
has a higher rate of growth, then this form would eventually predominate in the isolated product 
(32). Figure 1.6 shows the rates of nucleation as functions of supersaturation for a dimorphic 
system. As it can be seen in Figure 1.6, the rate of nucleation of the metastable Form I is never 
higher over the entire supersaturation ranges. This indicates that there may be conditions in 
which the nucleation rates of the two forms are similar hence their appearance probabilities are 
nearly equal. Under such conditions we might expect the polymorphs to crystallize 
concomitantly (29).  
 
 
Figure 1.6 – The rates of nucleation as functions of supersaturation for a dimorphic system.  
Note that both solutions A and C allow for simultaneous nucleation of the forms at supersaturation 
levels corresponding to the crossover of the curves (29). 
1.3 A comprehensive understanding of crystallization 
Crystallization is defined as a phase change that leads to the formation of a crystalline 
solid (33). The most frequent type of crystallization is crystallization from solution, in which a 
material that is a crystalline solid at a temperature of interest is dissolved in a solvent while 
crystallization is induced by changing the state of the system in some way that reduces the 
solubility of the solute in the solvent. Commonly, this kinetic process is described in terms of 
two distinct steps: nucleation and crystal growth. The properties of the crystals obtained are the 
result of the kinetic relationship between these two processes. This sub-section aims on the 
introduction of the basic concepts of nucleation and crystal growth from solution and impact of 
these phenomena on the properties of pharmaceutical materials, including the parameters that 
can influence crystallization.  
1.3.1 Driving force for crystallization 
Crystallization can occur over the concentration range limited by the equilibrium 
composition of the system at specified conditions (Figure 1.7). Thermodynamic equilibrium is 
achieved when the solution is saturated with respect to the solute, that is, the concentration of 
the solution represents the solubility value for that solid phase. Under these conditions the rates 
of dissolution and crystallization are equal. When the solute concentration is below the 
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saturation limit (solid line) a solution is termed under-saturated and the existing crystals will 
dissolve. The system must be carried into a non-equilibrium state where the concentration of the 
solute exceeds its equilibrium concentration (i.e., the solution is supersaturated) for the 
crystallization to occur. The driving force for crystallization is going to be the degree of 
supersaturation, which is defined as the difference between solution concentration and 
saturation concentration at a specific temperature. Commonly, the methods which are used to 
create supersaturation in a solution are: temperature change, solvent evaporation, chemical 
reaction, pH change, and changes in solvent composition (34). 
Supersaturation leads to the creation of metastable (far from equilibrium) liquid state 
and crystallization provides a means to reduce the free energy of the system to the most stable 
state (equilibrium) (35). The metastable limit determines the compositions at which spontaneous 
crystallization occurs. The region between the saturation limit and the metastable limit is named 
metastable zone. The metastable zone width varies depending on the purity of the system, the 
thermal history of solution and the density of foreign particles present in the solution. It is, 
therefore, important to know the metastable zone since it defines the working area for designed 
crystallizations (34). In order to produce just the required product, the concentration and 
temperature of the crystallization medium must be narrowly controlled within this zone. If the 
solubility line is crossed to the left, the seed crystals will dissolve and if the metastable zone 
limit is crossed to the right, spontaneous nucleation will take place and could result in unwanted 
crystal forms (34, 36).  The kinetics of nucleation and crystal growth are strongly dependent on 
supersaturation (37, 38).  
The metastable zone specifies the default region for operating an industrial 
crystallization process to avoid uncontrolled sizes (36). The solution has to achieve a certain 
concentration-temperature point where spontaneous nucleation occurs – this is the limit of the 
metastable zone.  
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Figure 1.7 – Schematic solubility/ supersolubility diagram. The metastable zone specifies the default 
region for operating an industrial crystallization process. The operating region of batch 
crystallization is bound by the solubility curve and the metastable limit. The concentration 
temperature profile (control trajectory, dashed line) lies within this region (36). 
1.3.2 Nucleation 
The step between the generation of supersaturation and initiation of nucleation is called 
the induction period. The length of this period depends on temperature, pressure, presence of 
impurities or seeds, and mechanical disturbances. The presence of seeds and increased 
supersaturation decrease the length of the induction period (39). 
Crystal nucleation encompasses the aggregation of dissolved molecules in the 
supersaturated solution into organized clusters (embryos) thus developing a surface that detach 
them from the environment. Nucleation can be either homogeneous or surface catalysed (Figure 
1.8). Homogeneous nucleation which occurs spontaneously in bulk solutions seldom occurs in 
volumes larger than 100 μl, as most solutions contain random impurities that may induce 
nucleation, so it is the usual mechanism in small scales (40, 41). Surface catalysed nucleation 
can be promoted by surfaces of the crystallizing solute (secondary nucleation) or by 
surface/interface of different composition than the solute may induce nucleation (heterogeneous 
nucleation) by decreasing the energy barrier for the formation of nuclei (35).  
Surfaces that promote heterogeneous nucleation may be introduced into the 
crystallization solution intentionally (with the goal of controlling crystal form of the product) 
(28) or unintentionally (dust and other impurities), or they can be an inevitable part of the 
process (crystallization vessel, vessel-solution interface and the solution-air interface). 
Heterogeneous nucleation is of practical importance in drug formulations, as excipients may 
provide the surfaces or interfaces necessary to promote nucleation. Moreover, heterogeneous 
nucleation happens at low driving forces and the favourable dissolution properties of the 
metastable drug may be lost due to the fast nucleation of the stable form (42). 
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Figure 1.8 – Mechanisms for crystal nucleation. 
The intentional addition of surfaces that catalyse nucleation, into crystallization 
solutions, is known as “seeding”. Commonly, seeding is carried out by introducing crystals of 
the solute that have the desired crystal structure that is preferred to obtain in the final product 
(43). Seeding techniques can be performed with different goals, namely, to initiate 
crystallization, to control particle size (normally when larger crystals with uniform size 
distribution are required), to control a polymorphic form, to obtain crystals of high purity and 
perfection, desired orientation and with a sufficient size for crystal structure determination by 
X-ray diffraction (34).  
1.3.3 Crystal Growth 
When a nucleus overcomes a certain critical cluster size it becames stable enough to 
grow into macroscopic crystals. The process of crystal growth is a multi-step process which 
includes, (i) transport of the growth units to the impingement site, which may not be the final 
growth site, (ii) adsorption of the growth units at the impingement site, (iii) diffusion of the 
growth units from the impingement site to the growth site, and (iv) incorporation into the space 
lattice to form the crystal structure. The mechanism of crystal growth can be volume-diffusion 
controlled or surface-integration controlled. In particular, the surface-integration can occur as 
continuous or by layers crystal growth. The three dimensional structure and crystal defects can 
also influence the growth rates and thus determine the interaction between surface and solution 
at a molecular level (44). 
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1.3.4 Factors that influence nucleation and crystal growth 
Previous studies have established that several factors such as solvent, temperature, 
concentration, pH, agitation and surfaces area and type in contact with growth solutions may 
influence nucleation and growth of crystals (44, 45). 
Solvents 
Solvents have a strong influence on the habit of crystalline material because they can 
preferential adsorb onto the different surfaces or facets of crystals as they develop, in this way 
hindering the deposition of solute molecules differentially on the different surfaces. Solvents 
may change the interfacial tension, an increase in the interfacial tension leads to a decrease on 
the growth rate. During the removal of solvent molecules, the face where the solvent molecules 
are more adsorbed will grow slower than the faces where the solvent molecules are less strongly 
adsorbed (46).  
Temperature 
Temperature can control nucleation and crystal growth by manipulating the solubility 
and supersaturation of the material (47).  When a certain compound is more soluble at high 
temperature, slow cooling is a commonly used approach for crystallization of saturated 
solutions.  On the other hand, slow warming can be applied if the compound is less soluble at 
higher temperatures. The approach of slow cooling or warming allows the thermodynamically 
most stable polymorph to form under conditions where the selectivity is the highest for 
nucleation and growth of that most stable form. By opposition, rapid cooling frequently 
generates nucleation and growth of several different polymorphs, particularly when the 
solubilities of the different polymorphs are similar (48, 49). 
Concentration 
The period needed for crystals to nucleate and begin growth depends on the 
concentration and the rate at which solvent evaporates. To achieve the supersaturation point for 
a given solution to initiate crystallization, it is required a reduction of the solvent amount (e.g., 
evaporation of solvent) or a reduction on the solubility of the solute. Thus, evaporation of 
solvent is one of the more commonly used methods for crystallizing compounds. Ostwald 
showed that unstable polymorphic forms have a greater solubility than the more stable forms in 
a particular solvent (50). Thus, crystallization by slow evaporation results often in formation of 
the most stable polymorph.  
pH 
pH can affect crystallization and the appearance of polymorphs, mainly for protein 
crystallization. In aqueous solution, a protein with hydrophilic groups on its surface is covered 
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with surface-bond water molecules. Consequently the addition of ions to solution results in the 
elimination of some water molecules on the surface of the protein. Therefore, the protein is free 
to bind to other protein molecules. Aggregation of proteins and subsequent nucleation and 
growth of crystals often can be therefore promoted simply by changing the pH of the solution 
(51). 
Agitation, mixing and stirring 
In industry, mixing of crystallization solutions and crystal slurries is often necessary, to 
ensure homogeneity (heat transfer, dispersion of additives, uniformity of crystal suspension, 
avoidance of settling, etc.). Its impact on nucleation (primary and secondary) and crystal growth 
is quite complex. A non-stirred solution can, generally, be cooled before the onset of nucleation, 
once the main goal of mixing is a decrease in the width of the metastable zone. In a stirred 
solution at constant supersaturation, with no crystals yet present, mixing intensity can reduce 
induction time – the time elapsed before crystals first appear. Induction time decreases up to a 
critical speed and then remains unchanged (52, 53). Mixing actively may origin secondary 
nuclei through crystal-crystal, crystal-vessel and crystal-impeller impacts. A larger number of 
nuclei created in stirred systems leads to a decrease in the final crystal size of the product.  
Addition of impurities and additives 
Crystallization may be affected by impurities (unintentionally present components) and 
additives (intentionally added substance). Examples of additives employed for controlling 
polymorphic outcome of pharmaceuticals include structurally related (tailor-made) organic 
molecules (54), polymers (55) and surface-active agents (56). Polymers and surfactants can also 
act as crystallization or phase transformation inhibitors in pharmaceutical formulations (57-60). 
In the case of the polymers, these substances may get adsorbed in the crystal lattice of a growing 
crystal and disturb the regular and repeating arrangements of the crystal, creating defects and 
leading to polymorphic modifications. They can also inhibit crystal growth at certain crystal 
faces, resulting in crystal habit changes (61). 
Polymeric crystallization inhibitors 
Polymers are molecules that when fully solubilized in a given solvent, exist as 
random/extended coils. This extended coil conformation exists as a result of the relative 
rotational freedom of the polymer backbone and due to the numerous conformations that the 
polymeric material can adopt when it does not establish significant intramolecular interactions. 
When the polymer is in a presence of a poor solvent, the conformation is more contracted in 
order to minimize the contact with the solvent (39). The impact that the polymers may have on 
the enhancement of the solubility of drugs, should be considered when we are examining the 
mechanism of crystallization inhibition. For instance, the increase on the induction times for 
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crystallization in the presence of the polymer is often used to provide an indication of the most 
effective crystallization inhibitor. Therefore, when the polymer addition results in the increase 
of the drug solubility, the degree of supersaturation (a prerequisite for precipitation) may be 
reduced and possibly reduced below the level of saturation. Under these circumstances, 
crystallization will be inhibited, but due to a change to the system thermodynamics (i.e. 
equilibrium solubility) (39). 
The increase of the saturation stability and therefore the reduction of the extent of 
supersaturation result from the formation of complexes between the polymer and the drug of 
interest. For the formation of the complexes, the polymers can interact with drug molecules via 
electrostatic bonds (i.e., ion-to-ion, ion-to-dipole and dipole-to-dipole bonds) but other types of 
forces, such as van der Waals' forces and hydrogen bridges, may frequently participate in the 
complex formation (62). In the literature one can find many examples of polymers showing to 
increase the equilibrium solubility of drugs. For instance, PVP showed to increase the solubility 
of acetazolamide and hydrocortisone (62), felodipine (63), and valdecoxib (64).  The addition of 
polymers, even at low fractions, may also cause stabilization by increasing the local viscosity, 
impeding diffusion of drug molecules, and increasing thermodynamic and kinetic barriers (65). 
The ability of polymers to kinetically stabilize the supersaturated state is thought to result from 
intermolecular interactions between the drug and polymer in solution (e.g. via hydrogen 
bonding or hydrophobic interactions) and/or the ability of the polymer to sterically hinder the 
crystallization process (66). 
In summary, polymers which inhibit crystallization may inhibit crystallization at both 
the nucleation and growth stages (kinetics and crystal habit). Several potential sites of action 
have been identified  (39) (67): 
- Changing the bulk solution properties such as surface tension (where decreasing surface 
tension moves crystallization from diffusion control to surface nucleation control) and 
solubility (where increasing solubility reduces supersaturation and the tendency for 
nucleation).  
- Altering the adsorption layer at the crystal–solution interface, including the properties of 
the hydrodynamic boundary layer surrounding the crystal, potentially decreasing the rate 
of diffusion of drug molecules to the crystal nuclei, increasing the kinetic barrier to 
nucleation. 
- Adsorbing to the crystal surface interface, by formation of hydrogen bonding between 
the polymer and the drug, blocking crystal growth by preventing the access of the solute 
molecules to the crystal terrace;  
- Adsorbing onto the growth terraces and thereby disrupting the growth of steps across the 
surface, blocking access of adsorbed molecules to the terrace steps and/or kinks; 
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- Adsorbing into surface imperfections causing rough surfaces to become flat, therefore 
eliminating growth spots; 
- Modifying the surface energy of the crystal face, potentially changing the level of 
solvation; 
1.4 Solvatomorphism 
The ability of a substance to form solvates is referred to as solvatomorphism.  
In solvatomorphism, the formation of various crystals is a result of the incorporation of 
solvent molecules in the crystal lattice (68). Solvates may contain solvent molecules within the 
crystal structure, in either stoichometric or non-stoichometric proportions. The introduction of 
solvent molecules in a crystalline drug structure is going to originate differences in the physical 
and pharmaceutical properties. For this reason, the properties of solvates, such as density, 
solubility, dissolution rate and bioavailability are different from those of non-solvated species. 
These physical properties changes are analogous to those associated with polymorphism, and 
therefore solvates are often referred to as pseudopolymorphs (69) (70) to distinguish them from 
polymorphs. When the entrapped solvent in a solvate is water, the term hydrate is used (71, 72).  
Regarding the prevalence of solvatomorphism among APIs, 29% of APIs have been 
reported to form hydrates and 10% to form other solvates (73). The ease to form and stabilize 
hydrates can be explained by the fact that molecules within the crystal will attempt to pack so 
that the amount of unoccupied space is minimized and the number of close contacts with 
neighboring molecules maximized (74). However, when large voids exist in the crystal 
structure, energetically favorable hydrogen bonds with solvents compensate for the loss of 
spatial efficiency and thus stabilize the crystal structure (75). 
Steroids, antibiotics and sulfonamids have the particular ability to form solvates. This is 
related to the cavities or large channels that are often present in the crystal structures of these 
substances. The size and chemical environment of the cavity or channel establish the type of 
incorporated solvent molecule as well as the type of interaction between guest and host (76). 
When the solvent molecules are trapped, as in clathrates, the solvate is more stable than when 
the solvent molecules are located along channels in the lattice. Table 1.3 lists some examples of 
the effect of solvation on drugs and solid dosage forms. 
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Table 1.3 –  Effects of solvation on drug activity (76) 
API Effect 
Ampicillin Anhydrate shows higher bioavailability compared to trihydrate. 
Hydrocortisone Hemiacetone solvates showed higher absorption compared to anhydrates. 
Caffeine Increased dissolution of anhydrous forms compared to hydrates. 
Theophylline Increased dissolution of anhydrous forms compared to hydrates. 
Glutethimide Increased dissolution of anhydrous forms compared to hydrates. 
Prednisolone Higher dissolution and activity of a solvate from pellets implanted. 
Griseofulvin 
Chloroformate solvate gives higher bioavailability compared to anhydrates, also 
solvation-desolvation results in increased surface area. 
Citric acid 
Hydrate used to provide mole of water as granulating agent in effervescent 
preparations. 
 
1.4.1 Solvated systems 
The stability of solvates depends on the pressure, temperature and partial pressure 
(activity) of the solvent of crystallization above the solid (77). Similarly to an energy diagram 
for polymorphic systems, the stability range of solvate and unsolvated form can be established 
using a van’t Hoff plot (natural logarithm solubility versus reciprocal temperature plot) (78). 
The relationship between free energy and an ideal solubility of a solid is given by: 
 
 ∆𝑮 = 𝑹𝑻 𝐥𝐧 𝑿 Eq. 1.3                                      
or 
 𝐥𝐧 𝑿 =
∆𝑺𝒇
𝑹
−
∆𝑯𝒇
𝑹
∗
𝟏
𝑻
  Eq. 1.4 
 
where, ∆Sf and ∆Hf are, respectively, the entropy and enthalpy of fusion, and R is the gas 
constant. A negative slope of a van’t Hoff plot is equal to ∆Hf/R, while the intercept yields 
∆Sf/R for each phase. It is commonly accepted that a solvate is the most stable thus, the least 
soluble form in its own solvent. Therefore, the aqueous solubility (and hence stability) order for 
solvated systems is typically the following: stable hydrate < metastable hydrate < anhydrate < 
solvate with organic solvent (Figure 1.9). 
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Figure 1.9 – Solubility diagram for a system of different solvates showing transition temperatures, 
Tt1  and Tt, between the anhydrate and the hydrates (78). 
1.4.2 Hydrates 
Hydrates frequently readily crystallize due to the small size of water molecules that can 
easily fill structural voids and form multidirectional hydrogen bonding with the drug molecules 
forming stable crystal structures (69). It is the activity of water in the medium that will 
determine whether a given hydrate structure will form. In accordance to this, the determination 
of the physical stability of anhydrous forms as a function of water vapor pressure is of great 
importance in order to avoid a reduction on the pharmaceutical performance of the API. The 
formation of hydrates during manufacturing can affect the solubility and, consequently, the 
bioavailability of a drug compound (79, 80). The solubility and dissolution behavior of 
anhydrous and hydrated forms is different, anhydrous forms having commonly greater aqueous 
solubility and faster dissolution rates than the hydrates (81). 
Crystalline hydrates have been classified either according to their structure or energetic 
related considerations. The classification of crystalline hydrates of pharmaceutical interest by 
their structural characteristics is the most common approach. Thus, depending on the structural 
characteristic of the hydrates, and the way how water molecules interact with drug molecules, 
the hydrates can be classified as:  
Isolated site hydrates (Class I), which represents the structures where the water 
molecules have a well-defined isolated location, the hydrates of this class often being 
stoichiometric. The water molecules are kept from contacting with other water molecules 
directly in the lattice structure. Although water molecules exposed to the surface of crystals may 
be easily lost, once they are removed they do not give access to the water molecules inside the 
crystal lattice. The thermogravimetric analysis (TGA) and the differential scanning calorimetry 
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(DSC) for this class of hydrates show thermograms with sharp endotherms reflecting the sudden 
release of molecules. Cephradine dihydrate is an example of this class of hydrates (80). 
Channel or planar hydrates (Class II) includes hydrates where water molecules form 
continuous channels or planes inside the crystalline structure, in a generally non-stoichiometric 
relationship. Special care should be taken with these hydrates, as inconsistencies in the moisture 
content as a result of absorption or desorption of water vapor may lead to variations in content 
uniformity in the drug product and may also result in materials with dissimilar powder 
properties. The TGA and DSC data show early-onset temperatures of dehydration and broad 
dehydration enthalpies. This is because the dehydration begins from the edges of the channels 
that are on the surface of the crystal. After water removal from the surface of the crystal, water 
molecules in the inner part of the crystal are continuously removed until all water molecules are 
eliminated through the channels. Some hydrates, called planar hydrates,  have water molecules 
in a 2D space (80). 
Ion-associated hydrate solids (Class III) contain metal-ion coordinated water. The 
interaction between the metal ions and water molecules is the major force in the structure of 
crystalline hydrates. Consequently, dehydration occurs at very high temperatures. These last 
hydrates can either be stoichiometric or non-stoichiometric. The TGA and DSC thermograms 
present very sharp peaks, expected at high temperatures, corresponding to dehydration of water 
bonded to metal ions (80). 
1.5 Process-induced phase transformations 
Throughout processing a drug is often exposed to temperature, pressure and humidity 
changes, which potentiate the occurrence of process-induced phase transformations. Special 
care should be taken with insoluble drugs, since their crystalline modifications can often lead to 
changes in solubility that will strongly affect the dissolution/ bioavailability of the drug in the 
final solid dosage forms. Process-induced phase transitions may lead to the formation of 
metastable polymorphs, amorphous forms, hydrates/solvates or desolvated forms depending on 
the drug and processing conditions. They can also induce changes in size and shape of the 
materials. Those transformations may be completed or not during the processing and may have 
crucial effects on the product quality (5). Furthermore, it can be difficult to predict and control 
them. It is then important to determine whether or not phase transformations do take place, in 
order to understand the mechanism and kinetics of phase transformations and factors that may 
influence them and finally, control them during manufacturing processes (82-84).  
With the advances in pharmaceutical materials and processing, an improvement in the 
understanding and monitoring of each step from raw material qualification to final product is 
required (85). For this reason, with a close monitoring of the process, a new understanding, and 
knowledge of critical control points are provided, facilitating a better control and predictability 
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of process variations. This item in particular guarantees the high quality and performance 
attributes of raw materials and final products (86). For the monitoring of the process, several 
methods are used for characterizing and for routine off-line testing of pharmaceutical solid 
polymorphs: X-ray powder diffraction (XRPD), microscopy (SEM, OM), thermal analysis 
(TGA, DSC) and spectroscopy (FTIR, NIR). 
1.5.1 Particle size reduction and particle engineering 
Particle size reduction is one of the oldest strategies for improving the dissolution rate 
of the APIs. As the particle size becomes smaller, the surface area to volume ratio increases, 
thus increasing the surface area available for solvation. Particle size reduction technologies are 
therefore routinely used to increase the bioavailability of poorly soluble drugs (87). Many solid 
dosage forms in the pharmaceutical industry are made of microparticles. Dry powders are 
inhaled as aerosols into the lung, delivered to the nose, filled into capsules, or pressed into 
tablets for oral applications, or even delivered transdermally (88). Conventional size reduction 
of pharmaceuticals is accomplished by mechanical comminution such as crushing, grinding and 
milling of previously formed larger particles. This process involves shearing/cutting, 
compressing, impacting or attrition of drug particles which create mechanical stress and often 
heat. Accordingly, this process could lead to polymorphic transitions, dehydration and 
amorphization of the drug. Milling induced polymorphic changes have been observed in many 
small drug molecules, such as ranitidine hydrochloride and indomethacin (89, 90). In the case of 
ranitidine, it was suggested that the transformation from form 1 to form 2 during milling 
occurred via an intermediate amorphous form. 
The supercritical fluid (SCF) technology comprises several applications for particle 
formation and design. It allows for a single step crystallization of particular pharmaceutical 
materials with precisely controlled characteristics, such as solid-state form, particle size, shape 
and crystallinity (91-93). This technology enables the tuning of the properties of the SCF (e.g. 
solvent ability) to target to a component in a complex matrix, or it can suddenly change these 
properties during the process due to changes in pressure and / or temperature, with the aim of 
achieving of very homogeneous supersaturation conditions, which in turn can lead to the 
production of fine powders with a narrow particle size distribution. In this work special 
attention will be given to this technology, with the aim of producing particles with reduced sizes 
and determining their solid-state characteristics.  
Supercritical fluids (SCFs), i.e., gases and liquids at temperatures and pressures above 
their critical points, have liquid-like densities with gas-like transport properties and moderate 
solvent power, which can further be adjusted with changes in pressure and temperature (94) and 
addition of other materials (e.g. surfactants). SCFs work as solvents with adjustable viscosity, 
density, and solvation strength (95). In the pharmaceutical field, the most used SCF is carbon 
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dioxide due to its low critical temperature (31.1ºC), which is attractive for heat-sensitive 
materials (96).  In the pharmaceutical field, precipitation from supercritical solutions composed 
of SCF and solutes (1) and precipitation from saturated solutions using SCF as an antisolvent 
(2) are the most commonly used modifications of the SCFs technology. In the first process, the 
solid product is solvated in the SCF forming a solution. This solution is rapidly depressurized 
through an adequate nozzle, causing an extremely rapid nucleation and particle formation. This 
process is termed Rapid Expansion of Supercritical Solutions (RESS). It is an attractive 
methodology due to the absence of organic solvents, as it is simple and relatively easy to 
implement. However, its application is restricted to the products that present a moderate 
solubility in the SCFs (e.g. low polarity compounds) (97). Due to RESS collisions during free 
jet expansion, particles at the organic-CO2 interfaces are forced to grow. This growth may be 
inhibited by expanding into an aqueous solution with the use of surfactants as stabilizers, a 
process known as rapid expansion of supercritical solutions to aqueous solutions (RESSAS) 
(98). In this usage of the technology, the supercritical solution is expanded through an orifice or 
conical shaped nozzle into an aqueous solution containing a stabilizer to minimize particle 
aggregation throughout the free jet expansion. Various process parameters influence the 
properties of the final particles manufactured by RESS, such as the extraction (understood in 
this context dissolution or solubilization of the drug) temperature, the extraction pressure, the 
pre-expansion temperature, the spray distance, post expansion pressure and the nozzle 
configuration (length, diameter and geometry) (99). The surfactants may be introduced into the 
CO2 phase, the aqueous phase or into both. During the expansion, the nuclei of the drug / 
material particles come in contact with an expanding CO2 phase and an aqueous phase 
simultaneously. This process combines aspects of phase separation with interfacial stabilization. 
RESSAS may also be used to enhance the dissolution rate of poorly water soluble drugs (100). 
The reduction of particle size and, therefore, an increase in interfacial area, lead to an increase 
of dissolution rates in the gastrointestinal tract. Furthermore, coating drug particles with 
polymeric and low molar mass hydrophilic stabilizers to enhance wetting and solvation by 
intestinal fluids, may further increase the dissolution rates of such drug particles. Stable 
suspensions of submicrometer-sized particles of cyclosporine, a water insoluble drug, have been 
produced by RESSAS with an aqueous solution containing polysorbate-80 (100). 
The second process referred previously (2) helps to overcome the solubility limitation of 
the SCF by dissolving the drug in a solvent. This process is based on the same concept of using 
antisolvents in solvent-based crystallization processes. It allows, throughout decompression, the 
efficient separation of the antisolvent from both the solvent and solid products (101). This 
process is named Supercritical Anti-Solvent (SAS). It is commonly used to prepare 
nanoparticles without the need for a grinding procedure. Some operating parameters such as 
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temperature, pressure, drug concentration have a great influence on particle size in the SAS 
process  (102). 
1.5.2 Wet granulation  
During wet granulation, several different steps are involved, such as wetting, 
mechanical stress and sieving, which provide an ideal medium for the crystallization of new 
phases of the drug (83). The extent of conversion is dependent on the amount dissolved with 
time, which results from the solubility of the forms, volume of solvent (granulation fluid) and 
the dissolution rate. Considering the fact that hydrated forms are more stable than anhydrous 
forms in the wet material, hydration will be the most likely transformation to occur. In the case 
of poorly soluble drugs in contact with the granulating fluid, the anhydrous phase will tend to 
convert into a hydrate by a solvent-mediated mechanism. The analytic techniques used for the 
detection of those transformations will depend on the drug load in the granules and the potential 
interference from the excipients (6, 103).  
The main question will be how that hydrate will behave in the subsequent drying 
process where the processing stress is due to the high temperature and the relatively low 
humidity. It has been described that a dehydration of a hydrated form can result in a metastable 
anhydrate, a lower hydrate, an amorphous form or a thermodynamically stable anhydrous form. 
The path of any transformation is kinetically controlled and dependent on the conditions for the 
duration of the wetting and drying steps, as well as on the duration of the process. Examples of 
the impact of such drying conditions on the formation of different crystal forms are 
phenobarbitone (104), chlorpromazine hydrochloride (105) and theophylline (106).  
Drying kinetics in fluid bed dryers has been well studied. It has been studied that two 
main stages exist during the fluid-bed drying process of granulations for pharmaceutical 
applications. The first stage is limited by the heat-transfer which occurs during the moment 
when the water molecules at the surface or the ones loosely bounded are evaporating from the 
surface of particles. The relationship between moisture content and time is, in this stage, linear. 
The second stage of drying is diffusion dependent, where the water inside the granules must 
diffuse to the surface of the granule before it can be removed by the drying fluid. Here, for 
spherical particles, the relationship between moisture content and time is exponential (83). 
1.5.3 Extrusion-spheronisation 
Pelletization of drugs is a worldwide used technology to create multi-particulate solid 
dosage forms. Pellets are spherical or nearly spherical, free-flowing granules with a narrow size 
distribution, typically varying between 500 and 1500 µm for pharmaceutical applications (107). 
These formulations have multiple advantages in comparison to the conventional single-unit 
solid dosage forms. For instance, due to the fact that pellets are much smaller than tablets, they 
are more rapidly emptied out of the stomach, regardless of the feeding state of the patient. 
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Secondly, each small pellet-unit contains only a small amount of drug. There is consequently 
less risk of high local drug concentrations or irritation of the gastric and duodenal mucosa. The 
use of pellets also gives the advantage of being able to combine multiple drugs that otherwise 
would not be compatible in one dosage form. Once pellets have been made they can be 
compressed into tablets or filled into hard gelatin capsules (107, 108). 
Among various methods of manufacturing pellets, the process of extrusion–
spheronisation is of particular interest. Extrusion–spheronisation is a process organized in five 
unit operations: blending, wet massing, extrusion, spheronisation, and drying (109). The liquid 
phase (generally water) provides inter-particle cohesion, lubricates particle contacts, promotes 
wall slip and can also bear some of the stress generated during the forming process (110). 
Extrusion and spheronisation of wet masses includes the wetting and drying steps of the 
materials together with mechanical stresses, which are also likely to promote solid-state 
modifications of an API.  Furthermore, the amount of wetting liquid used in this process is 
relatively high, when compared to other processes, namely fluidized bed granulation. Therefore, 
APIs to be included in pellets manufactured by extrusion of wet masses are more prone to 
undergo structural transformations than APIs manufactured by other drier and gentler 
technologies (111). The physical and chemical properties of the active pharmaceutical 
ingredient (API) are important in wet mass formulation: the solubility of the API in the liquid 
phase, its particle size characteristics and packing behavior can affect the amount of liquid 
necessary to obtain a wet mass with the required ‘plasticity’. Particle size, specific surface area 
and packing behavior has been identified as key factors affecting the variation in process ability 
(112). 
Extrusion–spheronisation produces well-densified pellets, offers a narrow particle-size 
distribution, yields low friability, ensures regular sphericity and maintains good flow properties. 
The properties of the final product depend on the physicochemical properties of the raw 
materials and the amount of each component in the formulation (113). Various process variables 
affect the quality of the pellets. These variables include: the type and quantity of solvent added 
to the powder mixture; mixing time and speed; type of extruder, design of the screen, and rate of 
extrusion; spheronisation speed, time, load, and plate design; and drying rate and time (108). 
1.5.4 Tableting 
The powders/granules may be subjected to compression forces as high as 40kN during 
tableting. Here, the pressure, temperature and mechanical stress may play a role. However, it 
may be difficult to know the contribution of each of these factors on solid-state transitions. 
Therefore, tableting may induce solid phase changes in either the drug or the excipients via the 
solid-state mechanism. Most of the data supports the idea that the transformations from one 
polymorphic form to another during tableting result from an intermediate amorphous phase. For 
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a form which resists to the mechanical stress it will be expected that the crystal behaves as 
predicted by its Pressure-Temperature phase diagram (83). Caffeine, sulfabenzamide and 
maprotiline hydrochloride have been reported to undergo polymorphic transformations during 
compression (114). 
1.6 Storage: Moisture-induced phase transitions 
The API and excipients in the formulation may have different moisture sorption 
properties. Hence, they can interact differently with moisture and produce unpredicted phase 
transitions. The study of the interaction of moisture with pharmaceutical solids is of practical 
interest since it allows a prediction of solid dosage form stability and shelf-life (4). Furthermore, 
the process of moisture sorption by amorphous and crystalline materials is different making 
their study important when designing new formulations and processes.  The amorphous 
character is common to the polymeric molecules used as excipients. As a consequence of the 
higher mobility and ability to interact with moisture, amorphous substances are also more likely 
to undergo solid-state modifications. The highly hygroscopic characteristics of such substances 
can also have significant consequences for the stability of pharmaceutical formulations. The 
impact of the excipient’s moisture present in the drug-excipient interaction, depends on its 
fraction in the formulation, as well as, the relative ability of each solid to uptake and retain 
water at a particular temperature and RH (6). 
1.7 Mechanism of phase transformations occurring during processing and 
storage 
Throughout the designing, development and manufacturing of a medicine it is essential 
to identify process-induced solid phase transitions of the API. For instance, for a drug which is 
sensitive to moisture or to a solvent, a process of dry granulation can be the appropriate process 
to manufacture this drug. Therefore, it is important to know the susceptibilities of each APIs, 
throughout an understanding of the mechanism(s) of phase transitions and the factors affecting 
their kinetics. These studies can provide an insight of such transitions during the manufacturing, 
allowing selection of a robust process to ensure consistent product manufacturing and 
performance (6, 34). 
1.7.1 Solid-state pathway 
Solid-state mechanism involves phase transitions that occur in the solid-state without 
passing through intervening transient liquid or vapor phases. The kinetics of phase transition via 
a solid-state mechanism is often induced by the environment (temperature, mechanical stress, 
vapor pressure, etc.), the presence of crystalline defects, particle size distribution and impurities. 
Phase transitions that occur through solid-state mechanisms are polymorphic transitions, 
hydration/dehydration, amorphous crystallization/ amorphisation (6). 
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1.7.2 Melt pathway 
Phase transitions occur when a solid is heated above its melting point and then cooled to 
the ambient temperature. In these cases, the original solid phase may be altered as a result of a 
phase transition through this heating/cooling cycle. The factors that will determine the final 
solid phase are the relative rates of nucleation, the crystal growth and the cooling rates. 
Impurities or excipients can also affect the course of crystallization. Amorphisation and 
polymorphic transitions are the most likely phase transitions obtained through this pathway (6). 
1.7.3 Solution pathway 
A drug is commonly dissolved, or partially dissolved, in a solvent (typically water) 
during pharmaceutical processing. For example, the drug may partially dissolve in water during 
wet granulation, or it may completely dissolve in water during freeze-drying or spray drying 
processes. If the following solvent removal (drying) induces a transformation, it is said that it 
has occurred through a solution mechanism. The solid formed may not be the same crystal form 
as the original phase or it may consist of a mixture of phases. However, only the fraction of drug 
that is dissolved can undergo this transformation. The solid formed may be a single phase or a 
mixture of amorphous and crystal forms, depending on the rate of solvent removal, the ease of 
nucleation and the crystal growth rate of the crystal forms when exposed to particular 
processing conditions. The fraction of solid material that did not dissolve may act as seeds and 
direct the crystallization to the original crystal form or, together with the insoluble excipients 
can provide surfaces for heterogeneous nucleation of a different phase. Soluble excipients may 
also affect the nucleation and crystal growth of the drug (52). It is also important to notice that 
the transitions explained by this mechanism can either be from a metastable phase to a stable 
phase or vice-versa (6). 
1.7.4 Solvent-mediated pathway 
In formulation and processing the stable crystalline form is usually preferred to its 
metastable counterpart. However, a metastable solid phase, with larger thermodynamic activity, 
may be chosen due to its better biopharmaceutical performance.  The disadvantage is that, since 
any system seeks to reach the thermodynamic equilibrium, a metastable form present in the 
formulation is liable to suffer a solvent-mediated transformation upon processing (e.g. wet 
granulation/ wet extrusion) and/or storage. This transformation is governed by the solubility 
difference between the two phases when the metastable phase is in contact with the saturated 
solution and allows for the transition from a metastable to the stable phase. Based on this, 
solvent mediated transformations are commonly used to produce the most stable polymorph 
(115). 
The solvent-mediated pathway only permits the transition from a metastable phase to a 
stable one. This transformation takes place when the metastable phase contacts the saturated 
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solution. The solubility differences between both phases enable these types of transformations. 
Three steps are involved in those transformations (116, 117): (1) the initial dissolution of the 
metastable phase into the solution to reach and exceed the solubility of the stable phase; (2) 
nucleation of the stable phase; (3) crystal growth of the stable phase coupled with the 
continuous dissolution of the metastable phase. Steps 2 or 3 are usually the slowest steps (6). 
When step (2) is the rate-controlling step, the overall transformation is influenced by factors that 
affect nucleation (e.g. solubility and solubility differences between the phases, processing 
temperature, contact surfaces, agitation, and soluble excipients/impurities). When step (3) is the 
rate determining step, the kinetics of the conversion is determined by the solubility difference, 
solid/solvent ratio, agitation, processing temperature, particle size of the original phase, and 
soluble excipients/impurities (6). The crystalline transformation occurring in a suspension or 
during kneading of a wet mass for granulation, can be outlined according to the following 
scheme: 
 
 
 
where, kd is the dissolution coefficient constant, kn is the nucleation rate constant and kc 
is the crystal growth rate constant. The SS* is activated supersaturated solution containing 
enough nuclei to start the growth of the crystal. Thus, the crystal transformation followed 
consecutive reaction kinetics and contemplates an induction period (118). 
This kind of transformation may also take place during solubility measurements, 
dissolution studies and accelerated stability tests in hydrated systems. The rate of transformation 
can be affected by the introduction of specific impurities that may delay the rate of dissolution 
of the less stable species (57). 
1.8 Excipients 
1.8.1 The importance of excipients selection 
Excipients’ proper characterization is paramount because variations in raw materials 
properties can lead to failures in production causing batch-to-batch variation and failed batches 
and/or dosage form performance (85).  
Most APIs used for oral administration require formulations with excipients. In spite of 
excipients having traditionally been thought of as being inert it has been demonstrated that they 
can interact with a drug to affect its absorption and bioavailability (119). Some excipients can 
also be added to a formulation specifically to take advantage of the interaction between the API 
and that excipient, when it affects the bioavailability of the drug.  
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Instability of APIs and excipients may be broadly classified as chemical (e.g. hydrolysis 
or oxidation) or physical instability (like polymorphism or pseudopolymorphism) which may 
have a potential impact on the absorption and bioavailability of the drug. In particular, the 
formation of metastable crystalline polymorphs of the API can be dangerous, since they may be 
chemically less stable than crystalline stable forms (5). The main factors that could cause the 
molecular transformation of an API in formulation are environmental (e.g. water vapor and 
sunlight), stresses during conversion to the dosage form (e.g. compaction processes with 
interactions between adjacent molecules of API), interactions between functional groups on the 
same molecules. Optimizing the selection of excipients in the formulation could reduce 
problems during manufacturing and storage of final dosage forms.  In addition, each excipient 
must be compatible with the other components in the formulation and perform efficiently its 
desired function in the final product (119). Accordingly, it is important that the processes of 
formulation design and development are properly integrated to obtain optimized drug delivery 
systems as early as possible (120). For this reason, in this study a special attention is paid to the 
interactions between the drug and excipients when they are exposed to aqueous environments, 
humidity, temperature and pressure changes, since they may potentiate or protect the occurrence 
of process-induced phase transformations.  
1.8.2 The water sorption behavior of excipients  
The interaction of moisture with pharmaceutical solids is crucial to an understanding of 
water-based processes, e.g. prediction of solid dosage form stability and shelf life.   
Different excipients have different abilities to interact with moisture from the 
surrounding atmosphere during storage. In general, materials which are not affected by water 
vapor are termed non-hygroscopic, while those in a dynamic equilibrium with water in the 
atmosphere are called hygroscopic. Generally, crystalline excipients, because of the close 
packing and high degree of order of the crystal lattice, do not absorb water into their structures, 
contrasting with amorphous solids that can absorb significant amounts of moisture within the 
material. Furthermore, water absorbed into the amorphous regions can act as a plasticizer and 
increase molecular mobility due to the breakage of hydrogen bonds between molecules (121). 
Water can interact with crystalline solids by different mechanisms: 1) adsorption on the 
surface of the particles; 2) incorporation into microporous regions by capillary condensation; 3) 
formation of crystal hydrate; and 4) deliquescence. The adsorption of water onto non-hydrating 
crystalline solids depends on the polarity of the surfaces and is proportional to surface area. 
When the specific surface area is large, e.g., very small or porous particles, the adsorption is 
particularly critical in affecting the properties of solids. The mechanism of water sorption into 
the solid depends on the crystal structure, water-solubility, porous structure and the ability to 
form crystal hydrates (58, 122). Crystalline excipients are commonly non-hygroscopic, 
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therefore, at low RH, water is adsorbed onto the surface of a crystalline material. As the RH 
increases, the water molecules become attached to the solid-vapor interface by weak interaction 
forces (e.g. van der Waals forces). Water interacts firstly with the polar groups on the crystalline 
surface, which is a surface effect. Thus, surface area, particle size and size distribution are 
important for the ability to adsorb moisture as a function of RH. As the RH is increased, some 
tendency for multilayer sorption is expected (123). 
Several processes, such as grinding, spray drying, wet granulation and thermal 
treatments, may introduce significant fractions of amorphous domains into pharmaceutical 
crystals (124).
 
Additionally, most pharmaceutical polymer excipients are substantially 
amorphous.
 
The amount of water sorbed into amorphous materials is commonly proportional to 
the volume/weight of the amorphous solid and independent of the surface area of the solid. 
Amorphous materials take up significantly higher amount of water than their crystalline 
counterparts, which could cause physicochemical instability in their formulations (125). 
Therefore, it is very important to study the water sorption ability of amorphous materials.  
Water absorbed into the amorphous regions can act as a plasticizer (depress the Tg) and 
could cause structural changes in amorphous materials (126). When the Tg
 
is below the 
environmental temperature, the solid enters the rubbery or supercooled liquid state. Therefore, 
glass transition must be considered when accelerated stability tests (increased 
temperatures/humidity) are designed - the mobility of drug molecules would increase and the 
viscosity would decrease above the glass transition, which could lead to a significant increase in 
the crystallization rate (127). 
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Chapter 2 -  Materials and methods 
2.1 Materials 
2.1.1 Olanzapine 
Olanzapine (OLZ), 2-methyl-4-(4-methyl-1-piperazinyl)-10Hthieno[2,3-b][1,5]benzo-
diazepine (Figure 2.1 A), belongs to a new generation of benzodiazepines for the treatment of 
schizophrenia and other related psychoses. It has structural and pharmacological properties 
resembling those of the atypical antipsychotic clozapine and an improved tolerability profile 
compared with the classical antipsychotic haloperidol (128).  It is a yellow and crystalline 
powder.  It is practically insoluble in water, freely soluble in methylene chloride and slightly 
soluble in ethanol (129). 
Olanzapine can exist in several crystalline forms, including polymorphic anhydrates, 
dihydrates, solvates and one higher hydrate structure (18). Bhardwaj et al. have recently 
calculated the crystal energy landscape of different forms of olanzapine and observed that 
olanzapine molecules have a packing efficiency of no more than 70%, which explained the 
tendency to form solvated forms (130). .  
OLZ is, therefore, a molecule with a certain degree of structural complexity. 
Consequently, the physical treatments and technological processes undergone by the drug may 
have an impact on its solid-state, which may affect its performance in terms of dissolution rate, 
absorption, and therapeutic activity and response. Moreover, the recommended daily oral 
olanzapine dose for schizophrenia ranges from 5 to 20 mg, which is a small amount, thus 
requiring a well-defined purity and an assessment of the nature of the active agent; the 
manufacturing process of solid olanzapine in practical terms can be complicated by its ability to 
form such different structures (131). 
 
 
Figure 2.1 – Olanzapine molecule (A) and one example of packing (B).  
Box in B shows two enantiomers of olanzapine. 
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All olanzapine crystalline forms present a structural building block which is composed 
by a dimeric unit (racemic pair), which is quite “rigid” irrespective of the packing environment, 
in spite of the weak interactions involved in its stability (Figure 2.1 B). These racemic pairs 
connect to each other through NH
…
N hydrogen bonds in anhydrous forms or by solvate-
mediated interactions (18). The system used for numbering the known olanzapine forms is 
sometimes confusing in the previous art disclosures. Thus, it was decided to follow SM Reutzel-
Edens et al. (18) nomenclature for both anhydrous and hydrated forms.  
Olanzapine raw material revealed to be in the anhydrous Form I and was used to 
prepare the different olanzapine forms (Chapter 3).  Form I is an anhydrous form and the most 
stable crystalline form of olanzapine. Its chemical structure and main physicochemical 
properties are presented below in Table 2.1. 
Table 2.1 – Physicochemical properties of olanzapine Form I (18, 132-134) 
Properties Olanzapine Form I 
IUPAC Name 
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno [3,2-
c][1,5]benzodiazepine 
Chemical Formula C17H20N4S 
General Designation Anhydrate Form I 
Molecular weight (MW) 312.43 g/mol 
Density (ρ) 1.30 g/cm3 (18) 
Entries in the CSD 
UNOGIN 
UNOGIN01 (18, 133) 
Recrystallization from 
solvents 
Can be recrystallised from anhydrous solvents such as ethyl 
acetate toluene, propyl acetate, isopropyl acetate, butyl acetate, 
tetrahydrofuran and acetone. Furthermore, it can be obtained 
from desolvation of several low alcohol solvates viz., methanol, 
ethanol and propanol and from dihydrates B, D and E (18) 
 
2.1.1.1 Olanzapine Anhydrous forms 
The first reported anhydrous form of olanzapine (herein referred to as Form II) revealed 
to be metastable and undergoes discoloration on exposure to air and moist environments (135). 
The second anhydrous polymorph to be reported (herein referred to as Form I) showed to have a 
higher stability and is therefore well adapted for commercial use (136). However, during its 
production, the stress created by temperature, mechanical treatment and the use of certain 
solvents may result in the concomitant appearance of both anhydrous polymorphic forms I and 
II as a final product (132). Olanzapine Form II is commonly prepared from de-solvation of 
methanol solvate and crystallized from acetonitrile and dichloromethane (18). 
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Many studies have been conducted on anhydrous forms I (most stable anhydrous form) 
and II (metastable form), for example, thermal behavior, vibrational spectroscopic and X-ray 
powder diffraction characterization (137-139). However, there is still a lack of information 
about how these anhydrous forms behave during processing and storage and how can they affect 
their pharmaceutical performance, being the latter one of the aims of the present work. 
Regarding the thermal studies performed to both forms, it was observed that both forms 
presented endothermic peaks when heated, which reveled not to be related to their degradation. 
In Form I a endothermic transition was observed at a Tonset of about 194ºC, whereas Form II 
presented an endothermic peak at 177ºC, followed by an exothermal signal (recrystallization) 
superposed to the latter and, finally, an endothermic peak at about 194ºC (137). The superposed 
signs of the first endotherm and the exotherm  reveled to be associated with the coexisting of 
Form II and Form I in the temperature range of 160-180ºC, when a X-ray powder diffraction 
diagram was taken to Form II in function of temperature (139). A satisfactory explanation for 
these facts was that the dimorphic monotropic relationship between both forms, where Form I is 
the most stable form at all temperatures below its melting point, and Form II is only converted 
into Form I after its melting due to the higher thermodynamic stability of Form I in relation to 
the melted Form II (137). 
The vibrational spectroscopy study of both anhydrous forms revealed that the 
differences between forms I and II should be related with the atoms involved directly or 
indirectly with the NH intermolecular hydrogen bond, suggesting that weaker intermolecular 
interactions are present in Form II, explaining its lower density. These results provided 
additional support to the monotropic relationship proposed for the olanzapine forms (138). 
Concerning the XRPD study carried out for both anhydrous forms, the powder pattern 
specific of each form was identified. The same study also developed a way to determine the 
amount of Form II olanzapine in Form I samples. However, the number of peaks, areas and 
preferred orientations showed to be strongly affected by the particle sizes (139). 
 
2.1.1.2 Olanzapine dihydrates 
Reutzel-Edens et al. (2003) (18) identified the structure of three OLZ dihydrates (B, D 
and E). Dihydrate D is considered to be the most stable, having a more organized crystal 
packing and therefore a higher dehydration temperature. Reference codes of the dihydrates of 
olanzapine found in the Cambridge Structural Database are: AQOMAU (dihydrate D), 
AQOMAU01 (dihydrate B) and AQOMAU02 (dihydrate E). 
Both anhydrous and dihydrates of olanzapine present the olanzapine dimer that has been 
proposed to be the crystal building block (racemic pair) of olanzapine structures. The neighbor 
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dimers may come in contact with each other by the olanzapine hydrogen-bond donor – N10H 
and by the two good olanzapine acceptors - N5 and N4’. 
While olanzapine Form I the NH-N5 bond links the crystal building blocks with no 
participation of the piperidine N4’, the hydrogen-bonding patterns in dihydrates B, D and E 
allow both N5 and N4’ to participate in hydrogen bondings due to the incorporation of water in 
their crystal forms. Therefore, the previously NH-N interaction in Form I is disrupted by 
bridging water molecules in hydrates- NH-Ow-Hw-Ow-N (Table 2.2). 
Table 2.2 – Hydrogen-bond distances (Å) for different olanzapine crystal forms (18) 
Forms D-H
…
A D
…
A 
Form I N10-H
…
N5 3.09 
Dihydrate B 
N10-H
…
O1 
O1-Ha
…
N4´ 
O2-Ha
…
N5 
O1-Hb
…
O1 
O2-Hb
…
O1 
2.91 
2.83 
2.99 
3.04 
2.94 
Dihydrate D 
N10-H
…
O1 
O2-Ha
…
N4´ 
O2-Ha
…
N5 
O1-Hb
…
O2 
O1-Hb
…
O2 
2.86 
2.82 
2.86 
2.85 
2.83 
Dihydrate E 
N10-H
…
O1 
O1-Ha
…
N4´ 
O2-Ha
…
N5 
O1-Hb
…
O2 
O1-Hb
…
O1 
2.89 
2.81 
3.06 
2.96 
2.96 
Higher hydrate 
N10-H
…
O1 
O1-Ha
…
N4´ 
O2-Ha
…
N5 
O1-Hb
…
O2 
O1-Hb
…
O1 
O2-Hb
…
O3 
O3-Hb
…
O2 
2.90 
2.79 
2.96 
2.78 
2.82 
2.61 
2.67 
 
The water molecules of crystallization are positioned between the olanzapine dimers 
forming different olanzapine crystal building blocks. In dihydrates B and E the olanzapine 
building blocks are aligned in a herringbone motif while in dihydrate D they are aligned end-on-
end and mounted directly on top of one another (Figure 2.2). 
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Figure 2.2 – Olanzapine crystal building blocks in (a) Form I, (b) dihydrate B, (c) dihydrate D and 
(d) dihydrate E [adapted from (18)]  
The stability of the dihydrates can be well correlated with their densities (D: 1.285 > B: 
1.278 > E: 1.239 g/cm
3
), having the dihydrate D (the thermodynamically most stable form) the 
most efficient crystal packing. 
2.1.1.3 Olanzapine higher hydrate 
It is a metastable form containing 2-2.5 mol of water. It converts to dihydrate E within 
few minutes after being isolated from the crystallization solution. This Form is also reported in 
the CSD: AQOMEY. Crystallize from EtOAc-toluene-water mixtures at temperatures lower 
than 55 
o
C and dichloromethane-water mixtures. 
2.1.2 Polyvinylpyrrolidone (PVP) 
Polyvinylpyrrolidone or Povidone (PVP) has the following chemical formula: 
(C6H9NO)n. It is a synthetic polymer consisting essentially of linear 1-vinyl-2-pyrrolidinone 
groups, the differing degree of polymerization of which results in polymers of various molecular 
weights.  
 
Figure 2.3 – Chemical structure of polyvinylpyrrolidone. 
It is characterized by its viscosity in aqueous solution, relative to that of water, 
expressed as a K-value. Povidone is an amorphous powder and extremely hygroscopic, meaning 
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that significant amounts of moisture can be absorbed at low relative humidity. PVP’s 
hygroscopic nature is attributed to the electronegative groups of the carbonyl group in the 
pyrrolidone structure which are able to establish hydrogen bonding with water (140). 
Although povidone is used in a variety of pharmaceutical formulations, it is mainly used 
in solid-dosage forms. For instance, povidone solutions are used as binders in wet-granulation 
processes, or be added to powder blends in the dry form and granulated in situ by the addition of 
water, alcohol, or hydroalcoholic solutions. PVP has been shown to enhance dissolution of 
poorly soluble drugs from solid-dosage forms (141, 142),  due to the presence of an hydrophilic 
lactam group and an hydrophobic vinyl in its molecular structure, which enables PVP to form 
amphiphilic micellar structures. The critical micelle concentration (CMC) of this polymer is 
0.1% (m/v) (143, 144). A poorly soluble drug which is solubilized by PVP is present in the 
aqueous phase as individual, non-crystalline molecules, usually with a higher bioavailability. 
The mechanism of action of this polymer results on the large dipole moment of this polymer’s 
side groups that are able to interact with any other dipole present in the system, forming 
complexes with the drug. PVP presents both hydrophilic and hydrophobic groups. Therefore, 
the polymer can interact with the poorly soluble drug and continuing to be water-soluble. The 
complex formation between the polymer and the drug is driven by entropy due to the release of 
water molecules previously bound to the polymer. However, the molecular interaction between 
the polymer and the drug resulting in a favorable enthalpy term is normally required for a good 
performance(145). 
Povidone solutions may additionally be used as coating agents or as binders when 
coating active pharmaceutical ingredients on a support such as sugar beads. Furthermore, PVP 
can also be used as a suspending, stabilizing, or viscosity-increasing agent in a few of topical 
and oral suspensions and solutions. The solubility of a number of poorly soluble active drugs 
may be increased by mixing them with povidone (146). 
When water is absorbed into the amorphous regions of PVP acts as a plasticizer, thus 
lowering the glass transition temperature (Tg) of the polymer (147). 
2.1.3 Polyethylene glycol (PEG) 
Polyethylene glycol (PEG) has the formula: HOCH2(CH2OCH2)mCH2OH, where m 
represents the average number of oxyethylene groups. Alternatively, the general formula 
H(OCH2CH2)nOH may be used to represent polyethylene glycol, where n is the number m in the 
previous formula + 1 (146), as shown in Figure 2.4. 
 
Figure 2.4 – Chemical structure of polyethylene glycol. 
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 Polyethylene glycols are stable, hydrophilic and water-soluble. PEGs are commercially 
available from 200 to 10000000 g/mol molecular weight (MW), with MWs above 600 g/mol 
existing as semi-crystalline solids at room temperature. PEG has been widely used in 
pharmaceutical dosage forms, presenting low toxicity and cost (148).  
In solid-dosage formulations, higher-molecular-weight polyethylene glycols can 
enhance the effectiveness of tablet binders and impart plasticity to granules. However, they have 
only limited binding action when used alone, and can prolong disintegration if present in 
concentrations greater than 5% w/w. Polyethylene glycols can also be used to enhance the 
aqueous solubility or dissolution characteristics of poorly soluble compounds by making solid 
dispersions with an appropriate polyethylene glycol (146). 
PEG is a hygroscopic material. Cohen et al. (149) have shown a correlation between 
PEG MW and moisture sorption; however, these results were limited to a particular temperature 
and relative humidity (37ºC, 75% RH). 
It was recently shown that semi-crystalline PEGs can undergo deliquescence at high 
relative humidity environments (148). Moisture sorption isotherms for PEG 1450, 3350, 6000, 
8000 and 100000 showed that, at high relative humidities, PEG sorbs atmospheric moisture 
through the mechanism of deliquescence and that the deliquescence relative humidity (RH) 
decreased as PEG MW decreased (148). 
2.1.4 Hydroxypropyl cellulose (HPC) 
Hydroxypropyl Cellulose is a partially substituted poly(hydroxypropyl) ether of 
cellulose. Hydroxypropyl cellulose is commercially available in a number of different grades 
that have various solution viscosities. 
 
 
Figure 2.5 – Chemical structure of hydroxypropyl cellulose. 
Molecular weight has a range of 50000–1250000. Hydroxypropyl cellulose is an ether 
of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated, 
forming –OCH2CH(OH)CH3 groups. HPC is often used in oral and topical pharmaceutical 
formulations. In oral products, hydroxypropyl cellulose is primarily used in tableting as a 
binder, film-coater and extended-release-matrix former. As an alternative technology to wet 
granulation, dry granulation and direct compression of HPC formulations have been reported to 
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exhibit acceptable tableting and flow characteristics for application in extended-release matrix 
tablets. Hydroxypropyl cellulose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative humidity of 
the surrounding air. Typical equilibrium moisture content values at 25ºC are 4% w/w at 50% 
relative humidity (146). 
Otsuka et al., (118) showed that HPC has an important role on the inhibition of the 
conversion between anhydrous and dihydrate forms of carbamazepine in aqueous solutions. 
They suggested that HPC altered the nucleation kinetics, and that this effect varied based on the 
grade and concentration of HPC. 
2.1.5 Hydroxypropyl methylcellulose (HPMC) 
HPMC is a partly O-methylated and O-(2-hydroxypropylated) cellulose. It is available 
in several grades that vary in viscosity and extent of groups substitution. Grades may be 
distinguished by appending a number indicative of the apparent viscosity, in mPa.s, of a 2% 
w/w aqueous solution at 20ºC. Molecular weight varies between 10.000–1.500.000. HPMC is 
widely used in oral, ophthalmic, nasal and topical pharmaceutical formulations. In oral products, 
HPMC is mainly used as a tablet binder, in film-coating and as a matrix for use in extended 
release tablet formulations. Concentrations between 2% and 5% w/w may be used as a binder in 
either wet- or dry-granulation processes. High-viscosity grades may be used to retard the release 
of drugs from a matrix at levels of 10–80% w/w in tablets or capsules. HPMC is hygroscopic. 
The inhibiting effect of HPMC on polymorphic transformation kinetics was first 
addressed by Katzhendler et al. (150). These authors observed that the transformation of 
carbamazepine anhydrous into its dihydrate Form in aqueous solution was inhibited when using 
HPMC in a sustained release tablet. It was suggested that the inhibition was related to hydrogen 
bonding between HPMC and carbamazepine (151). 
 
 
Figure 2.6 – Chemical structure of hydroxypropyl methylcellulose. 
 
Chapter 2 
40 
2.1.6 Microcrystalline cellulose (MCC) 
Microcrystalline cellulose is commonly used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-granulation 
and direct-compression processes (146). 
 
Figure 2.7 – Chemical structure of microcrystalline cellulose. 
 
Furthermore, microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting. MCC offers other advantages, including broad 
compatibility with APIs, physiological inertness, ease of handling and security of supply (146). 
MCC is a white, odorless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have different 
properties and applications. It is a hygroscopic material, which is related to the presence of 
abundant hydroxyl groups on cellulose chains. When exposed to 25°C and 50% relative 
humidity, its equilibrium moisture content is approximately 5%. However, different grades may 
contain varying amounts of water. The sorption mechanism involves water molecules tightly 
bound to accessible hydroxyl groups of the anhydroglucose units, followed by a second, less 
tightly bound layer, with further additional layers of water. Water is only sorbed in the 
amorphous regions of MCC, which are more hydrophilic than the crystalline regions. The 
crystallinity for microcrystalline cellulose showed to vary between 60–80%. Considering that 
the amorphous region is more hydrophilic, lower degrees of crystallinity should result in higher 
equilibrium moisture contents. Thus, it is proposed that the total amount of sorbed water is 
proportional to the fraction of amorphous material and is independent of the surface area (152). 
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2.1.7 Raw materials and raw materials suppliers 
The raw materials used in the different experiments are listed in Table 2.3 with the respective 
suppliers  
Table 2.3 – Raw materials and respective suppliers 
Category Substance Supplier 
APIs and Excipients 
Olanzapine Form I Pharmorgana (India) 
Olanzapine Form I Vega Pharma (China) 
PVP K12, K25, K30 (Kollidon
®
) BASF (Germany) 
HPC- LF (Klucel™) Ashland (Germany) 
HPMC; Pharmacoat 615 Syntapharm (Germany) 
PEG 6000 Sigma Aldrich (Germany) 
PEG 40000 Sigma Aldrich (Germany) 
PEG 40000 Serva (Austria) 
Tricalcium Phosphate Tribasic Sigma Aldrich (Germany) 
Polysorbate 80  Croda (Germany) 
MCC (Avicel
®
 PH-101) FMC corporation (USA) 
Sodium lauryl sulphate (Texapon K12 G)  Cognis (Germany)  
Lactose monohydrate (Granulac
®
  200) Meggle Pharma(Germany) 
Salts used for 
Stability Test 
Lithium chloride Sigma Aldrich (Germany) 
Magnesium Nitrate Sigma Aldrich (Germany) 
Sodium Chloride Sigma Aldrich (Germany) 
Potassium Nitrate Sigma Aldrich (Germany) 
Solvents 
Methanol Sigma Aldrich (Germany) 
Ethanol Sigma Aldrich (Germany) 
Methylene chloride Sigma Aldrich (Germany) 
Ethyl Acetate Sigma Aldrich (Germany) 
Toluene Sigma Aldrich (Germany) 
Materials used to 
Prepare Dissolution 
Media 
Hydrochloride Acid Sigma Aldrich (Germany) 
Potassium Dihydrogen Orthophosphate Fischer Scientific (UK) 
Sodium Phosphate Dibasic Sigma Aldrich (Germany) 
Gases 
Nitrogen Air Liquide (Portugal) 
Helium Air Liquide (Portugal) 
Carbon Dioxide Air Liquide (Germany) 
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2.2 Preparation of different polymorphic forms 
2.2.1 Olanzapine anhydrous Form I (OLZ FI) 
For the first study, where Form I and Form II were compared in terms of moisture 
sorption, olanzapine raw material (2 g) was recrystallized. It was suspended in ethyl acetate (20 
ml). The stirred suspension was heated to 76 °C to dissolve the solids (18). The solution was 
then cooled to ambient temperature (25 °C) with formation of crystals (prismatic shape). The 
solid product was collected by filtration under vacuum and dried in an oven (50 °C/ 2 days) 
providing a dried powder, as shown by thermogravimetric evaluation (0.0% mass loss). The 
diffractogram pattern of the crystallized material was according to the Cambridge Structural 
Database (refcode: UNOGIN), identified as monoclinic, with a space group of P21/c (with a = 
10.346 Å, b = 14.902 Å, c = 10.605 Å, β = 100.63°).  
2.2.2 Olanzapine anhydrous Form II (OLZ FII) 
Olanzapine Form II was obtained by recrystallization of raw olanzapine (1 g) from 
methylene chloride. Olanzapine was dissolved in 6 ml of methylene chloride and heated under 
reflux to assure dissolution of any remaining particles (70 
o
C/ 5 min). 0.1 g of a silica gel (37-63 
μm) was added to remove undesirable impurities. The suspension formed was filtered (153). 
The filtrate was rapidly cooled to about  0 
o
C and the lath shaped crystals formed were filtered 
off and dried in an oven (40 C / 2 days) showing no water present (thermogravimetry). The 
diffractogram obtained for this form was in accordance with Form II, which is described and 
characterized in many studies (137, 139, 153, 154). However, it must  be pointed out the 
findings by Rajni et al. (2013) (130) who found that the metastable polymorph II is always 
contaminated with a closely related structure of a third polymorphic Form (III). Fortunately, 
these authors were able to extract one single crystal of Form II, from a mixture of both Forms II 
and III, enabling them to solve the structure. The powder pattern obtained from our dried 
crystals was indexed (Appendix, CELREF software) and consistent with the described Form II 
(monoclinic, space group P21/c, with a =9.8448 Å, b = 16.3409 Å, c = 9.9834 Å, β = 92.280°). 
However, 3 peaks were identified as contamination of Form III, namely at 2Ɵ = 15.07○, 19.28○, 
25.48
○
. Based on the facts that the anhydrous Form II is never formed as a pure form, and the 
fraction of Form III is negligible, authors considered that the continuation of the study was 
justified and valid to enlighten and explain transformations during pharmaceutical production / 
crystallization of olanzapine polymorphs. For a better clarity of presentation, in this work the 
experimentally obtained Form II contaminated with traces of Form III, is referred to as Form II. 
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2.2.3 Olanzapine dihydrate B 
Olanzapine (2.5 g) was suspended in ethyl acetate (25 ml) and toluene (2 ml) under 
stirring before heating (80 C) for complete dissolution. Then, the solution was cooled down to 
60 C prior to the addition of water (30 ml) and further cooled down to room temperature, 
producing crystalline slurry. The crystals of the dihydrate B were collected by filtration under 
vacuum (18) (CSD refcode: AQOMAU01). 
2.2.4 Olanzapine dihydrate D 
Olanzapine (1 g) was suspended in water (10 ml) at room temperature for 7 days under 
stirring before filtration under vacuum for collection of the crystals formed (18) (CSD refcode: 
AQOMAU). 
2.2.5 Olanzapine dihydrate E  
Olanzapine (3g) was suspended in ethyl acetate (60ml) and toluene (3.6 ml). The 
suspension was stirred and heated to 80 C for complete dissolution. The solution was then 
cooled to ambient temperature to produce a slurry. The suspension was filtered, washed with 
water and dried at room temperature (18) (CSD refcode: AQOMAU02). 
 
2.3 Preparation of controlled humidity containers 
To achieve the different relative humidity conditions, desiccators containing saturated 
salt solutions were prepared. Four different humidity containers were prepared using the 
following salts: lithium chloride (11.30 ± 0.27 %, referred in the text as 11 % RH), magnesium 
nitrate (52.89 ± 0.22 %, i.e., 53 % RH), sodium chloride (75.29 ± 0.12 %, i.e., 75 % RH) and 
potassium nitrate (93.48 ± 0.55 %, i.e., 93 % RH) (155). 
 
2.4 Pelletization  
Extruders can be divided into three main categories, according to their feed mechanism: 
screw feed (i.e., single- or twin-screw), gravity-feed (i.e., sieve, gear, cylinder, and basket) and 
ram extruders (108, 109). 
In this work pellets were produced by ram extrusion. Ram extrusion is an example of a 
pumping mode process. A typical configuration is shown in Figure 2.8, where a moving ram 
compacts and extrudes a charge of paste through a die. Laboratory experiments usually feature a 
single-holed die plate, allowing the paste rheology to be characterized using capillary rheometry 
techniques (156). After the production of the extrudates they are spheronized and dried.  
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Figure 2.8 – Schematic representation of a ram extruder. 
2.4.1 Equipment used for the extrusion/spheronisation of materials 
In this work before the extrusion step powders were dry-mixed and kneaded in a 
planetary mixer (Chef, Kenwood, UK). Wet masses were extruded in a ram extruder (Lurga, 
Portugal) adjusted to a universal testing machine (LR 50K, Lloyds Instruments, UK) ﬁtted with 
a load cell to allow the collection of data for the applied force to the ram and its displacement 
(200 mm/min). The wet masses were forced to pass through a die (Length/Diameter = 6) and, 
after extrusion, the extrudates were immediately placed in a spheroniser (radial friction plate 
rotating at 500 rpm, Caleva, UK). The wet pellets were dried in a ﬂuid bed drier (Aeromatic-
Fielder AG, Switzerland) at 45 ºC. 
 
2.5 Preparation of nanoparticles by a technology using fluids in a 
supercritical state 
A pilot scale unit designed for high-pressure extractions and RESS-technique (Sietec-
Sieber, Switzerland) was used for particle design (Figure 2.9). Carbon dioxide was used as 
solvent in all experiments. The equipment comprises a tank, where the solvent is present in 
liquid state. Liquid CO2 is then conveyed via a high-pressure pump into the extraction vessel 
with a volume of 5 l. After dissolution of the material placed inside the extraction vessel is 
completed, or an equilibrium between solid and dissolved material is reached, the supercritical 
solution is passed through a micro valve, which regulates the flow through the 150 μm nozzle. 
Upon passage of the nozzle, the supercritical solution is expanded inside the expansion chamber 
which is equipped with a paper filter to reduce the speed of the gas flow, thereby holding 
particles back in the chamber. To compensate for the cooling effect inside the expansion 
chamber, the mantle temperature was set to 70 °C for RESS experiments and to 55°C for 
RESSAS experiments. The pressure of the expansion chamber was kept at atmospheric 
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conditions (1 bar / 25 ºC). All RESS and RESSAS experiments were conducted during 1 h of 
expansion time with a medium CO2 flow rate between 1.5 and 3.5 kg/h. 
 
 
Figure 2.9 – Pilot unit designed for high-pressure extraction (RESS-technique). 
2.6 Techniques considered for the characterization of materials and 
products 
For each technique the principles of operation are highlighted, followed by the 
specification of the equipment used for the characterization of the materials. 
2.6.1 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) is a thermal analysis technique that looks at 
how a material’s heat capacity (Cp) is affected by temperature. A sample of known mass is 
heated or cooled and the changes in its heat capacity are tracked as changes in the heat flow. 
This allows the detection of transitions such as melts, glass transitions and phase changes (157). 
There are two types of DSCs: Heat flow DSC and Power compensation DSC. The DSC 
used in the experiments carried out (TA Instruments, USA) operates by heat flux and its 
descriptions are schematically represented in Figure 2.10. In heat flow DSC, both sample and 
reference are placed symmetrically inside the furnace and share a common heat source. The 
temperature difference between the sample and the reference is recorded (by thermocouples) 
and converted to a difference in heat flow rate to the sample and to the reference, using a 
suitable calibration factor (158). 
Power compensation DSC involves two separated furnaces, one for the sample and a 
second one for the reference. The temperature difference between the two furnaces is kept 
similar by supplying an electric power to the sample furnace. 
 
Chapter 2 
46 
 
Figure 2.10 – Schematic representation of a heat flow DSC showing the sample and the  
reference pans location within the same furnace. 
 
The differential heat flow measured during DSC experiments can be expressed by: 
 
𝒅𝑸
𝒅𝒕
=
∆𝑻
𝑹
 Eq. 2.1 
Where, dQ/dt represents the heat flow (where Q is heat and t is time); ΔT is the temperature 
difference between the furnace and the sample and R is the thermal resistance of the heat path 
between the furnace and the crucible. 
When a given material is heated, the heat flow signal is determined by the heat capacity 
(Cp) of the material. Heat capacity can be described as the amount of energy required to raise 
the temperature of the sample by 1 K and can be expressed by: 
 
 
𝒅𝑸
𝒅𝒕
= 𝑪𝒑 ×  
𝒅𝑻
𝒅𝒕
 Eq. 2.2 
where dT/dt is the heating rate. 
 
An inert atmosphere is essential in all DSC experiments which can be achieved by 
purging an inert gas into the cell. The selected gas is usually nitrogen however, helium can also 
be used. The purge gas provides more efficient heat transfer between the cell and the sample 
pan, helps to cool the cell, and allows the removing of moisture or oxygen which may 
accumulate and damage the cell over time.  
To obtain accurate experimental results, routine calibrations processes and daily 
verification were carried out. The thermograms presented in this thesis were obtained with a 
Differential Scanning Calorimeter (TA instruments, Q200, USA). Dry N2 was used as the purge 
gas (N45, Air Liquide, 50 ml/min).  
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2.6.2 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) is a technique of thermal analysis which measures 
changes in physical and chemical properties of materials as a function of increasing temperature 
(at a constant heating rate), or as a function of time (at a constant temperature and/or constant 
mass loss). TGA can provide information about physical phenomena, such as second-order 
phase transitions, including vaporization, sublimation, adsorption, absorption and desorption. 
Likewise, TGA can provide information about chemical phenomena including chemisorptions, 
desolvation (especially dehydration), decompositions and solid-gas reactions (e.g. oxidation/ 
reduction). TGA is commonly used to determine selected characteristics of materials that 
exhibit either mass loss or gain due to decomposition, oxidation or loss of volatiles (such as 
water). 
All the thermogravimetric analyses in this work were carried out in a TGA (7, Perkin-
Elmer, USA). The samples were placed in an open platinum crucible. The balance chamber was 
kept under a positive nitrogen flow (Air Liquide N45) of 38 cm
3∙min −1 and helium (Air Liquide 
N55) at a flow of 22.5 cm
3∙min −1 was used as sample purge gas. The mass scale of the 
instrument was calibrated with a standard 100 mg weight. The temperature calibration was 
based on the measurement of the Curie points (TC) of alumel alloy (Perkin-Elmer, TC = 427.35 
K) and nickel (PerkinElmer; mass percentage 99.999%, TC = 628.45 K) standard reference 
materials. 
2.6.3 Scanning electron microscopy (SEM) 
Olanzapine powders and pellets were analyzed by scanning electron microscopy. The 
samples were mounted on aluminum stubs and coated with gold by ion sputtering (JEOL JFC-
1200 Fine Coater, Japan) and were observed under a scanning electron microscope (JSM-5200 
LV, Japan). 
2.6.4 Hot stage microscopy (HSM) 
Hot-stage microscopy (HSM) is a technique widely used to visually examine thermal 
transitions of the materials when the sample is heated or cooled. This analytical technique 
enables the characterization of physical properties of materials such as melting, solid state 
transformations, recrystallizations, etc. as a function of temperature. High resolution color 
cameras and image manipulation software are nowadays powerful accessories of HSM that 
enable the recording of thermal events happening during the heating/cooling cycles of the 
sample (159). 
In this thesis, the size and shape of different olanzapine forms were observed under a 
microscope with polarized light (Olympus BX51, Japan) fitted with a heating stage (Linkam 
THMS350V, UK). 
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2.6.5 Fourier transform infrared (FTIR) 
Fourier transform infrared (FTIR) is a spectroscopic technique that provides information 
about the molecular composition, structure and interactions within a sample based on its 
chemical bonds. In infrared spectroscopy, IR radiation is passed through a sample. Some of the 
infrared radiation is absorbed by the sample and some of it is passed through it (transmitted). 
The resulting spectrum represents the molecular absorption and transmission, creating a 
molecular fingerprint of the sample. Like a fingerprint, no two unique molecular structures 
produce the same infrared spectrum. This makes infrared spectroscopy useful for several types 
of analysis, being commonly used for identification, characterization, quantification, structure 
elucidation, reaction monitoring, quality control and quality assurance (160). 
In this technique, the samples are irradiated with a polychromatic light in the IR region 
(4000 to 400 cm
-1
) and a photon of light is absorbed when the frequency (energy) of the 
absorbed light matches the energy required for a particular bond to vibrate within the sample. In 
order for a vibration to be IR active, the molecular dipole moment must change during the 
vibration. Any IR light that has not been absorbed is transmitted to the sample to a detector. The 
fraction of transmitted light allows the absorbed frequencies to be determined (161). 
The FTIR spectroscopic analyses present in this thesis were performed in an IR 
Affinity-1 Shimadzu spectrophotometer (Japan). For the analyses, the samples were mixed with 
KBr. The mixtures (±200 mg) were compressed into a tablet of 12 mm diameter. The infrared 
spectra were measured at the absorption mode with 64 scans with a resolution of 2 cm
-1
. 
2.6.6 Diffuse Reflectance Infrared Fourier transform (DRIFT) 
DRIFT is an infrared spectroscopy technique used on powder samples. In this technique 
the preparation of the sample does not involve the preparation of a KBr tablet, and, therefore, no 
compression is involved. The preparation of the sample is achieved by the simple dilution of the 
material with nonabsorbent KBr. The spectra are plotted in Kubelka-Munk units versus 
wavenumber. The Kubelka-Munk units plots can relate reflectance to concentration using a 
scaling factor. 
In this work, the dilution of the sample in KBr powder was in appropriate weight 
proportions to obtain spectral absorbance in the range of applicability of the Kubelka–Munk 
transformation (162). 
 𝑲𝑴 = 𝑭(𝑹∞) =
(𝟏−𝑹∞)
𝟐
𝟐𝑹∞
=
𝒌
𝒔
=
𝜺𝒄
𝒔
=
𝟐.𝟑𝟎𝟑𝒂𝒄
𝒔
 Eq. 2.3 
 
where F (R∞) is the Kubelka–Munk spectrum; (R∞) is the absolute reflectance of the spectrum; s 
is the scattering factor, which is dependent on sample preparation; k is the absorption 
coefficient, equal to 2.303ac or ɛc; ɛ is the molar extinction coefficient of the analyte; a is the 
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absorptivity related to analyte species; and c is an analyte concentration. Therefore, KM 
intensity is linearly proportional to the concentration of the analyte if the scattering factor is 
controlled. 
In this work the spectra in diffuse reflectance mode were collected by a Nicolet 6700 
spectrometer (Thermo Electron Corp., Madison, USA) equipped with a deuterated triglycine 
sulfate (DTGS) detector (4000–400 cm−1) and a Smart Diffuse Reflectance (SDR) kit (Thermo 
Electron Corp.). Spectra were obtained from 528 scans with a resolution of 2 cm
−1
 for the 
sample and background experiments. Data was acquired with the OMNIC 8.1 software (Thermo 
Fisher Scientific, USA). 
2.6.7 Near Infrared spectroscopy 
Near-infrared spectroscopy (NIRS) is a spectroscopic method that uses the near-
infrared region of the electromagnetic spectrum from about 700 nm to 2500 nm. NIR can 
typically penetrate much farther into a sample than mid infrared radiation. Near-infrared 
spectroscopy is not a particularly sensitive technique, but it can be very useful in probing bulk 
material with little or no sample preparation. The molecular overtone and combination bands 
seen in the near-IR are commonly very broad, leading to complex spectra; it can be difficult to 
assign specific features to specific chemical components. Multivariate (multiple variables) 
calibration techniques (e.g., principal components analysis, partial least squares, artificial neural 
networks) are often used to extract and summarize the data. 
A Thermo Scientific Antaris FTNIR spectrometer equipped with an InGaAs detector 
was used in this study. The spectrum was acquired with a reflectance probe (Sabir, Thermo 
Nicolet, USA) having an illumination area with a diameter of 0.5 cm. The equipment is 
controlled via the RESULTS software (Thermo Scientific, USA).  
2.6.8 X-ray powder diffraction (XRPD) 
X-ray powder diffraction (XRPD) is a rapid analytical technique primarily used for 
phase identification of a crystalline material and can provide information on unit cell 
dimensions.. X-rays are generated by a cathode ray tube which works as a source of electrons, 
which are then accelerated and strike a target (the anode) and produces a characteristic X-ray 
spectrum (163). When X-rays pass through the sample they interact with the electron cloud of 
atoms in the molecules and the intensity and position of the emergent X-rays are recorded by a 
detector. The interaction of the incident rays with the sample produces constructive interference 
(and a diffracted ray) when conditions satisfy Bragg’s Law (nλ=2d sin θ, where n is a positive 
integer and λ is the wavelength of incident wave). This law relates the wavelength of 
electromagnetic radiation to the diffraction angle and the lattice spacing in a crystalline sample. 
These diffracted X-rays are then collected, processed and counted. By scanning the sample 
through a range of 2θ angles, all possible diffraction directions of the lattice should be attained 
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due to the random orientation of the powdered material. The regularly spaced atoms (electrons) 
in a crystal solid can be described by imaginary planes and the distance between these planes is 
called the d-spacing. The intensity of the d-space pattern is directly proportional to the number 
of electrons (atoms) that are found in the imaginary planes. Every crystalline solid will have a 
unique pattern of d-spacings (known as the powder pattern).  Therefore, XRPD is a gold 
standard technique in the characterization of pharmaceutical materials in the solid state. It is 
mainly used for fingerprinting and quantification analysis due to its high sensitivity to small 
chemical changes. Prior to the analysis of the material, it should be finely ground and 
homogenized and average bulk composition is determined. 
 
In this work, XRPD analyses of solids were performed in two different equipment: 
Equipment 1: The X-ray powder diffractograms were recorded at room temperature by a 
diffractometer (Philips PW1730, Netherlands) with automatic data acquisition software (APD 
Philips v.35B, Netherlands) using a Cu Kα radiation source. The tube amperage was 30 mA and 
the tube voltage 40 kV. Equipment 2: The structural characterization of the samples was carried 
out by X-ray powder diffraction (XRPD) on an Analytical X’Pert PRO apparatus (Netherlands) 
set with a vertical PW 3050/60 goniometer (θ-2θ mode) equipped with X’Celerator detector and 
with automatic data acquisition (X’Pert Data Collector (v2.0b) software), using a 
monochromatized CuKa radiation as incident beam, 40 kV–30 mA. The scanning range was 
based on the characteristics peaks of each sample. 
2.6.9 Dissolution testing 
Dissolution testing of pharmaceutical solids is a very important test in drug product 
development, manufacturing and in regulatory assessment of the drug product quality. It 
provides essential information on the rate and extent of drug dissolution (164). 
The dissolution process of solids comprehends two main steps. Firstly, the molecules at 
the solid-liquid interface are wetted, solvated and detached from the solid surface. Secondly, the 
solvated molecules diffuse away from the interface to the bulk solution. Thus, it is the diffusion 
rate of the molecules in the media and/or the wetting and solvation of the surface molecules that 
determine the dissolution profile of a certain compound (165). 
The dissolution rate (δM/δt) of a solid in a liquid can be described by the  
Noyes-Whitney equation as presented below: 
 
𝜹𝑴
𝜹𝒕
= 𝑨 ×
𝑫
𝒉
 (𝑪𝒔 − 𝑪𝒃) Eq. 2.4 
where, M is the mass; t is the time; A is the surface area of the undissolved solid in contact with 
the solvent; D is the diffusion coefficient (m
2
/s); h is the thickness of diffusion layer; Cs is the 
solubility; Cb is the concentration in the bulk solution; and Cs-Cb is the concentration gradient. 
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The above equation assumes that the surface area and thickness of the hydrodynamic diffusion 
layer remain constant. 
Dissolution experiments were carried out using a dissolution apparatus (AT7, Sotax, 
Switzerland, paddle method). Each vessel was filled with 900 ml of dissolution medium, the 
temperature was set at 37.0±0.5 
o
C and a rotation speed of 50 rpm was used. The concentration 
of each API through the dissolution tests was assessed spectrophotometrically at the respective 
wavelength of maximum absorbance, λmax, using a UV spectrometry (λ= 254 nm, Hitachi U- 
2000, Japan). 
Dissolution profiles may be considered similar by virtue of the overall profile similarity 
and similarity at every dissolution sample time point. The comparison of dissolution profiles 
may be carried out using model independent methods. A simple model independent approach 
uses a difference factor (f1) and a similarity factor (f2) to compare dissolution profiles  (166). 
The concept of similarity factor (f2) has been endorsed by the Food and Drug Administration 
(FDA) turning this factor widely adopted in formulation and development and accepted by 
health authorities (167). The difference factor (f1) calculates the percentage (%) difference 
between the two curves at each time point and is a measurement of the relative error between 
the two curves: 
 𝐟𝟏 = {[∑ |𝐑𝐭 − 𝐓𝐭|
𝐧
𝐭=𝟏 ]/[∑ 𝐑𝐭
𝐧
𝐭=𝟏 ]} ∗ 𝟏𝟎𝟎 Eq.  2.5 
where, n is the number of time points; Rt is the dissolution value of the reference batch at time t; 
and Tt is the dissolution value of the test batch at time t. The similarity factor (f2) is a 
logarithmic reciprocal square root transformation of the sum of squared error and is a 
measurement of the similarity in the percentage (%) dissolution between the two curves: 
 𝐟𝟐 = 𝟓𝟎 ×  𝐥𝐨𝐠 {[𝟏 +  (
𝟏
𝐧
)  × ∑ (𝐑𝐭 − 𝐓𝐭)
𝟐𝐧
𝐭=𝟏 ]  
−𝟎.𝟓 × 𝟏𝟎𝟎} Eq. 2.6 
For 2 curves to be considered similar,  f1 values should be close to 0 and f2 values should 
be close to 100. Generally, f1 values up to 15 (0-15) and f2 values larger than 50 (50-100) ensure 
sameness or equivalence of the two curves and, therefore, of the performance of the test and 
reference pharmaceutical products. This independent model method is most suitable for 
dissolution profiles comparison when more than four dissolution sampling time points are 
available. Furthermore, the following recommendations should also be considered (167): 
 The dissolution measurements of the test and reference batches should be made under 
the exact same conditions. The dissolution time points for both profiles should be the 
same (e.g., 10, 20, 30, 60 min). The reference batch used should be the most recently 
manufactured product; 
 Only one measurement should be considered after 85% dissolution of both products.  
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 To allow use of mean data, the percent coefficient of variation at the earlier time points 
(e.g., 15 min) should not be more than 20%, and at other time points should not be more 
than 10%. 
To compare the dissolution profiles between 2 drug products, model-dependent 
approaches such as zero-order, first-order, Hixson-Crowell, Higuchi, quadratic, Weibull or 
logistic models may be applied. 
2.6.9.1 Zero-order model 
For zero-order release kinetics, the dissolution of a drug molecule is only a function of 
time. This model holds true only in the case of very slow drug release. For instance, this relation 
can be used to describe the drug dissolution of several types of modified release pharmaceutical 
dosage forms, such as some transdermal systems, matrix tablets with low soluble drugs, coated 
forms, osmotic systems, etc. 
Zero-order release is therefore modeled as follows: 
 𝐖𝐨 − 𝐖𝐭 = 𝐊𝐭 Eq.2.7 
where, W0 is the initial amount of drug in the pharmaceutical dosage form; Wt  is the amount of 
drug in the pharmaceutical dosage form at time t; and K is the zero-order release constant (168). 
2.6.9.2 First-order model 
Nowadays most drug delivery systems present first-order drug release kinetics, where 
the plasma level of the drug is extremely high after administration and then decreases 
exponentially. This has disadvantages such as minimal therapeutic efficacy due to reduced drug 
levels or drug toxicity which can take place at high concentrations (169). The First-Order model 
is derived from First-Order release kinetics, which states that the change in concentration with 
respect to change in time is dependent only on concentration. 
The release of the drug which followed first order kinetics can be expressed by the 
equation: 
 
𝐝𝐂
𝐝𝐭
= −𝐊𝐂 Eq. 2.8 
where, C is the concentration of the drug molecule; and K is first order rate constant expressed 
in units of time. 
 Integrating the equation, one has: 
 𝐥𝐧(𝐂𝐭) = 𝐥𝐧 (𝐂𝟎) + 𝐊𝐭 Eq. 2.9 
where, C0 is the initial concentration of drug; Ct is the concentration of the drug at the time t; 
and K is the first order rate constant (168). This relationship can be used to describe the drug’s 
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dissolution in pharmaceutical dosage forms, such as those containing water-soluble drugs in 
porous matrices. 
2.6.9.3 Hixson and Crowell model 
Hixson and Crowell proposed an equation which expresses the rate of dissolution based 
on the cubic root of particle weight: 
 𝐖𝟎
𝟏
𝟑 − 𝐖𝐭
𝟏
𝟑 = 𝐊𝐬𝐭 Eq. 2.10 
where, W0 is the initial amount of drug in the pharmaceutical dosage form; Wt is the remaining 
amount of drug in the pharmaceutical dosage form at time t; and K is a constant incorporating 
the surface–volume ratio (168). This expression is applicable to pharmaceutical dosage forms in 
which dissolution happens in planes parallel to the drug’s surface (e. g., tablets), maintaining the 
drug’s original geometry. The equation 2.10 can be rewritten as: 
 𝐖𝟎
𝟏
𝟑 − 𝐖𝐭
𝟏
𝟑 =
𝐊´𝐍
𝟏
𝟑𝐃𝐂𝐬𝐭
𝛅
 Eq. 2.11 
where, N is number of particles; K’ is a constant related to the surface area, shape and the 
density of the particle; D is the diffusion coefficient; C is the solubility in the equilibrium at 
experience temperature; and δ is the thickness of the diffusion layer. The shape factors for cubic 
or spherical particles should be kept constant if the particles dissolve in an equal manner in all 
sides.  
2.6.9.4 Higuchi model 
This is the first mathematical model that describes drug release from a matrix system. 
This model is based on the following hypothesis: (1) initial drug concentration in the matrix is 
much higher than drug solubility; (2) drug diffusion takes place only in one dimension (edge 
effect should be avoided); (3) drug particles are much smaller than thickness of system; (4) 
swelling of matrix and dissolution are small or negligible; (5) drug diffusivity is constant; and 
(6) perfect sink conditions are always attained in the release environment  (168).  The study of 
dissolution from a planar system having a homogeneous matrix can be obtained by the equation: 
 𝒇𝒕 =
𝑴𝒕
𝑨
= √𝑫(𝟐𝑪 − 𝑪𝒔). 𝑪𝒔𝒕 Eq. 2.12 
where: Mt is the cumulative absolute amount of drug released at time t; A  is the surface area of 
the controlled release device exposed to the release medium; C is the drug’s initial 
concentration; CS is the drug solubility in the matrix media; and D is the diffusivity of the drug 
molecules (diffusion constant) in the matrix substance (170). 
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2.6.9.5 Korsmeyer–Peppas model 
Korsmeyer–Peppas model propose a simple relationship which describes the release of 
a drug from a polymeric system according to the following equation (171) : 
 𝒇𝒕 = 𝑲𝒕
𝒏 Eq. 2.13 
where, ft is fraction of drug released at time t; k is the release rate constant; and n is the release 
exponent. The diffusion of a drug from a controlled release polymeric system with the form of a 
plane sheet of thickness δ can be represented by:  
 
𝝏𝒄
𝝏𝒕
= 𝑫 (
𝝏𝟐𝑪
𝝏𝒙𝟐
) Eq. 2.14 
where, D is the drug diffusion coefficient (concentration independent). If drug release occurs 
under perfect sink conditions, the following initial and boundary conditions can be assumed: 
 𝐭 = 𝟎     −
𝐝
𝟐
< 𝐱 <
𝐝
𝟐
     𝐜 = 𝐜𝟎 Eq. 2.15 
 𝐭 > 𝟎         𝐱 = ±
𝐝
𝟐
         𝐜 = 𝐜𝟏 Eq. 2.16 
where, c0 is the initial drug concentration in the device; and c1 is the concentration of the drug at 
the polymer–water interface. 
The solution equation under these conditions was developed initially by Crank: 
 
𝑴𝒕
𝑴∞
= 𝟐 (
𝑫𝒕
𝜹𝟐
)
𝟏
𝟐
[𝝅 −
𝟏
𝟐
+  ∑ (−𝟏)𝒏𝒊 𝒆𝒓𝒇𝒄 
𝒏𝜹
𝟐√𝑫𝒕
∞
𝒏=𝟏 ] Eq. 2.17 
A sufficiently accurate expression can be obtained for small values of t due to the 
elimination of the second term in Eq. 2.17, becoming: 
 
𝑴𝒕
𝑴∞
= 𝟐 (
𝑫𝒕
𝜹𝟐
)
𝟏
𝟐 = 𝒂𝒕
𝟏
𝟐 Eq. 2.18 
Hence, when the diffusion is the main drug release mechanism, a graphical 
representation of the drug amount released in the referred conditions versus the square root of 
time should form a straight line. Under certain experimental situations the release mechanism 
deviates from the Ficks equation, following an anomalous behavior (non-Fickian). In these 
cases a more generic equation can be used: 
 
𝑴𝒕
𝑴∞
=  𝒂𝒕𝒏 Eq. 2.19 
Where, n value is used to characterize different releases for cylindrical shaped matrices; in the 
case of cylindrical tablets, 0.45 ≤ n corresponds to a Fickian diffusion mechanism, 0.45 < n < 
0.89 to non-Fickian transport, n = 0.89 to Case II (relaxation) transport, and n > 0.89 to super 
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case II transport. In order to determine the value of the exponent ‘n’, only the portion of the 
release curve where Mt/ M∞ < 0.6 should be used (168). 
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Chapter 3 -  Production, characterization and stability over storage of 
two olanzapine anhydrous polymorphic forms 
 
3.1 Abstract 
The focus of this study was the understanding of the hydrate transformations of 
anhydrous olanzapine forms I and II upon exposure to different moisture conditions (11, 53, 75, 
93% RH) and direct contact with water (e.g. aqueous slurry) and the impact of hydration on the 
aqueous dissolution rates of the polymorphs. The kinetics of the transformations and the 
identification of polymorphs were evaluated by differential scanning calorimetry, 
thermogravimetry, infrared and X-ray powder diffraction. The results showed that anhydrous 
forms I and II have undergone water vapor phase induced transformations at 93% and 75% RH, 
respectively. At 93% RH, anhydrous forms I and II showed to hydrate into dihydrates D and B, 
respectively, the latter with a higher hydration rate. The conversion of form I into the dihydrate 
D showed to affect the dissolution rate of olanzapine (f2<50). As slurries both forms showed to 
hydrate into a mixture of two different forms – dihydrate B and higher hydrate. The study 
provided an understanding of the conversion pathways of the different forms when they were 
exposed to humid air or aqueous environments, resembling the transformations that might occur 
during processing, storage or during the persecution of dissolution tests to assess the quality of 
dosage forms delivering olanzapine. 
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3.2 Introduction 
Approximately one third of all compounds used in the manufacture of medicines are 
able to hydrate. The new unit cells, in which water is a part of the crystal, may be obtained 
presenting completely new properties (172).  
The behavior of the anhydrous form of a drug substance in equilibrium with water can 
be reflected by phase diagrams which are drug substance specific (81, 173). A crystal hydrate is 
typically the most stable form of a drug substance in an aqueous environment, presenting as a 
consequence lower solubility and dissolution rates than its anhydrous counterpart (174) . 
Therefore, the conversion of an anhydrous form into a hydrate form, during processing or 
storage may modify the bioavailability of the drug, particularly when the dissolution in an 
aqueous environment is the rate limiting step for the  absorption of that drug  (5, 70). 
The study of the physical stability of both anhydrous and hydrate forms of olanzapine, 
as a function of water vapor pressure, is important to understand and prevent a reduction on the 
therapeutic performance of the drug as a result of their inter-conversion (75, 175). Thus, 
understanding the stabilities of the different forms with a potential interplay is paramount to the 
selection of the appropriate storage conditions for the molecular structure to be kept stable (6). 
When active pharmaceutical ingredients (API) are subjected to different water vapor pressures, 
solid-state polymorphic transitions are likely to take place (176). A solid-state conversion 
requires the migration of water through the crystal lattice and a potential change in the crystal 
structure.  Often, the kinetics of phase transition via a solid-state mechanism can be very slow, 
and in the early stages of drug development it is generally not possible to run an extended 
stability program, which enhances the difficulties to select the appropriate form of the material 
to progress the program (177).   
Olanzapine (OLZ) is a drug that can crystallize in several forms, including various 
anhydrates, solvates and hydrates (18). All olanzapine crystal phases present a structural 
building block which is composed by a dimeric unit formed by two racemic olanzapine 
molecules. This racemic pairs are connected to each other through NH
…
N hydrogen bonds in 
anhydrous forms or by solvate-mediated interactions in solvates and hydrates (18).  
The first reported anhydrous form of olanzapine (referred to herein as Form II) revealed 
to be metastable and underwent discoloration on exposure to air and moist environments (135). 
This discoloration revealed to be caused by the formation of olanzapine hydrates, which present 
a less intense color than anhydrous olanzapine. However, the type of hydrates obtained, the 
moisture required, expressed as relative humidity, needed for their appearance and the impact of 
such phenomenon on the performance of the olanzapine solid dosage forms has not been 
reported, to the authors’ best knowledge.  
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The second anhydrous polymorph to be reported (referred to herein as Form I) showed 
to have a higher stability and therefore is well adapted for manufacture purposes (136). 
However, during its production, the stress created by temperature, mechanical treatment and the 
use of certain solvents (e.g. methylene chloride) may result in the concomitant appearance of 
both anhydrous polymorphic Forms I and II as the final product (132). Because both forms have 
different crystalline structures, a contamination of Form I by Form II may result in changes on 
the physical characteristics of the final product, which may inﬂuence the therapeutic 
performance of olanzapine. 
Although many studies have been conducted on the characterization of these two 
anhydrous forms (e.g. thermal behavior, infrared spectroscopy and X-ray powder diffraction, 
(137-139), there still is a lack of information about the hydration mechanism and rate of 
conversion of these anhydrous forms in response to exposure to  humid environments (e.g. 
slurries or different relative humidity environmental conditions) and the potential ability of 
hydrated forms to dehydrate into the ones considered before storage or processing. The 
identification and quantification of such conversions is of importance to firstly understand and 
secondly prevent a change on the drug’s structure with a deleterious impact on its therapeutic 
performance due to solubility differences of the different polymorphs reflecting different 
crystalline structures. Furthermore such knowledge can also allow the selection of the 
appropriate storage conditions for a particular molecular structure to be kept stable improving 
the final quality of the medicine 
The type of hydrates, the conditions needed to promote their appearance and the impact 
of such phenomenon on the performance of the olanzapine solid dosage forms has not been 
reported, to the authors’ best knowledge. Furthermore the consequences of those expositions on 
dosage form’s performance, namely olanzapine dissolution rate have not been studied. This 
study, therefore, gains a special interest in the olanzapine molecule since it may crystallize into 
different hydrates (namely, dihydrate B, D, E and one higher hydrate form) and their mixtures.  
Olanzapine is a drug commonly used in the treatment of schizophrenia, an illness which 
requires patients to be kept clinically stable and in good compliance with the treatment. Thus, 
minor changes on olanzapine’s bioavailability turns patients unstable followed by a decrease on 
compliance. Furthermore, the small recommended dose for olanzapine (maximum dose of 20 
mg per day) (178), enhances potential problems due to changes on the solubility of olanzapine 
with impact on the drug dissolved and then on absorption into the plasmatic stream, simply due 
to minor modifications of the crystalline structure of the drug. 
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3.3 Purpose 
This study aims, firstly, to compare the stability of 2 anhydrous Forms (I and II) during 
storage at different relative humidity, to identify the relative humidity and the exposure time 
needed to promote crystalline changes in both anhydrous polymorphic structures. Secondly, to 
prepare two model tablet formulations containing the different forms obtained before and after 
exposure to humidity, focusing on the understanding of the relationship between the solid state 
of the drug and their dissolution rate. Finally, the conversions of the hydrates which occur due 
to exposure to moisture are compared with the hydrate transformations which occur in aqueous 
environments. The studies help to identify the phase transitions that may occur during storage or 
processing of olanzapine raw-materials. 
 
3.4 Material and Methods 
3.4.1 Production of the different olanzapine forms 
Olanzapine anhydrous Form I (Form I), anhydrous Form II (Form II), dihydrate B 
(dihyd.B), dihydrate D (dihyd. D) and dihydrate E (dihyd. E) were prepared as shown in 
materials and methods section. Olanzapine raw-material was purchased from Pharmaorgana 
laboratories (India). 
3.4.2 Samples preparation and storage under controlled relative humidity environment  
Particle size, size distribution and habit have been shown to influence significantly the 
water uptake, and therefore, the approach of gentle grinding and sieving the materials was 
necessary to obtain the two crystal forms with similar particle size and size distribution in the 
same range (179). In the present study, the materials were gentle milled for 1 min with a mortar 
and a pestle and subsequently sieved (< 63 um) in order to obtain the two crystalline forms 
within the same particle size and size distribution. The materials showed not to undergo any 
solid phase transition during milling.  After sieving, the anhydrous Forms I and II of olanzapine 
were stored in different controlled relative humidity environments (24 C) in desiccators 
containing saturated salt solutions (155), namely, lithium chloride (11 % RH), magnesium 
nitrate (53 % RH), sodium chloride (75 % RH), potassium nitrate (93 % RH). Samples of 
olanzapine powder were collected at 0, 7, 14, 21, 30, 60 and 180 days of storage prior to 
characterization. 
3.4.3 Preparation of tablets 
Tablets containing olanzapine were prepared to evaluate the impact of moisture which 
might be present as absorbed/adsorbed within the tablets on the dissolution performance of 
olanzapine. Six sets of tablets (150 mg) were prepared and characterized for each olanzapine 
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polymorph (5mg) – OLZ FI, OLZ FII, prior and after 6 month storage at 93% RH condition. All 
olanzapine particulate samples were sieved (<63 µm) and dissolution tests conducted under sink 
conditions. The excipients for tableting were lactose monohydrate (145 mg, Granulac 200 
Meggle, Germany) or a mixture of 40% (58 mg) of lactose monohydrate and 60% (87mg) of 
microcrystalline cellulose (Avicel, FMC Corp., USA). The different formulations aimed to 
evaluate the release profile of olanzapine in immediate and sustained release solid dosage forms. 
Tablets were manufactured with punches and die with 6.5 mm in diameter, at compaction forces 
of 20.0 kN applied by the upper punch moving at a speed of 10 mm/min, assembled in an 
universal mechanical press (LR 50K, Lloyd’s Instruments, UK).  
3.4.4 Experiments with Slurries  
In order to evaluate the conversion of anhydrous forms into hydrated forms in aqueous 
environments, anhydrous powders where initially suspended in aqueous solutions. The 
olanzapine suspensions were prepared by adding 5 ml of water to 50 mg of each anhydrous 
olanzapine form. The slurries were stirred with an overhead mechanical stirrer at approximately 
250 rpm. Samples of 50 µl were taken at 15, 30, 60, 90, 120 and 1440 min of agitation and 
filtered under vacuum, before their characterization carried out as described for the pure 
polymorphs. 
3.4.5 Characterization of different OLZ polymorphic forms 
Thermo Gravimetric Analysis (TGA) 
Thermogravimetric analysis (Perkin-Elmer TGA 7, USA) was performed on olanzapine 
samples (3-4 mg) placed in an open platinum crucible heated at 10 C/min scanning rate 
between 20 to 150
o
C. The balance chamber was kept under a positive pressure nitrogen flow 
(N45, Air Liquide, Portugal) of 38 cm
3
/min and helium (N55, Air Liquide, Portugal) at a flow 
rate of 22.5 cm
3
/min was used as the sample purge gas.   
Differential scanning calorimetry (DSC) 
Thermograms of different olanzapine forms were obtained with a Differential Scanning 
Calorimeter (TA instruments, Q200, USA) after calibration with indium (TA instruments, USA; 
Tfus =156.55°C, ΔfusH = 28. 51 J/g). Dry N2 was used as the purge gas (50 ml/min). For 
anhydrous olanzapine, 2 to 3 mg were placed in hermetic crucibles, while for stored olanzapine 
samples the same amount was placed only in non-hermetic crucibles. The option to use non-
hermetic crucibles was made in order to avoid the possible rupture of the crucibles due to 
pressure of water vapor and also to prevent the appearance of metastable forms due to free water 
vapor in the atmosphere around the crystal (180). Samples were heated up at 10 C/min within 
0-210 C temperature range. 
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Assessment of particle size distribution 
The particle size distribution was measured with laser diffractometry (LD) using a 
Mastersizer 2000 (Malvern, Germany) equipped with a Hydro 2000S sample dispersion unit. 
The olanzapine powder was suspended in a dispersant solution (0.1% polysorbate in water) in 
order to achieve a good contact between the particles and surfactant/dispersant and to efficiently 
promote OLZ particle disaggregation. The suspension was shaken with a vortex prior to the 
measurement. The obscuration values were between 2 and 5% for the different measurements 
(n=6). Particle size and size distribution were obtained from the manufacturer’s software 
(Malvern, Germany). 
Hot stage microscopy 
The size and shape of different olanzapine anhydrous forms were observed under the 
microscope with polarized light (Olympus BX51, Japan) fit with a heating stage in order to 
visualize of the change in shape of the crystals of form II with temperature (Linkam 
THMS350V, UK). The sample of anhydrous form II was heated up to 220 ºC with a scan rate of 
10 ºC/min. 
X-Ray powder diffraction (XRPD) 
The X-ray powder diffractograms were recorded at room temperature by a 
diffractometer (equipment 1: Philips PW1730, NL). The samples were mounted on an 
aluminum sample holder and  scans in the range of 7 to 35° (2θ) in the continuous mode, with a 
step size of 0.015 (2θ) and an acquisition time of 1 s/step. 
Diffuse Reflectance Infrared Fourier Transformed Spectroscopy (DRIFT) 
Different olanzapine samples were diluted in KBr (olanzapine concentration about 0.1 
% w/w). The spectra in diffuse reflectance mode were collected on a Nicolet 6700 spectrometer 
(Thermo Electron Corp., Madison, WI), with 528 scans being acquired for each sample with a 
resolution of 2 cm
−1
. 
3.4.6 Quantification of olanzapine hydration using the DRIFT spectra  
This analytical method has been effectively used in combination with a chemometric 
technique, partial least squares (PLS) for quantification of polymorphs. 
PLS or projection to latent structures has been frequently applied in the area of 
chemometrics. It is a factor analysis method that relates a matrix of independent variables, X, 
with a matrix of dependent variables, Y. PLS decomposes both X and Y matrices, the spectral 
data and polymorph concentrations, respectively, into their principal components, i.e. obtaining 
score and loading matrices. The principal components are called latent variables or PLS 
components. These latent variables are obtained by maximizing the variance of the data. The 
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number of latent variables is much lower than the number of original variables. However, PLS 
may possibly extract as much of the initial information as possible while acquiring maximum 
correlation between the latent variables of X and Y (181).  
The number of latent variables for the PLS algorithm is determined using the full cross-
validation method. With cross-validation, some samples are kept out of the calibration and used 
for prediction. This process is repeated so that all samples are kept out once. The value for the 
left out sample is then predicted and compared with the known value. The prediction error sum 
of squares (PRESS) obtained in the cross-validation is calculated each time a new latent variable 
is added to the model. The optimum number of latent variables is concluded as the first local 
minimum in the PRESS vs latent variable plot. PRESS is defined as: 
 
𝐏𝐑𝐄𝐒𝐒 = ∑ (?̂? − 𝐲)𝟐𝐧𝐢=𝟏                Eq. 3.1 
Where ŷ is the estimated value of the i the object and y is the corresponding reference 
value of this object. The goodness of fit is evaluated by root mean squared error (RMSE) which 
is defined as: 
𝐑𝐌𝐒𝐄 = √
𝐏𝐑𝐄𝐒𝐒
𝐧
                                                                            Eq.  3.2 
Where n is the number of samples. 
 
For the quantification of the hydration of anhydrous Forms I and II during storage, 
reference samples were prepared as binary mixtures containing different fractions of OLZ 
FI/dihydrate D and OLZ FII/dihydrate B prepared at 10% (w/w) intervals by geometric mixing 
in a mortar (n=3). These samples were analyzed and their spectra collected. From this 
evaluations, a set of spectra collected at each concentration were set aside to form the test set. 
Internal cross validation (one sample removed per cycle) was performed to the calibration 
samples. Model equations were performed using The Unscrambler X (CAMO Software AS, 
Norway) software. The informative regions between 950 and 1025 cm
-1
 were selected for 
comparison and analysis of the anhydrous FI/dihydrate D calibration samples, whereas the 
regions between 740-806 cm
-1
 were selected for use in anhydrous FII/dihydrate B calibration 
sample. 
The selection of these spectral regions for calibration was based on the wavenumber 
regions that showed the largest differences between the components and therefore provided the 
greatest contribution to the linear regression equations. The data was SNV (standard normal 
variate) transformed and mean centered prior to analysis (182). The quality of the model was 
evaluated by the root mean square error of calibration (RMEC, calibration error, i.e. the 
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residuals of the calibration data), prediction (RMSEP, prediction error, i.e. measured on 
independent testing set and compared to reference values),cross-validation (RMSECV, errors 
are calculated on test/train splits using a cross validation scheme for the splitting) and by the 
squared correlation coefficient of the experimental and predicted values (R
2
) and the cross-
validation squared coefficient (Q
2
).  
3.4.7 Dissolution tests of different olanzapine entities 
Dissolution tests were performed for olanzapine tablets. The dissolution tests were 
carried out in a dissolution apparatus (AT7, Sotax, Switzerland), paddle method (50 rpm), 900 
ml of phosphate buffer (pH= 6.80, 37 °C  0.5 °C, n=3). Samples were collected at time 
intervals of 5, 10, 15, 20, 30, 40, 50, 60, 90, 120 min for fast-released tablets  (drug/lactose) and 
at time intervals of 5, 15, 30, 60, 90, 120, 240, 360, 480, 720, 980 for sustained release tablets 
(drug/MCC/lactose) . The fraction of released olanzapine was determined by UV spectrometry 
(λ= 254 nm, Hitachi U- 2000, Japan).  
The comparison of the dissolution performances between the different olanzapine 
samples was based on the similarity factor (f). This is an independent model that measures the 
similarity in percentage between two proﬁles of dissolution (167). f2, which is the reciprocal 
logarithmic square root transformation of the square error of results (Eq. 2.6), was used to 
compare the dissolution profiles. When f2 values are higher than 50 (i.e., 50–100) it indicates 
the equivalence of both compared proﬁles. In the comparative dissolution testing, only one 
measurement was considered after both compared profiles have reached 85% dissolution. 
3.5 Results 
3.5.1 Characterization of olanzapine anhydrous crystal forms 
Both OLZ anhydrous forms were characterized for particle size and size distribution, 
thermal, infrared and X-ray powder diffraction analysis before storage. Starting materials of 
olanzapine presented broad particle size distributions, with spans of 2.10 and 1.64 for Forms I 
and II, respectively, with Form I samples presenting smaller particles size than Form II particles 
(Table 3.1). 
Table 3.1 – Particle size distribution (µm) of crystalized OLZ FI and FII 
Material d10 (µm) d50 (µm) d90 (µm) Span 
OLZ FI 8.41 ± 0.99 18.35 ± 1.83 46.94 ± 3.79 2.10 
OLZ FII 12.38 ± 2.10 22.03 ± 2.66 48.43 ± 4.78 1.64 
d10, 50, 90 - maximum particle diameter below which 10, 50, 90 % of the sample population of particles 
exists 
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The thermogram of Form I showed a melting endotherm at Tmonset=194.08  0.18 
o
C with 
an enthalpy of ∆H=133.56  1.90 J/g, whereas Form II presented 2 melting endotherms at 
Tmonset=177.69  0.73 
o
C and at Tmonset=193.78  0.37 
o
C (Figure 3.1, a).  
In the thermogram of Form II, the first endotherm represents melting of the material while 
the second endotherm represents the melting of Form I, after recrystallization of the first form 
into the latter form. The exothermic event between both endotherms represents the 
crystallization of Form I from the melt, due to the higher thermodynamic stability of Form I in 
comparison to the molten Form II (137, 138). The coexistence of both forms in the thermal 
range of 160-180C explains the difficulty of measuring the changes on enthalpy of the 
melting/recrystallization phenomena (137).  
Hot-stage polarized light microscopy analysis has shown crystals of OLZ FII, which were 
lath-shaped (before milling), converting to plate shaped crystals when heated above their 
melting temperature, which can be assumed as the conversion to Form I (Figure 3.1 a). 
For both forms, an amorphous state became visible when the samples were cooled 
down, with a glass transition at Tg = 70.04  0.19 C (Figure 3.1, a) and no recrystallization 
occurring in the second heating run. The thermogravimetric analysis has shown that the 
degradation of Form I started after the melting, with degradation at Tonset255 
o
C, independently 
of the polymorphic form.  
In respect to the diffraction analysis of both forms of the powders, each polymorphic 
form showed distinctive peaks, which could be used for their identification (2 = 8.62, 12.46, 
14.64 for Form I and 2 = 10.91, 14.01, 18.49, 19. 73 for Form II) (Figure 3.1 b) with the 
maxima being identical to data previously reported for these structures (139).   
Concerning the infrared spectra of anhydrous Forms I and II, the differences in their 
spectra were mostly related to the atoms involved directly or indirectly with the intermolecular 
N10H-N5 hydrogen bond which is the primary intermolecular interaction of anhydrous 
olanzapine structures (138). For instance, the stronger intermolecular hydrogen bond in Form I 
results in a lower NH stretching wavenumber in Form I (3219.6cm
-1
) than in Form II 
(3237.9cm
-1
) (Figure 3.1 c). Both polymorphic forms adopt different packing arrangements of 
the olanzapine racemic pairs (i.e., the building block of the olanzapine crystal), therefore, the 
atoms which support the molecular skeleton are less sensitive to changes of the crystalline form 
than the atoms at the rim of the molecule (138). Hence, both forms can easily be distinguished  
through the maxima in the spectra at 671, 746, 887, 965 and 1009 cm
-1
 in OLZ Form I that shift 
to 661, 758, 904, 971, 1005 cm
-1
 in OLZ Form II. 
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Figure 3.1 – Characterization of olanzapine forms by different techniques: 
a) Thermograms of anhydrous Forms I and II. Form II crystal shape modifications of Form 
II on heating. 
b) Diffractograms (XRPD) of OLZ Form I (*) and Form II (
.
) 
c) Infrared spectra (DRIFT) of OLZ Form I and Form II. The arrow represents the shift in 
NH stretching band. 
3.5.2 Dihydrates of olanzapine 
Three olanzapine dihydrates were produced in order to understand and characterize the 
crystalline changes that both anhydrous forms may undergo over their storage, at different 
relative humidity environments. The diffractograms produced from the 3 dihydrates by powder 
diffraction were shown to be in good agreement with the data previously reported for these 
structures (18). On the other hand, to the best of our knowledge, there is no data in the literature 
related to the identification by infrared spectroscopy of dihydrates B, D and E. The data 
obtained by DRIFT in this report revealed that this was a powerful technique for identification, 
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characterization and quantification of the potential presence of mixtures of olanzapine 
hydrate/anhydrous content in the same samples. In fact, all 3 dihydrates could be distinguished 
between them by their fingerprint region. As an example one may cite the out of plane bending 
of the benzene moiety (138) which has a distinct wavenumber for each form.  This band was 
located respectively, at 745 cm
-1
 and 757 cm
-1 
in Forms I
 
and II and it has shifted to 750 cm
-1
 in 
dihydrate D,
 
767 cm
-1 
in
 
dihydrate B and 755 cm
-1 
in dihydrate E (Figure 3.2). 
Comparing the infrared spectra of the dihydrate forms with the anhydrous forms, one may 
find several differences among them, especially in the region between 3300 and 3550 cm
-1
 
(Figure 3.2). In that region, all dihydrates present two broad bands which are not observed in the 
anhydrous forms. The appearance of these bands was related to the OH-stretching due to 
hydrogen-bonded water molecules present in the crystal (183, 184).  
 
Figure 3.2 – DRIFT spectra of anhydrous OLZ Form I, Form II, dihydrate D (dihyd D), dihydrate 
B (dihyd B) and dihydrate E (dihyd E).  
Grey bars highlight the differences between the different forms. 
 
3.5.3 Thermogravimetric and calorimetric evaluation of Forms I and II after storage at 
different RH  
Solid-state forms commonly differ in their moisture sorption behavior. In this study, the 
water sorption profiles of anhydrous Form I and Form II, when stored at 11, 53, 75 and 93 % 
RH for 180 days, were observed. The results revealed that in the range 11-53 % RH, both forms 
gained almost no moisture (< 0.1 % w/w) after 180 days. However, at 75 % RH, OLZ 
polymorphic Forms I and II had different moisture sorption behaviors: the mass gain due to 
moisture sorption was respectively 0.27  0.07 % (w/w) and 7.91  0.15 % (w/w) for the 
anhydrous Form I and Form II, (Figure 3.3, a). At 93% RH both samples increased significantly 
their masses, showing an increase of mass of 7.88± 0.24 % and 8.41 ± 0.28 %, respectively 
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(Figure 3.3, a). The water sorption by both Form I and Form II was attributed to the hydration of 
both forms into two different dihydrates - D and B, respectively (confirmed by X-ray 
diffractometry, shown below). The thermogravimetric profiles of both samples stored for 180 
days at 93% RH displayed the weight loss due to dehydration that starts at lower temperatures 
for the stored Form II samples (Ton= 54.39  1.08 C) than for the stored Form I samples (Ton= 
62.92  0.93 C, Figure 3.3b), indicating that water was more tightly bound in the dihydrate 
formed during the storage of Form I (dihydrate D) (21, 70).   
During the 180 days at 93% RH, a higher moisture sorption rate was observed for Form 
II than for Form I samples (4.44  0.53 vs 1.08  0.28 % after 8 days, Figure 3.3 c), revealing 
that the polymorphic Form I had a longer induction period to take up water under these 
conditions. In spite of the higher induction period of Form I, it was in the first month of storage 
that the mass of both samples increased the most. For a complete conversion of anhydrous 
forms into dihydrates, olanzapine should absorb a maximum water content of 10.3 % w/w, 
which is the water ratio (w/w) in all dihydrate olanzapine forms (18). The increase of mass of 
about 8 % (w/w) in both samples revealed that the process of hydrate conversion during storage 
(180 days / 93 % RH) was not completed for all the anhydrous material. This observation was 
confirmed by XRPD studies (see below). 
The calorimetric analysis by DSC, carried out in a crucible with a non-hermetic lid to 
avoid pressure build up due to the coverlid, evidenced a broad endotherm below 100 
o
C for both 
olanzapine forms stored at 93 % RH (Figure 3.3 d). The temperature (Tmax) and enthalpy values 
(ΔH) of the new endotherm increased with storage time for both forms. The thermogravimetric 
and calorimetric curves recorded for this process had only one slope, regardless of the heating 
rate applied (2, 5, 10, 20, 40 
○
C/min), which may indicate that the dehydration occurred in a 
single stage. This observation suggested that all water molecules were almost simultaneously 
lost and there were no differences in the removal rates of the two water molecules present in the 
dihydrate structures. After the dehydration it was observed the melting peaks for each 
anhydrous form. The dehydration of each hydrate into the same original anhydrous form was 
confirmed by infrared analysis of the dehydrated powder (dihydrate D dehydrates to F I and 
dihydrate B to Form II), showing a reversible process of hydration. 
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Figure 3.3 – Mass variation and calorimetric evalutation of samples  
of olanzapine Forms I (
___
) and II (---): 
a) As a function of RH (11, 53, 75 and 93 % RH) at days 180 of storage; 
b)  Mass loss as function of temperature increase (TGA, 10 ⁰C/min) on storage at 93% RH;  
c) Mass increase for different time periods on storage at 93% RH; 
d) Thermograms of Forms I and II before and after storage at 93 % RH for different days. 
3.5.4 XRPD and DRIFT characterization of Forms I and II after storage at different RH  
The X-ray powder pattern of both anhydrous forms registered changes when they were 
stored at the highest relative humidity (93 % RH) for 180 days. However, these changes were 
different for each form, as a result of the hydration of each anhydrous form into different 
dihydrate structures (Figure 3.4, a and b). The crystalline modifications increased with storage 
time, which became apparent as a consequence of the gradual decrease of the peaks of the 
anhydrous forms and the appearance of the characteristic peaks for the dihydrates, already 
within one week of storage. For instance, in Form I samples the peaks at 2 = 8.62o, 14.64o, 
22.30
o
 tended to vanish whereas new peaks, characteristic of the dihydrate D, at 2 = 11.58o, 
12.01
o
, 15.55
o
, 23.58
o
, 26.49
o
 appeared. However, the peaks of the anhydrous Form I did not 
disappear completely after 6 months of storage (2 = 8.62o, 23.94 o for example, Figure 3.4, a), 
suggesting that after 6 months under this environment a mixture of 2 different forms may be still 
encountered - anhydrous Form I and dihydrate D.  
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The samples of Form II stored at the highest RH (93 %) suffered different 
modifications, by comparison with the samples of Form I under the same conditions: the new 
peaks at 16.4
o
, 19.7
o
, 20.4
o
, 21.3
o
, 22.7
o
 and 23.7
o
 were characteristic of the dihydrate B (Figure 
3.4, b). However, the hydrate conversion of this form at 75% RH was slightly different. 
Although 30 days of storage have not caused major crystalline changes on anhydrous Form II, 
the diffractograms of these samples after 180 days showed a mixture of peaks due to the 
presence of both dihydrates B and E (Figure 3.4, c). The presence of both dihydrates at this 
humidity level might be related to the notable structural similarity of both hydrates (18). 
However, the higher stability of the dihydrate B in comparison to the dihydrate E (18) might 
have accounted for its distinct appearance at a higher relative humidity. At a lower humidity (< 
75% RH) both Forms I and II remained stable during the 6 months of test. 
 
Figure 3.4 – X-ray diffractograms of  OLZ Form I (FI) and OLZ Form II (FII) stored for different 
time periods (7, 30 and 180 days) at 93 % RH (a and b, respectively); (c) OLZ Form II (FII) stored 
at 75 % RH.  
Different symbols are used to distinguish the characteristic peaks of each form. Peaks which appear on top of 
the following symbols: ( . ), ( - ), ( + ),  ( * ), ( .. ) highlight the characteristic peaks of Form I, Form II, 
dihydrate D, dihydrate B and dihydrate E, respectively. 
After characterization of each dihydrate by infrared analysis (DRIFT analysis, Figure 
3.5), it was possible to evaluate the conversions of both olanzapine anhydrous Form I and Form 
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II, as a result of changes on the frequency of several IR bands scattered throughout the spectra. 
For example, Form I bands describing the deformations of the piperazinyl group coupled to Me 
(2) (1009 cm
−1
) or to the azepine and thiophene moieties (965 cm
−1
) (138), changed to 1004 
cm−1 and 971 cm−1, respectively, at 93% RH. The out of plane deformation of the ‘CH’ bonds 
changed from 745 cm
-1
 to 750 cm
-1
 (Figure 3.5 a). The IR spectrum of the anhydrous Form II 
changed over storage for both environments (93 % and 75 % RH, Figure 3.5, b and c). The 
changes on the spectrum of OLZ F II were mainly confined to the region below 800 cm
-1
 (the so 
called ‘fingerprint’ region), and the region above 3400 cm-1 (due to the entrance of water 
molecules). The NH-stretching band in Form II (3237 cm
-1
) did not shift, as occurred with Form 
I when water molecules were introduced in the crystal lattice (Figure 3.5, b vs c).  
 
Figure 3.5 – IR spectra of OLZ Form I (FI) and OLZ Form II (FII) stored for different time 
periods (7, 30, 180 days) at 93 % RH (a and b, respectively); (c) OLZ FII stored at 75 % RH. 
 
3.5.5 Quantification of OLZ hydrate conversion 
The quantification of olanzapine hydrate conversion was possible to calculate from the 
DRIFT data (Figure 3.6, a1 and a2) in combination with a chemometric technique, partial least 
squares (PLS). The PLS regression model for FI/dihydrate D calibration curve had 1 PLS 
components and displayed values of 1.55%, 1.93% and 2.08% for RMSEC, RMSEP and 
RMSECV, respectively. The R
2
 of the experimental and predicted values of polymorphic 
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contents of the binary mixtures was 0.997. The cross-validated R
2
 (termed as Q
2
) was 0.996. 
The regression model for the pair FII/dihydrate B had 1 PLS components and displayed values 
of 2.50%, 2.60% and 2.82% for RMSEC, RMSEP and RMSECV. The R
2
 and Q
2
 values were 
0.993 and 0.992, respectively. The RMSECV below 3% for both models suggested good 
predictive ability of the models (182). The hydrate conversion rate is shown in (Figure 3.6, b). 
The mean values of the weight increase, obtained by the thermogravimetric analysis, were also 
converted into percentage of OLZ dihydrate existing in the samples at each time of storage 
(knowing that an OLZ dihydrate form presented 10.3 % w/w of water content). These results 
were correlated with the dihydrate content obtained by the results from the DRIFT 
spectroscopy, which gave rise to a regression line (R
2
=0.997 and 0.998, for Forms I and II, 
respectively) between the two curves (Figure 3.6, c). These results suggested that most of the 
water taken up by the olanzapine at 93 % RH was converted in water of crystallization, giving a 
good correlation with a unit slope. 
 
Figure 3.6 – a) Changes on IR spectra of olanzapine Form I (a.1) and Form II (a.2) during storage at 
93% RH (a); Calculation of hydrate conversion of form I (▲) and II (■) at 93% RH from the 
DRIFT data using a PLS model (b); Hydrate conversion when two different methodologies were 
considered (TGA and DRIFT) (c). 
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3.5.6 Drug performance assessed by dissolution 
To evaluate how (in)appropriate storage conditions of olanzapine may influence the 
dissolution of the drug, dissolution tests on freshly prepared tablets containing Fom I and Form 
II (with immediate and sustained releases), prior to and after storage (180 days at 93% RH) 
were carried out (Figure 3.7). For each formulation, the fraction of excipients in the 
formulations was the same, so the solid state of OLZ could have been assumed to be the only 
factor influencing the drug’s dissolution rate. The drug content for both formulations containing 
anhydrous olanzapine was at 98.6%–100.1% of the expected values. The formulations 
containing olanzapine samples stored at 93% RH for 180 days presented a drug content of 91.6-
92.7 % of the measured olanzapine mass. This result was consequence of the water content 
entrapped in the crystalline structure of both olanzapine samples that led to an increase of the 
sample mass. Consequently, the graphical representation of data was adjusted for the mass of 
olanzapine released, as anhydrous olanzapine, as a function of time. In the formulation 
containing lactose only (i.e., immediate release formulation), Form I and Form II prior and after 
storage (93% RH) showed more than 85% dissolution within 15 min of test, reflecting similarity 
between their dissolution profiles (167). By opposition, only 85% of Form I, stored at 93% RH, 
was dissolved after 90 min of test. The comparison of the dissolution profiles of stored Form I 
(93% RH) with the other samples’ profiles was performed by the calculation of the similarity 
factor, f2.  The f2 values showed to be < 50 for all the compared curves [f2(Form I/Form I 93%) 
= 23.8; f2(Form II/Form I 93%) = 25.4; f2(Form II 93%/Form I 93%) = 27.8], indicating that 
hydration of the anhydrous Form I promoted a significant reduction on the dissolution rate of 
olanzapine.   
For the sustained release formulations, the rank order for olanzapine dissolution rate 
was – Form I, Form II, Form II 93% and Form I 93% RH, for both formulations  (Figure 3.7).  
The unstable Form II showed to dissolve more slowly than the stable Form I. However, due to 
the higher free energy of the unstable form, it would be expected to dissolve more rapidly than 
the corresponding stable form. Since both forms can hydrate when placed in contact with water, 
it would be expected that olanzapine would also hydrate when the tablets were placed in the 
dissolution medium. Therefore, the dissolution rate of anhydrous olanzapine depends on 
olanzapine’s rate of hydration. For faster rates of hydrate conversion, the process of dissolution 
would have occurred predominantly from the hydrate forms formed in situ.  
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Figure 3.7 – Dissolution profiles of OLZ Form I (-■-), OLZ Form II (-▲-), OLZ Form I stored for 
180 days at 93% RH (--■--) , OLZ Form II stored for 180 days at 93% RH (--▲--) considering the 
mass of anhydrous olanzapine. The dissolution tests were performed for tablets formulated with 
lactose (left) and with MCC/ lactose (right). 
3.5.7  Hydration of Forms I and II in aqueous slurries  
The experiments with the aqueous slurries performed for both anhydrous olanzapine 
forms helped to elucidate the different behaviors of hydration that each form of olanzapine 
might have in water. The OLZ sediment collected at different times (by filtration) was analyzed 
by DRIFT to evaluate the moment at which the conversion into the hydrate started to occur.  
Taking into consideration the spectral bands at 782 cm
-1
 and 914 cm
-1
, which are unique to 
the dihydrate B, they became visible after 15 min in the experiments carried out with the 
anhydrous Form II, whereas for Form I samples, those bands became visible after 60 minutes  
only (Figure 3.8). These results showed the rate of appearance of dihydrate B was much slower 
for stable form I. The continuous evaluation of the course of hydration of each form over 24h 
(1440 min) showed that both forms hydrated into a mixture of two different crystalline products, 
namely, the higher hydrate form and the dihydrate B form. A higher content of the higher 
hydrate form was found for the initial sample of anhydrous Form II (Figure 3.8 b, c).  
The crystallization of olanzapine into these different hydrates indicates that hydrate 
formation of olanzapine in water has a different mechanism than when only subjected to water 
vapor. 
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Figure 3.8 – IR spectra of OLZ FII and FI after being suspended in water for different time periods 
(a); IR spectra (b) and XRPD diffractograms (c) of OLZ FI and FII suspended in water for 24h.  
 
3.6 Discussion 
Water adsorbed to the surface of a crystalline material tends to be very low (< 0.1%) 
(185). However, one-third of APIs are known to form hydrates. For this reason, studies of the 
interaction of water and anhydrous APIs have received some attention in the literature (70, 173). 
The knowledge of the interaction of moisture with pharmaceutical solids is, therefore of a 
practical interest since it enables developing robust conditions for preparing and packaging the 
APIs, bringing them to a successful solid dosage form (4, 175). 
In the present study, differences in water uptake between the two anhydrous crystal 
forms were clearly observable. Olanzapine Form I and Form II showed to be physically stable 
up to a RH of 75% and 53%, at 25 ⁰C, respectively, since no hydrate formation was observed 
when these forms were stored at these RH conditions for 6 months. These results indicate that 
storage at room temperature and below these RHs will not promote solid –state changes of 
olanzapine polymorphs. This control on the formation of hydrates during the long-term storage 
of olanzapine is crucial to ensure that the quality attributes of the final product are not affected 
(186). At 93% RH and 75% RH, water molecules were absorbed in the bulk solid structures of 
anhydrous Form I and Form II, respectively, and hydrate formation has occurred. Since the 
amount of water vapor absorbed by a solid at any RH and temperature is critically dependent on 
the orientation and accessibility of polar functional groups, the distinct water sorption behavior 
of both polymorphs may be explained by their different crystal structures (179). The IR data of 
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both structures has shown that the differences in both spectra were mostly related to the atoms 
involved directly or indirectly with the intermolecular NH
…
N hydrogen bond, which is the 
primary intermolecular interaction of anhydrous olanzapine structures (138). For instance, the 
stronger/shorter intermolecular hydrogen bond in Form I resulted in a lower NH stretching 
wavenumber as compared to Form II (Figure 3.2 b). Therefore, the longer intermolecular 
hydrogen bonds in Form II (138, 187) may have created an easier access to water molecules 
through the hydrophilic sites in its structure (188-190), making this form less resistant to 
humidity. This lower storage stability of anhydrous Form II makes it less suitable to industrial 
use. 
Infrared spectroscopy is very sensitive to vibrations of water O-H bonds. Comparing the 
infrared spectra of the dihydrates with the anhydrous forms, one may observe several 
differences among them, especially in the region between 3300 and 3550 cm
-1
 (Figure 3.2). In 
that region, all dihydrates presented two broad bands which were not observed in the anhydrous 
forms. The appearance of these bands is related to OH-stretching due to hydrogen-bonded water 
molecules present in the crystal. The wavenumber of the OH-stretching bands from the water 
molecules was related to the strength of the hydrogen bonds formed with the H-bond acceptors. 
For instance, strong hydrogen bonds weaken the covalent OH bonds causing them to vibrate at 
lower frequencies (183, 184). In the dihydrates of olanzapine both water molecules can establish 
hydrogen bonds with other water molecules and/or with the olanzapine molecules. However, 
both water molecules form hydrogen bonds with variable strength (18), supporting the 
appearance of two broad OH stretching bands at different wavenumbers in each dihydrate.  
As a consequence of incorporating water molecules, the intermolecular hydrogen bonds 
in anhydrous forms (NH
…
N) are going to be disrupted by bridging water molecules (N-H
…
Ow- 
Hw
…
Ow-Hw
…
N). In all of the hydrates, the water molecules are held by two or three hydrogen-
bonding interactions. The results obtained in the thermogravimetric and calorimetric analyses 
revealed that both dihydrates formed during storage at 93% RH have low dehydration 
temperatures (Ton< 70 ⁰C), with a lower Ton for the dihydrate B formed during storage at 93% 
RH of OLZ F II samples. This observation may be explained by longer intermolecular hydrogen 
bonds of olanzapine molecules with nearby water molecules in the dihydrate B (N10-H
…
O1 - 
2.91Å; O1-H
…
N4- 2.83Å; O2-H
…
N5 - 2.99Å) than in dihydrate D crystal lattice (N10-H
…
O1 - 
2.86Å; O1-H
…
N4- 2.82Å; O2-H
…
N5 2.86Å) (18) , which may weaken the interaction between 
the molecules and, thus, facilitate the dehydration process (191). Furthermore, the broad 
dehydration endotherm of both hydrates (Figure 3.3) revealed that the evaporation of water 
molecules exposed to the surface of crystals should provide access to the water molecules inside 
the crystal, resulting in a slow and continuous dehydration until all water molecules were 
removed. This behavior contrasts with the common behavior of isolated site hydrates (water 
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molecules were isolated and kept from contacting with other water molecules directly in the 
lattice structure), which commonly present a sharp dehydration endotherm (192). 
The results have shown that the curve representing the weight increase of anhydrous 
Form I during storage at 93 % RH had a sigmoidal shape. In the first week, the mass increase 
was minimal (induction period), followed by an acceleration (8-30 days) and then a decay 
period, where the rate of hydrate formation was reduced (30-180 days). This behavior of hydrate 
conversion was slightly different from the hydrate conversion of anhydrous Form II at 93 % 
RH, since this form seemed to have a short or completely absent induction period indicating a 
lower energy barrier for hydrate nucleation in the solid state.  
The decay period (30-180 days) was very long for both stored samples and even after 
six months of storage the final water content in the solids did not reach the stoichiometric value 
for the dihydrate - 10.3 % (w/w) (18). The fact that some anhydrous content was still present in 
the sample (XRPD and IR data), has shown that hydration was not completed. This 
phenomenon may be related with the wide particle size distribution in both samples, since the 
particles with an increased size have a reduced specific surface area exposed to water, and 
therefore, the reduced number of molecules/atoms at the surface of such particles available to 
interact with water molecules. Hence, a slower conversion rate was observed for larger than for 
smaller particles (188). In spite of the uncompleted hydrate conversion during this long-term 
storage procedure, this approach simulated the hydrate rate conversion of bulk olanzapine at 
room temperature and humidity, which is important to anticipate its shelf life (193). Variable 
fractions of hydrate/anhydrous olanzapine may result in variations in the water content of the 
final product, with impact on both the stability and content uniformity of the drug product. 
Consequently, solid dosage forms with unpredictable bulk powder properties may also be 
obtained (191). 
The samples of olanzapine Form I stored at 93 % RH showed to hydrate directly and 
progressively into the dihydrate D. The crystallization of the dihydrate D from the anhydrous 
Form I might have been related to the similar organization of the crystal building blocks in their 
structures (Figure 3.9). In both cases they are aligned end-to-end and assembled directly on top 
of one another. In the conversion to a dihydrate D form, the water will occupy the sites between 
the olanzapine dimers in the lattice, changing the shape of the unit cell (18). 
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Figure 3.9 – Crystalline structure of form I (a), II (b), dihydrate D (c) and B (d) of 
olanzapine. Arrows highlight water molecules. 
 
The direct conversion of the anhydrous Form I into the dihydrate D when stored at 93 % 
RH was different from its behavior when it was stirred directly in water with multiple 
conversions into other hydrated forms. The anhydrous Form II stored at 93 % RH showed to 
hydrate into a different form: dihydrate B. Figure 3.9 shows that olanzapine molecules in both 
Form II and dihydrate B adopt a herringbone arrangement, suggesting minor structural changes 
during the process of hydration of anhydrous Form II sample.   
Hydrates of olanzapine showed to be generated by both water vapor sorption or simply 
by suspension of the anhydrous moieties in water. The suspension of both anhydrous forms in 
water led to the formation of 2 hydrates- the dihydrate B and the higher hydrate. The different 
hydrates formed in each environment were in accordance with the different mechanisms 
associated to the hydrate conversion in each environment. In the aqueous suspensions the 
anhydrate to hydrate transformation is expected to occur by a solution-mediated transformation 
(SMT) (194, 195). This transformation started with the dissolution of the metastable anhydrate 
form, leading rapidly to supersaturation with respect to the stable hydrate form and providing 
the thermodynamic driving force for nucleation of the stable hydrate. The final growth of the 
stable hydrate will deplete the solution concentration resulting in further dissolution of 
anhydrous solid. The hydrate crystal will continue to grow until all of the anhydrate material has 
dissolved and the concentration of the drug in solution reaches the solubility of the hydrate, as 
observed previously for other APIs (196, 197). Since the dissolution of the metastable phase is a 
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prerequisite for the transformation to take place, the solubility of the metastable form will 
initially provide the thermodynamic driving force for the phase transformation. Therefore, the 
higher rate of hydration for anhydrous Form II when suspended in water may be associated with 
the higher solubility of this form in relation to the anhydrous Form I, which was not unexpected, 
due to the higher free energy of the metastable forms (179).  
The concomitant crystallization of the dihydrate B and higher hydrate in aqueous 
environments can be related to the simultaneous and closed nucleation rates of both forms (29). 
The appearance of these 2 hydrates instead of the dihydrate D form (the most stable olanzapine 
hydrate) at the beginning of the process can be explained by the Ostwald’s Step Rule. This rule 
states that it is not the most stable state, with the lowest free energy, that is initially formed, but 
the least stable state lying nearest to the original state in free energy (50). Therefore, our results 
indicated that the dihydrate D form is more likely to be formed during storage, during which 
olanzapine Form I is exposed to low water activity for long periods, than during dissolution 
tests or pharmaceutical processing involving water (e.g. wet granulation), in which agitation, 
higher water activity and reduced contact time between olanzapine and water molecules are 
involved. 
The dissolution profiles of both anhydrous Forms I and II in fast release tablet 
formulations showed almost complete dissolution within 15 min. The rapid tablet disintegration 
resulted in a significant fraction of olanzapine going into solution soon after coming in contact 
with water. The samples which were stored at 93% RH showed to have a slower dissolution rate 
when compared to the freshly prepared anhydrous forms. A significant decrease in the 
dissolution rate was observed for stored OLZ Form I, due to the higher stability of the 
olanzapine dihydrate D structure (18) formed during storage.  Due to the fact that olanzapine is 
a drug whose absorption is mainly limited by its dissolution, the appearance of this dihydrate D 
is likely to affect the bioavailability of olanzapine present in solid dosage forms. Although Form 
I just hydrates at a higher RH than Form II, the hydration into the dihydrate D caused a negative  
impact on the bioavailability of olanzapine as compared to the conversion of Form II into the 
dihydrate B. 
For the tablets containing microcrystalline cellulose (MCC), olanzapine molecules 
contacted with water for a longer period of time before coming into solution due to the sustained 
release promoted by MCC. During dissolution the hydrate formation of APIs can occur if the 
dissolution rate of anhydrous APIs is slower than the rate of transitions of anhydrous APIs into 
hydrates (106). In our experiments both forms showed to be hydrated in less than 60 minutes 
when suspended in aqueous environments, with a faster hydration rate for anhydrous Form II. 
Furthermore, previous studies showed olanzapine to undergo hydrate conversion during 
dissolution from microcrystalline pellets  within 360 min (198). Therefore, in the present case, 
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the long period that olanzapine was in the hydrated tablet matrix before complete dissolution 
(940 min) could have led both olanzapine anhydrous forms to undergo, at least partially, hydrate 
conversion before dissolution. The faster hydrate transition of anhydrous Form II may have led 
to the reduction of its dissolution rate, since now it showed to reflect the dissolution profile of 
the hydrates formed in situ, presenting a similar dissolution profile to the dihydrate B formed 
during storage of anhydrous Form II at 93% RH.  
Overall, the interconversion between the different forms is schematically shown in  
. One may observe that the hydrates formed in aqueous suspensions (higher water 
activity) are the same for both forms, which was not the case when each form was stored at 93% 
RH. This shows that the slow phase transitions occurring in the solid-state are more sensitive to 
the different crystal conformations of the anhydrous olanzapine forms than the hydrate 
conversions occurring in aqueous environments. 
 
3.7 Conclusion 
The present research was performed mainly on the solid-state transformation of two 
known anhydrous olanzapine forms in order to provide fundamental information concerning 
stability of these forms over wet processing and long-term storage.  
The present study showed that OLZ can be hydrated differently depending on its 
starting point polymorphic structure and vapor pressures to which it is submitted. Form I 
showed to hydrate systematically into the dihydrate D and Form II into the dihydrate B after 
prolonged exposition to 93% RH and not into a different hydrate. This transformation would 
have been different if a lower RH would have been considered. The different dihydrates formed 
in each anhydrous sample revealed to have similar crystalline structures to the anhydrous forms 
which originated them, suggesting minor structural changes during the process of hydration.  
It was observed a higher stability of olanzapine Form I in comparison to Form II at 75% 
RH, which confirms its suitability for pharmaceutical purposes. However, the storage conditions 
of anhydrous Form I still need to be controlled to avoid the appearance of a lower soluble form 
(dihydrate D) that may have impact on the bioavailability of the drug. This study helped 
therefore to predict the stability of both forms upon short and long term exposure to humidity. It 
also highlighted the importance of a correct selection of storage conditions for both the bulk 
olanzapine and the final drug product (preferably below 75% RH, at room temperature), in order 
to prevent the appearance of new crystalline forms or variations in the content uniformity in the 
drug product. 
 Both dihydrates formed during storage showed to dehydrate at relatively low 
temperatures (Tonset < 70 ◦C) showing that water molecules form weak interactions with nearby 
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molecules in the crystals lattice. It was observed a reversible transformation into the anhydrous 
forms after dehydration without amorphization of the drug. 
The anhydrate to hydrate transformations in water was found to occur by a different 
mechanism (solution mediated transformation).  In an aqueous medium both anhydrous 
olanzapine forms showed to hydrate into the same hydrates (higher hydrate and dihydrate B). 
Worth to point out that these conversions happened within minutes to few hours before stability 
of the new entity is reached. These rapid hydrate transitions of both olanzapine forms in a wet 
environment helped to elucidate the type of conversions that olanzapine can undergo over 
pharmaceutical processes, such as, wet extrusion or granulation. This study also has shown that 
conversion of polymorphs throughout a test of dissolution may occur, in which a more soluble 
form converts into a less soluble one. This has implications on the assessment of the quality of 
the solid dosage form by dissolution testing and in vivo, olanzapine’s bioavailability might be 
diminished. 
The data obtained in this study enabled the construction of a schematic representation 
for the interconversion pathway between the different anhydrate and hydrate forms, thus 
providing an improved understanding of the role of water on the solid-state changes of this API 
.  
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Chapter 4 -  Role of excipients on the kinetics of hydrate transformation 
of olanzapine Form I over storage 
 
4.1 Abstract 
The study elucidates the hydrate transformations of anhydrous olanzapine Form I (OLZ 
FI) when stored at a high relative humidity or suspended in an aqueous media in the presence of 
polymers. OLZ FI and physical mixtures (3:1 and 1:1 as powders or compacts) of olanzapine 
with polyethylene glycol (PEG-6000), polyvinylpyrrolidone (PVP K25) and 
hydroxypropylcellulose (HPC-LF) were stored (75%RH and 93%RH) for 28 days. OLZ FI and 
the physical mixtures were also suspended in demineralized water and stirred (200rpm/60min). 
Samples were collected at different time points and vacuum filtered. OLZ FI showed to hydrate 
at 75%RH when stored in the presence of HPC and PEG. At 93%RH all polymers affected the 
kinetics of hydration of OLZ FI with PVP as the only polymer with the ability to avoid the 
formation of the hydrate. When olanzapine was suspended in water with HPC and PVP, OLZ 
hydrate formation was inhibited. Compaction of the powders before storage led to an increase of 
the hydrate conversion rate of OLZ on the first week of storage, due to a partial amorphization 
of olanzapine present at the tablet surface. When stored at high humidity environments OLZ FI 
converted into dihydrate D and when exposed to aqueous environments in the presence of 
different polymers converted into dihydrates B and E. From an industrial point of view, this 
study highlighted the importance of the excipient’s choice for OLZ formulations, so that a final 
OLZ product can have a consistent quality performance throughout the product’s shelf life. 
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4.2 Introduction 
A pharmaceutical solid dosage form is a combination of an active pharmaceutical 
ingredient (API) and excipients which are added to the formulation to ensure physical and 
chemical stability of the formulation, as well as its manufacturability and the bioavailability of 
the final product (199). During manufacture and subsequent storage of the solid dosage forms 
both APIs and excipients can take up unacceptable amount of moisture which are capable of 
altering the solid dosage form stability and lately the physical and chemical stability of the APIs 
(200). Therefore, it is important to know the different moisture sorption properties of both APIs 
and excipients in a certain formulation for an adequate selection of the excipients to be 
considered and the manufacturing process to be followed. Only an optimized formulation and 
process allow the assurance of the dosage form’s stability and the prediction of the shelf-life 
(201).  
Depending on the solid-phase of the raw materials, i.e, crystalline or amorphous solids, 
the interaction with water may occur by different mechanisms. Crystalline materials may 
interact with water by four different mechanisms: adsorption on the surface of the particles, 
incorporation into microporous regions by capillary condensation, formation of crystal hydrate, 
and deliquescence (122, 201, 202). The crystal structure, water-solubility, porous structure, and 
the ability to form crystal hydrates is going to determine the mechanism of water sorption into 
the solid (122).  The water vapor in amorphous materials, on the other hand, is absorbed into 
their amorphous regions and not simply adsorbed on the surface: in these amorphous solids the 
amount of water uptake is not directly related to the specific surface area of the solid (203). 
Water can act as a plasticizer and increase molecular mobility due to the breakage of hydrogen 
bonds between molecules (204, 205). The amount of moisture absorbed by amorphous solids is 
commonly much larger than the one absorbed by nonhydrated crystalline materials below their 
critical relative humidity (RH0) (123). 
OLZ Form I is the most stable polymorphic form of this drug, being therefore well 
adapted for manufacture purposes (18, 136). Recent OLZ case studies (206, 207) pointed out 
problems on the novel generic formulations, such as undesired side effects or lack of efficiency, 
which authors claimed to be caused by the ability of OLZ to undergo polymorphic 
transformations. Consequently, excipients should play a key role in promoting the stability of 
OLZ in a reproducible medicine and certainly not being the cause of such instability. 
For this study, different amorphous and partially amorphous excipients were selected 
due to their ability to sorb larger amounts of water than purely crystalline materials and due to 
their regular use in pharmaceutical formulations. Furthermore, amorphous or partial amorphous 
excipients facilitate the characterization of OLZ polymorphic transformations by X-ray 
diffraction. Two groups of polymers were selected for the study, namely, one partially 
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amorphous and water soluble polymer (PEG) and two amorphous and water soluble polymers 
(HPC, PVP). 
4.3 Purpose 
The aim of present chapter was to study the phase transitions of OLZ when exposed to 
different degrees of humidity in the presence of different excipients. Furthermore, the study 
investigates how different excipients, interacting with water vapor by different mechanisms of 
water sorption, may change the rate of solid phase transitions of OLZ. 
It was also considered to compact (standard treatment in production of tablets) the 
different mixtures of drug and excipients before exposing them to different humidity conditions 
in order to evaluate how pressure may affect the formation of OLZ hydrates. The study aims 
also to provide a clarification of the mechanism of interaction between OLZ and various 
excipients in aqueous suspensions.  
4.4 Materials and methods 
OLZ anhydrous Form I was purchased from Pharmorgana, India. The different 
excipients were Polyethleneglycol (PEG 6000, Sigma-Aldrich, Germany), 
Hydroxypropylcellulose (HPC LF Pharm grade, Klucel™, Ashland, Germany), and 
Polyvinylpyrrolidone (PVP K25, BASF Chemicals, Germany). 
4.4.1 Preparation of samples for moisture sorption studies 
PEG, PVP and HPC were sieved to eliminate agglomerates of particles with collection 
of particles below 180 μm diameter. Approximately 1g of each polymer was placed in a 20 ml 
glass vial and stored at 11% RH (lithium phosphate) for 7 days prior to persecution of the vapor 
sorption experiments in order to decrease and normalize the water content in samples. 
Thereafter, these polymers were used to prepare physical mixtures with OLZ (OLZ: polymer, 
25:75 w/w and 50:50 w/w, Table 4.1) by mixing OLZ and each polymer in glass vials rotating 
in a roller mixer for 10 min. 200 mg mixtures were prepared in triplicate and split in halves. One 
half (100 mg) was used to obtain compacts with 10 mm in diameter at a compaction force of 40 
kN with an upper punch speed of 10 mm/min, using a universal mechanical press (Lloyd 
Instruments LR 50K, UK). Overall 36 samples (powder mixture and compacts) were prepared 
for each polymer. 6 samples (3 powder mixtures and 3 compacts) of each OLZ:polymer ratio 
were stored at 2 different conditions: 75%RH, and 93%RH for 28 days. These samples were 
analyzed periodically (7, 14, 21 and 28 days). Each polymer and OLZ (raw materials) were also 
stored under the same conditions and used as controls. 
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Table 4.1 – Formulations for moisture sorption studies 
 Code Samples 
Drug/Excipient composition 
(mg, w/w) 
 
M
o
is
tu
re
 
S
o
rp
ti
o
n
 S
tu
d
ie
s A OLZ 100:0 
B1 OLZ:PEG 50:50 
B2 OLZ:PEG 75:25 
C1 OLZ:HPC 50:50 
C2 OLZ:HPC 75:25 
D1 OLZ:PVP 50:50 
D2 OLZ:PVP 75:25 
 
so
lv
en
t-
m
ed
ia
te
d
 
co
n
v
er
si
o
n
 
st
u
d
ie
s 
E OLZ 75:00 
F OLZ:PEG 75:25 
G OLZ:HPC 75:25 
H OLZ:PVP 75:25 
 
4.4.2 Preparation of samples for solvent-mediated conversion studies 
Polymers (25 mg) were dissolved in 12.5 ml demineralized water (n=3). OLZ (75 mg) 
was suspended under agitation (200 rpm) in both water and polymer solutions (12.5 ml) for 60 
min (Table 4.1). The sediment was recovered by vacuum filtration to remove excess of water 
and immediately transferred to XRPD for analysis. 
4.4.3 Gravimetric water vapor sorption 
Water vapor sorption was determined gravimetrically by storing samples at 25 °C for 28 
days in desiccators containing saturated salt solutions to maintain the relative vapor pressure, 
namely, sodium chloride (75.29 ± 0.12 %, i.e., 75 %RH), and potassium nitrate (93.48 ± 0.55 
%, i.e., 93 %RH). During this period the masses (weights) of each sample were periodically (7, 
14, 21, 28 days) measured with a Mettler–Toledo analytical scale. Simultaneously,  spectral 
(FTIR), calorimetric (DSC) and X-ray (XRPD) analysis were performed. 
4.4.4 Characterization of OLZ, polymers and mixtures of thereof during storage 
X-ray powder diffraction (XRPD) 
The structural characterization of OLZ formulations were carried out by X-ray powder 
diffraction (XRPD) on an Analytical X’Pert PRO apparatus (Equipment 2). Diffractograms 
were obtained by continuous scanning in a 2 ɵ -range of 7–35◦ with a step size of 0.017◦ and 
scan step times of 20 s. 
Differential scanning calorimetry (DSC) 
Thermograms of different polymers were taken after their storage at 11% RH for 7 
days. The physical mixtures of polymers and OLZ which were stored at different RH for 
different time periods were analyzed immediately after their removal from the container. The 
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OLZ particles recovered from the different polymeric solutions were allowed to dry at 
25°C/53% RH for 24h prior to calorimetric analysis. The analysis was performed in a 
Differential Scanning Calorimeter (TA instruments, Q200, USA). Dry N2 was used as the purge 
gas (Air Liquide, 50 ml/min). 2 to 3 mg were placed in pinhole crucibles. Samples were heated 
at 10 C/min within 0-210 C temperature range. 
FT-Infrared spectroscopy (FTIR) 
Polymers and physical mixtures before and after storage were mixed with KBr at a 
concentration of 0.5 w/w. The mixtures (about 200 mg) were compressed into compacts of 12 
mm diameter each. The infrared spectra were obtained at the absorption mode (IR Affinity-1 
Shimadzu spectrophotometer, Japan) with 64 scans with a resolution of 2 cm
-1
. Comparisons 
between FTIR spectra of the OLZ:polymer samples after storage at different conditions of 
humidity and temperature were made possible by using a partial least square regression (PLS)  a 
chemometric technique often used for this purpose (181). The spectral region of 875-915 cm
-1
 
was selected for the PLS analysis because in this region both polymorphic forms can be 
distinguished due to the peaks at 886 cm
-1
 and 904 cm
-1
, which are indicators of the existence of 
anhydrous Form I or dihydrate D (the one present after storage), respectively. This region was 
also chosen for analysis because the polymers’ spectra showed not to interfere in this spectral 
region (208).  
Physical mixtures of OLZ F I and dihydrate D of compositions ranging from 0% to 
100% were used as the calibration set. The spectra were pretreated by standard normal variate 
transformation in order to reduce spectral noise (Unscrambler X, Camo software). From this, a 
set of spectra collected at each concentration were set aside to form the test set. Internal cross 
validation (leave-one-out) was performed to the calibration samples.  
Near Infrared spectroscopy (NIR) 
The polymers which were stored for a period of 1 month at different RH were analyzed 
by an Antaris FT-NIR spectrometer (Thermo Scientific, USA) equipped with an InGaAs 
detector. Each NIR spectrum was recorded between 10 000-4000 cm
-1
 with a resolution and 
number of scans of 8 cm
-1
 and 32 cm
-1
, respectively. 
Scanning electron microscopy (SEM) 
Physical mixtures of OLZ and polymers were analyzed by scanning electron 
microscopy. The samples were mounted on aluminum stubs and coated with gold by ion 
sputtering (JEOL JFC-1200 Fine Coater) and observed under (JSM-5200 LV, JP) scanning 
electron microscope. 
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4.5 Results 
4.5.1 Characterization of the starting materials 
The characteristic XRPD diffraction patterns of all 4 excipients were observed using 
XRPD in the angular range of 7–35 (2Ɵ). Figure 4.1 a) shows the XRPD diffraction patterns 
measured for the crystalline OLZ, partially amorphous PEG and amorphous PVP and HPC 
compounds. Crystalline OLZ exhibited strong diffraction peaks while materials that lack long-
range molecular order (PVP and HPC) scatter X-rays to produce a diffuse or ‘‘halo’’ pattern. 
The evaluation of the different water sorption behaviors of each excipient contributes to 
elucidation on how they may alter the kinetics of hydration of OLZ in formulations due to the 
likely competitiveness to water molecules. The moisture uptake when various materials are 
exposed to 75% RH and 93% during 4 weeks is represented in Figure 4.1 b. For instance, partial 
crystalline PEG showed to sorb low amounts of water at 75% RH.  However, the change of 
PEG powder’s mass recorded at 93% RH was as high as 53% w/w. The amorphous and 
hydrophilic PVP showed to sorb considerable amounts of water when exposed to both 75% and 
93% RH. HPC showed also be able to take up water vapor at a humidity of 75% RH. However, 
at 93% RH, this polymer was less hygroscopic lower than both, PVP and PEG.  
The calorimetric analyses carried out in pin-holed crucibles lids showed a broad 
endotherm below 100 ⁰C for OLZ stored at 93 %RH (Figure 4.1c). This endotherm was related 
with the water loss, which was confirmed by thermogravimetric analysis (data not shown). After 
the dehydration of the sample, one could observe the peak of melting of the anhydrous form. 
The thermograms of the polymers on heating showed the apearance of a broad band, between 
75-120⁰C, due to the presence of water in the sample, except for PEG. PEG’s thermogram 
showed the disapearance of the peak of melting which result from the ability of the crystalline 
regions of PEG to dissolve into the water absorbed by the amorphous regions of the 
polymer(201).  
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Figure 4.1 – XRPD pattern of the inicial excipients (a), their change in mass after exposed to high 
levels of humidity (b) and their thermal behavior after 28 days of storage at each environmental 
conditions (c). 
 
The effect of moisture sorption on all excipients was investigated with NIR 
spectroscopy after a 4-week storage under conditions of different RH and temperature 
conditions. As a result of the water vapor sorption, a common feature to all spectra was the 
increased absorbance with an increase in water activity for wavelengths greater than 1300 nm 
(Figure 4.2). This trend was especially evident in the 1400-1450 nm (first overtone of -OH 
stretch) and 1900-1950 nm (combination of -OH stretch with -OH deformation) water 
absorption regions. For PVP and HPC polymers a significant increase of the absorbance 
observed in the spectra at the region between 1400-1450 nm could be identified for the samples 
stored at both 75% and 93%RH.  
With regard to the position of the band due to water molecules, the 1850-1950 nm 
region, the maximum absorption is strongly dependent on the hydrogen-bonding reflecting the 
molecular mobility of water molecules. Therefore, the broadening of these bands and a decrease 
on their wavelength maximum indicated an increase in free water molecules (higher molecular 
mobility) when polymers were stored at high humidity conditions. The water absorbed to PEG 
was seen as a distinct absorption maximum at 1933 nm after storage at 75% RH. At 93% RH, 
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free water showed an absorption maximum at around 1900 nm. Furthermore, the bands related 
to the PEG’s structure showed to reduce their intensity at 93% RH. 
 
 
Figure 4.2 – NIR spectra of OLZ (a); PEG (b), HPC (c), PVP (d) stored at different humidity 
conditions (11% (
__
);75% RH (
….
); 93% RH (
__
)) for 28 days. The main shifts are represented with a 
grey bar. 
 
4.5.2 Phase transformation of OLZ during storage 
The effect of humidity on the different OLZ samples is shown on the Figure 4.3. At 
75% RH it was possible to observe changes on the diffraction pattern of OLZ when it was 
physically mixed with both PEG and HPC (B1 and C1, Figure 4.3 a), due to the appearance of 
new crystalline peaks (grey bar) in the diffractogram. Although 3 different dihydrates of OLZ 
are known (Dihydrate B, D and E) (18), the characteristic peaks of OLZ dihydrate D (at 2 = 
9.27
o
, 9.49
o
, 11.62
o
, 12.01
o
) appeared along with the peaks of Form I in the diffractograms of 
these 2 OLZ:polymer samples. The dihydrate D specific peaks are more evident in OLZ:PEG 
XRPD profile, due to the higher content of the dihydrate D form in this sample. The presence of 
characteristic peaks of both anhydrous and dihydrate forms of OLZ showed that the dihydrate 
conversion was not completed in the time scale of the test.  
At 93%RH, the X-ray powder pattern of OLZ, which was stored without any excipient, 
revealed a reduction of the intensity of the peaks, characteristic of the anhydrous form I, and the 
presence of new peaks, characteristic of the dihydrate D (Figure 4.3 b). Regarding OLZ which 
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was physically mixed with different excipients and stored at 93%RH, its hydration showed to 
have increased or decreased, depending on the polymer in which the drug was mixed. For 
instance, the XRPD pattern of D1 sample showed only the specific peaks of anhydrous OLZ F I, 
whereas the XRPD pattern of OLZ:PEG (1:1) showed only the characteristic diffraction pattern 
of OLZ dihydrate D. 
 The characteristic XRPD pattern of PEG which present 2 broad bands with maximum 
peaks at 2 = 19.7 ° and 23.8 ° ( Figure 4.1a)  was visible in B1 samples stored at 75% RH but 
no longer visible in B1 samples stored at 93% RH. This may result  from the dissolution of the 
polymer on the absorbed water, which is phenomenon that can occur with crystalline and highly 
soluble material (148).  
 
Figure 4.3 – XRPD of physical mixtures (A, B1, C1and D1) stored 28 days at 75% RH (a) and 93% 
(b). 
 
The different OLZ forms can be easily distinguished by FTIR analysis, as a result of 
changes on the frequency of several IR bands scattered throughout the spectrum (Figure 4.4, a). 
When OLZ Form I was converted into the OLZ dihydrate D form, the infrared bands at 886cm
−1
 
and 745cm
-1
 were shifted to 904cm
-1
 and 750cm
-1
,
 
respectively. The hydration of OLZ was not 
completed by the end of storage (28 days at 93%RH) according to the presence of characteristic 
bands of both OLZ anhydrous and dihydrate forms (Figure 4.4, b). At 75% RH, no changes 
were visible on the OLZ spectrum. The calorimetric study (Figure 4.4, c) evidenced a broad 
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endotherm below 100 
o
C for samples stored at 93% RH due to the presence of dihydrate D 
content within the sample.  
 
 
Figure 4.4 – FTIR characterization of OLZ samples (700-1300 cm-1) after 28 days of storage at 
different RH (a), dihydrate conversion of olanzapine when stored at 75% RH and 93% RH (b) and 
thermograms of olanzapine after exposure to different RH for different time periods (c). 
 
The FTIR spectra between 850cm
-1
 and 915cm
-1
 enabled the quantification of OLZ 
hydrate conversion in OLZ:Polymer mixtures when a multivariate analysis tool (PLS method) 
was used. The PLS best model contained 1 PLS component for the analysis in binary mixtures. 
This component captured 94% of the variance in the X-variables, demonstrating that the 
information contained in the spectral data was effectively used in calibration models. The 
correlation coefficient (R
2
) of the experimental data was 0.995 and the cross-validated R
2
 (also 
termed as Q
2
) was 0.994. The root mean square errors of calibration (RMSEC) and cross 
validation (RMSECV) were 1.89% and 2.24 %, respectively. The value for the root mean square 
error of prediction (RMSEP) was 2.73 %. The region was chosen due to the absence of 
excipient’s interference in this region.  
At 75%RH/25⁰C, OLZ dihydrate D became evident in OLZ:PEG (1:1 and 3:1) and 
OLZ:HPC (1:1) samples. The dihydrate D content of these 3 samples after 7, 14, 21 and 28 days 
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are shown in Table 4.2. After 28 days all samples presented mixtures made of OLZ anhydrous 
Form I and dihydrate D.  
 
Table 4.2 – OLZ dihydrate content in samples stored at 75% RH/ 25ºC, for different  days 
Time (days) 
Dihydrate conversion (%) 
Formulations (API: Polymer proportions) 
B1 (1:1) B2 (3:1) C1 (1:1) 
7 0.5 ± 0.2 0.2 ± 0.0 0.3 ± 0.1 
14 9.5 ± 1.6 0.5 ± 0.1 0.9 ± 0.2 
21 35.2 ± 1.5 7.8 ± 0.7 10.6 ± 0.4 
28 55.2 ± 2.6 20.2 ± 0.9 14.0 ± 0.7 
 
At 93% RH, PEG showed to increase the rate of hydrate formation of OLZ; within 2 
weeks OLZ was completely hydrated, regardless of the PEG content in the sample ( 
Table 4.3).  
The hydrate conversion rate of OLZ in the presence of lower contents of HPC 
(OLZ:HPC, C2) showed to increase in comparison to the OLZ sample which was stored without 
the addition of any excipient ( 
Table 4.3).  
Higher contents of the same polymer (OLZ:HPC, C1) showed to reduce the hydrate 
conversion rate significantly when these mixtures were stored at 93%RH. This suggests that 
changes on the HPC due to humidity may cause changes on the hydrate conversion rate. 
 
Table 4.3 – OLZ dihydrate content present in each sample stored at 93% RH/ 25ºC for different 
periods 
 
 
Time 
(day) 
Dihydrate conversion (%) 
Formulation (API: Polymer proportions) 
A B1 (1:1) B2 (3:1) C1 (1:1) C2 (3:1) D1 (1:1) D2 (3:1) 
7 8.4  ± 0.2 93.1 ± 0.4 76.1 ± 2.7 9.3 ± 0.8 8.7 ± 1.3 2.8 ± 0.5 2.0 ± 0.6 
14 29.1 ± 0.2 99.4 ± 1.1 99.8 ± 1.2 25.2 ± 0.5 34.5 ± 2.1 2.6 ±  1.1 1.7 ± 0.4 
21 48.2  ± 0.3 100.1 ± 0.6 100.3 ± 0.6 29.6 ± 0.8 56.2 ± 1.2 2.4 ± 1.3 1.6 ± 1.2 
28 62.1  ± 0.4 99.8 ± 1.1 100.2 ± 0.4 35.0 ± 0.7 65.6 ± 1.1 2.8 ± 0.8 1.8 ± 0.6 
 
The thermograms of the physical powder mixtures before storage showed that OLZ’s 
enthalpy was largely reduced when physically mixed with either PEG or PVP (Figure 4.5 a and 
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c), showing the ability of both polymers to dissolve OLZ when the mixtures were heated, 
contrarily to HPC.  
The samples stored at different humidity showed a broad band due to the water 
evaporation. These bands were broader for OLZ mixed with PEG, PVP and HPC stored at 93% 
RH due to the increased water sortpion ability of these polymers at this high humidity. 
Figure 4.5 a) shows the elimination of the melting peak associated with PEG, when 
these samples were stored at 93% RH which is indicative of a polymer crystallinity loss. The B1 
samples (75% RH), showed a broad band due to water evaporation after the melting of the 
polymer. Figure 4.5 b) revealed two overlapped broad bands between 70-110 ºC when 
OLZ:HPC mixtures were exposed to 75% RH and 93% RH. These two broad bands may 
originate from the elimination of the water molecules present in both HPC and OLZ dihydrate D 
structures (Figure 4.5 b). All the OLZ:HPC stored samples showed broader melting peaks for 
OLZ with the OLZ Tmonset starting about 2 ºC before the physical mixture. The water sorption 
by PVP also led to the broadening of OLZ melting peak, with the Tmonset of OLZ registering a 
decrease of about 10 ºC for all the stored D formulations. (Figure 4.5 c). 
 
Figure 4.5 – Thermal analysis of the drug:excipient samples after being kept at different conditions 
of storage during 28 days. a) Formulation B1 (OLZ:PEG); b) Formulation C1 (OLZ:HPC); c) 
Formulation D1 (OLZ:PVP) 
The observation of particles' surface by electronic microscopy (SEM) revealed that OLZ 
raw material presented an irregular shape. The hydrate conversion of OLZ did not lead to any 
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change of the particles’ shape (Figure 4.6), which suggests that the phase transition occur in the 
solid-state without passing through intervening transient liquid phase.  
The mixtures of OLZ with the 3 polymers stored at 93% RH showed that the amount of 
water absorbed by the polymers resulted in coverage of OLZ particles by the plasticized 
polymers, which did not allow observing changes on the particles surface. The optical 
microscopy with polarized light was useful on the observation of the OLZ particles even in the 
presence of the polymers. It was noticeable that OLZ particles in PEG samples can completely 
change their morphology; the irregular particle shape was converted to a lath shaped 
morphology, suggesting that the hydrate mechanism of OLZ in this sample occurred by a 
different mechanism.  
 
Figure 4.6 – SEM pictures and MO with polarized light pictures of the anhydrous starting 
materials (a), formulation A (b), formulation B2 (c), formulation C2 and D2 (e). 
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4.5.3 Phase transformation in compacts: 
Thermograms of powders and freshly prepared compacts of formulations A, B2, C2 and 
D2 are presented in Figure 4.7 a). It was possible to observe a reduction of melting temperature 
(Tm) and melting enthalpy (∆H) of OLZ when OLZ or the physical mixtures of OLZ:polymer 
were compacted. Figure 4.7 b) exhibits a reduction of the intensity of the crystalline peaks of 
OLZ (A P) when it is compacted (A C), reflecting a loss of crystallinity of the sample.  
 
Figure 4.7 –Themograms and the respective melting temperature and enthalpy of OLZ (a) in 
different formulations before (powders, p) and after (compacts, c) compaction; b) shows the X-ray 
diffractograms of OLZ before and after compaction.    
 
Figure 4.8 shows the OLZ dihydrate D content in different formulations (powders and 
compacts) after being stored for 7 and 28 days at 93% RH. OLZ, compressed alone, showed to 
have an increased dihydrate D content in the first days of storage when compared to the OLZ 
raw material stored as a powder. However, after 28 days the dihydrate D content present within 
the compactes showed to be about 12%, which was much lower than the dihydrate D content in 
OLZ powder sample (62 %). 
For compacts containing mixtures of drug and polymer, a larger percentage of dihydrate 
D in the compacts after 7 days of storage when compared to the uncompressed material was 
found. In the case of OLZ:PEG compacts, a complete hydration of OLZ was observed in only 
one week. As found for OLZ, the compacts of physical mixtures showed a slight increase or 
stagnation of hydrate formation between the 7
th
 and the 28
th
 days.  
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Figure 4.8 –OLZ dihydrate D content in formulations A, B1, C1 and D1 (a) and formulations B2, 
C2 and D2 (b), stored for 7 days and 28 days at 93% RH. The figure includes the formulations as 
powders or compacts.  
 
4.5.4 Conversion kinetics of OLZ in aqueous suspensions 
This study was conducted to obtain an insight into the mechanism of interaction 
between OLZ and various polymers in aqueous environments and to have a deeper 
understanding of the observed results during storage. Figure 4.9 shows the FTIR spectra of OLZ 
within the 720-1020 cm
-1 
range. The spectra display OLZ powders filtered after being 
suspended in water or polymeric solutions for different periods (15, 45 and 60 minutes) and 
dried at room temperature 25ºC/24h. Experiment E showed a mixture of anhydrous OLZ and 
dihydrate B after 45 minutes (Figure 4.9), whereas in experiment F only anhydrous OLZ was 
found after 45 minutes. This result revealed a slower hydration rate of OLZ when suspended in 
PEG solutions. The hydrates formed in this experiment were different from the ones obtained 
during storage at 93% RH. In spite of the aggitation (secondary nucleation is likely to take 
place) and the high content of free water molecules availabe to bind OLZ molecules, OLZ 
showed to remain anhydrous when stirred in HPC and PVP solutions (G and H) for 60 minutes. 
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Figure 4.9 – FT-Infrared spectra of powders recovered after 15, 45 and 60 min from the different 
suspensions.  The main shifts are represented with a grey bar. 
 
4.6 Discussion 
Pharmaceutical formulations are commonly multi-component systems. In these systems 
the moisture sorption may exhibit a complex and non-additive behavior (148), which needs to 
be understood in detail, especially when absorbed moisture may induce unexpected phase 
transformations with new properties in the solid-state. The physical stability of an API when 
exposed to high RH in the presence of hygroscopic excipients has been the focus of a number of 
literature reports (200, 209, 210) and it has been observed that hygroscopic excipients are prone 
to retard hydration kinetics under humid conditions (211). In our studies, it was observed that 
excipients could enhance, retard, or have little effect on the hydration rate of OLZ.  
4.6.1 Polyetyleneglycol (PEG) 
PEG is a semi-crystalline material (201). In addition to PEG’s surface adsorption ability 
of, it is widely accepted that it can also absorb moisture into its amorphous regions (201). When 
water is absorbed into the amorphous regions of the polymer, it serves to increase the disordered 
fraction of PEG (148, 212), which is a mechanism that is going to be taken into consideration on 
the following discussion. 
Results showed that PEG displayed small weight changes at 75% humidity ( 2.5±0.9% 
after 28 days) but at 93%RH, the water uptake was about 53% w/w after 28 days. Regarding the 
water uptake mechanism for this polymer, a number of favorable polymer–water hydrogen 
bonds are firstly created, forming a film of adsorbed water molecules on the polymer surface 
(213). It was proposed that when this first water film is formed, to allow more water uptake, the 
PEG chains will adapt the desired conformation of the polymer chains to be able to form 
extensive hydrogen bonds with water, allowing the uptake of more water. PEG’s ability to sorb 
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large amounts of moisture results from the presence of ether oxygen atoms (–O–) in the 
oxyethylene polymer backbone as well as hydroxyl (–OH) end groups, both of which can form 
several hydrogen bonds with water (213). 
Results from calorimetric experiments showed a decrease and elimination of the melting 
transition when PEG was exposed for 4 weeks at 75% RH/25 ºC and 93% RH/25 ºC, 
respectively, which reveals loss of crystallinity. Previous studies have observed that at RH 
below 70% water molecules can enter in the PEG matrix forming hydrogen bonds with oxygen 
atoms in the PEG chains. However, water molecules do not form condensed clusters when there 
are still oxygen atoms in PEG available to act as an electron donor for H-bonds with water 
molecules (214). At RH of over 70%, the full amount of oxygen atoms in the polymer chain is 
taken by water molecules. For this reason, the additional water molecules will interact with the 
ones already absorbed in the PEG structure, forming water clusters (214). Furthermore, 
absorbed water also acts as a plasticizer for the polymer (214), which enables the growth of 
water clusters in the polymer due to the increased mobility of polymer chains and increased 
available space due to swelling. An increase in RH (>90%) may lead to an amount of absorbed 
water sufﬁcient to dissolve the PEG (213, 215). This was observed in our experiments. The 
visual inspection of the PEG samples during the 28 days at 93% RH showed a solid-to-solution 
phase transformation of this polymer, which indicated that PEG started to dissolve on the 
condensed adsorbed water. 
Our results revealed that OLZ could undergo hydrate formation at 75% RH when mixed 
with PEG, which was never observed when OLZ was stored alone. At 93% RH, OLZ samples 
could fully hydrate and increased PEG contents showed faster hydrate conversions. The 
complete conversion of anhydrous OLZ into the dihydrate D form (weight increase of 10.3 % 
w/w) was completed by the end of 15 days, regardless of the PEG content. The hydration of 
OLZ at lower relative humidity and at faster rates when physically mixed with PEG may be 
explained by the formation of condensed water (water clusters) within the mixture, which were 
available to dissolve OLZ particles. The complete change of morphology of the crystals of OLZ 
indicate that the transformation could potentially occur (at least partially) in solution (201), i.e, 
anhydrous OLZ was able to dissolve into the bulk water and the nucleation and crystal growth 
of the more stable dihydrate form has occurred. The higher rates of hydrate conversion of OLZ 
in compacts with PEG may be explained by the partial loss of crystallinity of the sample and the 
more intimate contact between the drug and the polymer, resulting in a complete hydrate 
formation in one week for both OLZ:PEG ratios used. 
4.6.2 Polyvinylpyrrolidone (PVP) 
PVP is an amorphous and hygroscopic polymer (216). At 25 
°
C PVP absorbs 
approximately 5-/10% moisture at 10% RH, but this value increases significantly as the relative 
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humidity above the samples is increased (126). On exposure to 93% RH, our results showed that 
PVP could absorb approximately 55% of moisture, based on the dry mass of the sample. Water 
vapor is a well-known plasticizer. Also, water molecules can influence the free volume due to 
the breakage of hydrogen bonds between the molecules in the solid. This can lower the glass 
transition temperature (Tg) to (or below) the operation temperature, changing it from a glassy to 
a rubbery solid-phase states (216). 
The kinetics of vapor absorption for PVP samples stored at the different humidity 
environments were examined and it was found that PVP rapidly absorbed moisture and reached 
apparent equilibrium (i.e., becomes saturated with vapor) after one week of storage (data not 
shown). The rate of moisture sorption appears to be much shorter than the observed timescale 
for hydrate transformation, once PVP was able to inhibit hydrate conversion during the 28 days 
of storage at all three different environment conditions. This suggests that desiccant effect of 
PVP is not the only mechanism responsible for hydrate inhibition of OLZ. Obviously, the 
viscoelasticity and the volume of the polymer tremendously changes due to the glassy to 
rubbery transition (216). It was possible to visualize the smoothening of the surface of PVP 
(SEM images) due to the increased molecular mobility associated with the transitions from the 
glassy state to the super-cooled liquid. Therefore, the physical state of the polymer at high 
humidity needs to be considered (60). It was also observed that this change in polymer structure 
when exposed to high humidity resulted on the decrease of the tensile strength of compacts, 
making them soft and deformed at touch (216). Thus, this highly plasticized PVP covered OLZ 
particles, becoming in intimate contact with the API particles. However, contrary to PEG, no 
hydrate conversion was verified. In samples with PEG the dissolution of the polymer in the 
condensed water enhanced hydration of OLZ by providing an aqueous medium for 
transformation to occur in solution phase. In the case of PVP, there are a number of possible 
explanations for these changes to be inhibited. Firstly, the extent of dissolution into PVP should 
be reduced due to the higher viscosity of the plasticized polymer that showed to present a “gel-
like” structure (visual inspection). This was also observed in a previous study where PVP k90 
showed to form a highly viscous structure after exposure to 94% RH, reducing the contact area 
with the API, and, consequently, the hydrate formation (60). Secondly, in the aqueous slurries 
of OLZ in PVP and PEG solutions (higher contents of water available), one has observed that 
no hydrate transformation of OLZ was visible in the presence of PVP, showing that this 
polymer is a much more effective inhibitor than PEG in aqueous environments. The higher 
hydrogen bond ability of this polymer relatively to PEG (194) may justify the stronger 
inhibitory effect of PVP. The formation of hydrogen bonds between polymers and the drug 
inhibits the latter from establishing hydrogen bonds with water molecules. Thus, the protection 
of pseudopolymorphic transformations is likely to be a combination of all these factors, 
resulting in the observed differences. 
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4.6.3 Hydroxypropyl cellulose (HPC) 
Water vapor absorption by HPC occurs by the same basic mechanism as it does with 
other types of celluloses, i.e, water is only absorbed in the non-crystalline regions of celluloses 
(217). Therefore, the high content of amorphous domains in the HPC excipient results in its 
higher water absorption ability when compared to other celluloses, such as, microcrystalline 
cellulose (218). In this study, OLZ showed to hydrate faster in the first week when mixed with 
HPC. Since moisture is commonly selectively taken up by the most hygroscopic component, the 
increase of OLZ hydrate formation would not be expected, which leads to a deeper 
understanding of water uptake by this polymer. Water-vapor sorption-desorption isotherms 
which were calculated to characterize the uptake of water by HPC showed to fit the Young-
Nelson model (219), a model originally developed to account for water uptake by wheat.  It 
assumes that moisture absorbed by the solid has 3 locations: monolayer adsorption (bound 
water), externally adsorbed moisture (normally condensed) and internally absorbed moisture. In 
the case of HPC, the internally absorbed moisture results from the water diffusion through pores 
into the core of the particle from the adsorbed monolayer (218, 220). Therefore, the absence of 
protection of the OLZ hydration by this hygroscopic polymer may be justified by the interaction 
of the condensed water molecules encountered on the surface of HPC (water molecules above 
the monolayer moisture, i.e, externally adsorbed moisture) with OLZ molecules. Furthermore, 
HPC has shown to have a lower capacity to absorb water vapor internally when compared to, 
for instance, other hydroxypropyl celluloses with low degrees of substitution (L-HPC) (218). 
When water molecules penetrate the HPC structure they include themselves into the 
hydrogen-bonded links between adjacent polymer chains. As a consequence, polymer chains 
become more independent of each other and occupy more space, resulting in the swelling of the 
polymer mass (218). As a result of the swelling process, the chains are extended, resulting in 
more locations available for hydrogen bonding and further molecular entanglements (221). The 
latter process requires certain time to reach deeper layers (222). As a result of extension of 
chains and the increase of more hydrogen bonding locations, hydrogen bonding with OLZ may 
occur justifying the abrupt reduction of the hydrate formation rate, when higher contents of 
HPC were used in the formulation. This hydrogen bonding with OLZ may hinder the hydrogen 
bonding of OLZ with water molecules. When OLZ was suspended in HPC solutions it did not 
hydrate as occurred with PVP. The hydrogen bonding between the drug and the excipients has 
been pointed out as an important factor on polymorphic inhibition in aqueous solutions (194). 
Therefore, the presence of both hydrogen bond donor and acceptor groups in the HPC ring 
structure may have facilitated the interaction with OLZ molecule. Furthermore, the 
plasticization of the polymer seemed to form a thick gel layer around the OLZ particles, which 
was observed by SEM and visual inspection. The formation of this gel may also hinder OLZ 
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particles’ dissolution into condensed water and/or prevent moisture penetration into the OLZ 
crystal when higher contents of HPC were used. 
4.6.4 Pseudopolymorphic transformations in compacts 
Tableting is a process which may potentiate the occurrence of phase transformations in 
either the drug or the excipients via the solid-state mechanism. Most of the data supports the 
idea that the transformations from one polymorphic form to another during tableting results 
from an intermediate amorphous phase (83). These transformations are current as exemplified 
by caffeine, sulfabenzamide and maprotiline hydrochloride which have been reported to 
undergo polymorphic transformations during compression (114). 
The diffractograms of compacted OLZ showed neither missing nor new diffraction 
peaks of OLZ, which means that no polymorphic transformation occurred under compression. 
However, it was observed that, upon compression, diffraction experiments showed a loss of 
intensity and broadening of OLZ peaks. This was probably due to the induction of lattice 
disorder in the surface of anhydrate promoted by compaction. The reduction of melting 
temperature enthalpy of OLZ also revealed loss of crystallinity of the drug induced by 
application of pressure. This phenomenon was observed for both drug and drug:polymer 
mixtures. 
For all the compacts OLZ showed to hydrate faster after 7 days of exposure to 93% RH 
than in the physical powder mixtures. In solids, nucleation tends to proceed from dislocations in 
a crystal because of their higher free energy; for this reason, the activation energy barrier for 
transformation is lower at these sites (114). Moreover, during compression the plastic flow 
induces dislocational strains in a crystal, thereby facilitating nucleation. However, the OLZ 
compacts showed only a minimal increase on the dihydrate D content after 28 days. The 
reduced hydrate conversion may be justified by the low specific surface area of the compacts in 
relation to the powders. This fact resulted on a reduction of the amount of molecules of OLZ in 
direct contact with the water vapor. Furthermore, the diffusion rate of water molecules through 
the OLZ crystal lattice may be compromised on the core of the tablet. 
4.6.5 Conversion kinetics of OLZ in aqueous suspensions 
Results showed that no hydration occurred for OLZ suspended in PVP and HPC 
polymeric solutions, whereas hydrate conversion was observed in PEG solution. Previous 
studies have shown that the effectiveness of a polymer as a crystallization inhibitor is highly 
dependent on its structure, due to the formation of specific intermolecular interactions between 
the polymers and the drugs (143, 223). These interactions have been found to contribute to the 
adsorption of polymer onto solids and thus, controlling a number of interfacial processes such as 
crystal growth. Specific intermolecular interactions (such as hydrogen-bonding) and non-
specific hydrophobic drug–polymer interactions appeared to be important in determining the 
Chapter 4 
104 
impact of a given polymer on crystal growth effectiveness (143). The adsorption to the crystal 
surface interface promotes sterically hindrance to the access of the solute molecules to the 
crystal terrace. 
All of these polymers have the ability to form hydrogen bonds with OLZ molecule. 
PEG has ether oxygen groups in its chain and two hydroxyl groups at the two ends of the 
polymer chain; PVP presents one acceptor hydrogen bonding group in its ring structure. 
However, the carbonyl oxygen of PVP is able to form stronger hydrogen bonds than the ether 
oxygen groups of  PEG, explaining its stronger protection against crystal growth (194). In other 
study with acetaminophen, the stronger inhibitory effect of PVP was also attributed to lower 
mobility of the functional groups involved in specific polymer-drug interactions when compared 
to PEG. 
HPC is constituted by a cellulose derivative polymer, with both hydrogen bond donor 
and acceptor groups in its ring structure, also presenting a certain hydrophobic nature that 
showed to have an impact on avoiding and retarding the hydrate conversion of a few of other 
drugs  (194, 196). 
The effect of these polymers on crystallization of OLZ is going to be explored in the 
next chapter in more detail. 
4.7 Conclusion 
This study provided an insight into the role of hygroscopic polymeric additives on the 
stabilization of OLZ anhydrous Form I. The study showed that the stabilization of anhydrous 
OLZ in humid environments was dependent on the type of polymer and the amount of polymer 
present in the formulation. For example, both PEG and HPC showed to induce hydrate 
transformations of OLZ at a relative humidity of 75%. Since OLZ cannot hydrate at this 
humidity when it is stored alone, this result highlighted the importance of the right choice of 
formulation design in order to maintain the drug stable in the final product. At 93% RH, PEG 
showed to absorb high contents of moisture, which allowed OLZ to undergo a solvent-mediated 
transformation, accelerating the hydrate conversion rates of OLZ. PVP also showed to uptake 
high moisture contents but, contrary to PEG, PVP was able to protect OLZ from undergoing 
hydrate transformation. In aqueous environments, when a higher content of free water 
molecules was available to bind OLZ, PVP also showed to protect OLZ from hydration. It was 
therefore possible to extrapolate that PVP could form specific interactions with the drug, which 
inhibited OLZ to form hydrogen bonds with the water molecules. Regarding HPC, the protector 
effect of this polymer seemed to be related to the content of this polymer within the sample. 
Since during the swelling of the polymer there are more hydrogen bond locations available to 
bind with the OLZ molecule, this process was amplified when there were more molecules of 
HPC in the system available to bind with the OLZ molecule. Compaction of OLZ revealed to 
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slightly reduce its crystallinity, inducing a faster hydrate formation in the first days of storage. 
Compaction also led to close contact between OLZ and polymers, which resulted in an 
acceleration of hydrate formation when OLZ was mixed with PEG. 
Overall, since the choice of the formulation design is important, in order to produce a 
product with a consistent quality performance throughout the product’s shelf life, attention 
should be payed to the excipients used in the formulation, helping to avoid the formation of 
metastable phases that may affect the final product quality. Furthermore, being OLZ a drug 
commonly used in the treatment of schizophrenia, an illness which requires patients to be kept 
clinically stable and in good compliance with the treatment, minor changes on the 
bioavailability could affect the stability of the patients, with a decrease on their compliance. 
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Chapter 5 -  An insight into the impact of polymers on the hydrate 
conversion of olanzapine Form I in aqueous suspensions 
 
5.1 Abstract  
Hydrate conversion of anhydrous drugs may occur during wet agglomeration processes 
(e.g. fluidized bed granulation). The objective of this study was to assess the  
polyethyleneglycol’s (PEG-6000/ PEG-40000), polyvinylpyrrolidone’ s (PVP K30) and 
hydroxypropylcellulose’ s (HPC LF) potential to inhibit the hydration process of OLZ in an 
aqueous environment (e.g. suspension), thus understanding their mechanims of action. OLZ 
Form I (OLZ FI) was suspended either in double-distilled water (A) or in aqueous polymer 
solution (2, 0.2, 0.02 and 0.002%) [PEG 6000 (B), PEG 40000 (C), HPC LF (D) or PVP K30 
(E)] and stirred at 200 rpm for 3h. Samples were collected at different times and were filtered 
and analyzed by different techniques (XRPD, FTIR, DSC, 
1
H-NMR). The results suggested that 
OLZ suspended in PEG solutions (B and C) showed to hydrate regardless of the polymer chain 
and concentration considered. OLZ hydrate conversion showed to be faster in water than in 
PEG solutions. OLZ recovered from D and E suspensions remained anhydrous at concentrations 
of 2-0.02%.  The nuclear magnetic resonance measurements revealed that all of these polymers 
are able to establish hydrogen bonding with the OLZ molecule. It was found that all of these 
polymers can increase the OLZ saturation solubility. Only HPC LF and PVP K30 showed to 
increase the wettability of the OLZ particles after exposure to the respective solutions, 
suggesting binding of these polymers to the surface of OLZ crystal surfaces.  The inhibition of 
the process of hydration by both polymers showed to be related to both the H-bond ability and 
the stronger bonding of these polymers to the crystal surfaces of the hydrate nuclei / first 
crystals, preventing the crystal growth.  This study provided an insight into the main 
mechanisms of hydrate protection of OLZ by polymers confirming the advantage of using either 
PVP K30 or HPC LF as excipients in granulation processes to prevent OLZ hydrate formation, 
in aqueous solutions in concentrations as low as 0.02%. 
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5.2 Introduction 
The previous chapter showed that different polymers may interact differently with OLZ 
Form I (OLZ FI) in aqueous environments. Since in wet agglomeration processes, such as wet 
granulation or extrusion in particular, the formation of hydrates may pose severe problems 
during manufacturing (79) (80). The study of the interactions of OLZ with polymers in aqueous 
environments is, thus, important to be explored in more detail. Furthermore, the small 
recommended dose for OLZ (maximum dose of 20 mg per day) (178) enhances potential 
problems due to changes on its solubility, with an impact on the amount of drug dissolved and 
consequently on the absorption into the plasmatic stream, which may simply be due to minor 
modifications of the crystalline structure of the drug (e.g. hydrate formation). 
In recent years, the study of the impact of addition of polymeric excipients on the 
preventing the hydrate formation of APIs in aqueous environments has attracted some attention 
(196, 224, 225). Polymers may inhibit crystallization at both the nucleation and growth stages 
and several mechanisms may be involved (194, 197). For instance, polymers can change 
viscosity, solubility or the properties of the hydrodynamic boundary layer surrounding the 
crystal, thereby decreasing the rate of diffusion of the drug molecules to the crystal nuclei (226). 
They can also adsorb into the crystals surface interface, due to hydrophobic and hydrogen 
bonding type interactions, blocking the access of the solute molecules to the crystal terrace (39, 
196, 227). The different inhibitory behaviors therefore result from the type of interactions 
between drug and polymer, which may vary for each polymer and API. Nuclear magnetic 
resonance (NMR) has been shown to be a powerful tool to detect intermolecular interactions 
between different components and to characterize the type of interactions between the drugs and 
excipients. NMR has already been used to detect specific binding between drugs and 
cyclodextrines, surfactants or polymers (143, 228, 229).  
OLZ is commonly used in the treatment of schizophrenia, an illness which requires 
patients to be kept clinically stable. The small recommended dose for OLZ (maximum dose of 
20 mg per day) enhances potential problems due to changes on its solubility, with an impact on 
the amount of drug dissolved and consequently on the absorption into the plasmatic stream, 
which may simply be due to modifications of the crystalline structure of the drug (e.g. hydrate 
formation). 
5.3 Purpose 
The purpose of this study was to explore the OLZ hydrate transformation in an aqueous 
medium and the mechanism of interaction between OLZ and various polymers in aqueous 
suspension. For this study, OLZ was suspended in different polymer solutions, namely 
polyethyleneglycol (PEG), hydroxypropylcellulose (HPC) and polyvinylpyrrolidone (PVP). In 
particular, this study aims: (1) to characterize the potential hydrate conversions of OLZ in 
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polymeric solutions over time; (2) to detect changes in the wettability of the powders collected 
due to potential binding to polymers; and (3) to understand the mechanisms of inhibition of 
hydrate formation by the polymers through the study of the rheological properties of the 
polymeric solutions and the saturation solubility of OLZ in each polymeric solution. 
5.4 Materials and methods 
OLZ anhydrous Form I [OLZ FI, molecular weight (Mw) = 312.43 g/mol] was 
purchased from Pharmorgana, India. The polymers considered in the study were polyethylene 
glycol with different molecular weights (PEG, Mw = 6000 and 40000, Sigma-Aldrich, 
Germany), hydroxypropyl cellulose (HPC LF Pharm grade, Mw = 95000, Klucel™, Ashland, 
Germany) and polyvinylpyrrolidone (PVP, Kollidon 30, 44000 < Mw < 54000, BASF 
Chemicals, Germany). Other chemical were supplied by Sigma-Aldrich, Germany. 
5.4.1 Preparation of samples for solvent-mediated conversion studies 
OLZ (100 mg) was dispersed in triplicate into 5 mL aqueous solutions/polymer solution 
with different polymer concentrations (Table 5.1) during 180 min. Suspensions were agitated 
using a magnetic stir bar (200 rpm) and then recovered by vacuum filtration to remove excess of 
water. The powders were transferred into XRPD sample holders and analyzed immediately. 
 
Table 5.1– Formulations for hydrate conversion studies.  
5.4.2 Characterization of the different formulations 
X-ray Powder Diffraction (XRPD) 
The structural characterization of OLZ formulations were carried out by X-ray powder 
diffraction (XRPD) on an Analytical X’Pert PRO apparatus, NL (Equipment 2, chapter 2). 
Diffractograms were obtained by continuous scanning in a 2θ range of 7–35 with a step size of 
0.017° and scan step times of 20 sec. X-ray diffraction characterization was performed to the 
different formulations before and after the end of the study (180 min) in order to observe the 
hydrate conversions of OLZ in each sample. 
Polymers 
Formulation 
code 
 Experiments 1 2 3 4 
No polymer A  OLZ:Polymer ratio 1:1 10:1 100:1 1000:1 
PEG 6000 B  
Polymer concentration 
(%, w/v) 
2% 0.2% 0.02% 0.002% 
PEG 40000 C  Each formulation with a different polymer has a different letter 
(formulation code) and each OLZ:polymer ratio used has a 
different number 
 
HPC LF D  
PVP K30 E  
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Differential Scanning Calorimetry (DSC) 
Thermograms of different samples were obtained with a Differential Scanning 
Calorimeter (TA instruments, Q200, New Castle, USA). Dry N was used as the purge gas (Air 
Liquide, mL/min). OLZ was allowed to dry at room humidity and temperature (55% RH/25 ºC) 
before analysis in order to remove the excess of water. Samples (2–3 mg) were placed in 
pinhole crucibles and heated at 10 ºC/min within 0–210 ºC temperature range. 
FT-Infrared Spectroscopy (FTIR) 
Each sample was mixed with KBr in a 1:100 proportion and the mixture (200 mg) 
compacted into compacts (12 mm diameter). The infrared spectra were collected in the 
absorption mode (IR Afﬁnity-1Shimadzu spectrophotometer, Kyoto, Japan) based on 64 scans 
with a resolution of 2 cm
-1
. 
Scanning Electron Microscopy (SEM) 
OLZ powders were analyzed by scanning electron microscopy. The samples were 
mounted on aluminum stubs and coated with gold by ion sputtering (JEOL JFC-1200 Fine 
Coater, Tokyo, Japan) and observed under scanning electron microscope (JSM-5200 LV, 
Tokyo, Japan). 
5.4.3 Wettability Measurements 
In order to measure the wettability of OLZ before and after being exposed to polymeric 
solutions, the contact angles in bi-distilled water were measured (Wilhelmy plate technique, 
Krüss Tensiometer K12, Hamburg, Germany). Samples of powders were made to adhere on a 
rectangle shape substrate (20 x 20 mm) uniformly coating its surface. All measurements were 
performed at a controlled temperature of 25 ± 0.5 ºC by ﬂowing water from a circulator (Krüss).  
5.4.4 Viscosity studies 
The viscosity of the polymeric solutions at 2% and 0.2% w/v was measured. The 
capillary measurement method was used. The constant of the viscometer (k) is 0.02978 mm/s
2
 
and the equation used, based on the Poiseuille's Law, was: η = k. t. ρ, where: η represents the 
viscosity of the solution; k is the constant of the viscometer; t represents the time the liquid 
takes from going from A to B (2 points marked in the viscometer); and ρ represents the density 
of the solution, measured beforehand with a densitometer. 
5.4.5 Determination of OLZ solubility in different solutions 
An excess of OLZ powder (approximately 10 mg) was placed into 4 ml Eppendorf cups 
and 2 ml of the respective stabilizing medium was added (PVP, HPC and PEG solutions at 2%, 
0.2%. 0.02%, 0.002% w/v). The cups were sealed and placed into a water bath at 25 ºC shaking 
at 100 rpm. After 36 h the Eppendorf cups were centrifuged at 12000 rpm for 20 min (Sigma 
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202K, Germany). The concentrations of dissolved OLZ were determined with a UV apparatus 
254 nm (Higuchi, Japan). 
5.4.6 1H- RMN measurements 
A solution of OLZ (10 mg) in 0.5 mL of deuterated chloroform (CDCl3 ) was prepared. 
Afterwards, a solution of the polymer (10 µL, 1.0 mg/mL) was added to the OLZ solution and 
the latter was allowed to stabilize for 5 min before the 
1
H-NMR spectra measurement 
(OLZ:polymer 1000:1). A solution of the polymer (10 uL, 9.0 mg/mL) was added to the 
previous solution. This solution was allowed to stabilize for 5 min and the 
1
H-NMR spectra was 
measured (OLZ:polymer 100:1). To the above solution, 0.9 mg of the polymer was added and 
allowed to stabilize for 5 min before the 
1
H-NMR spectra measurement (OLZ:polymer 10:1). 
Finally, to the previous solution 9.0 mg of the polymer was added and allowed to stabilize for 5 
min before the 
1
H-NMR spectra measurement (OLZ:polymer 1:1). 
NMR spectra were recorded in a Bruker Avance II 300 Ultrashield  Plus. The 
1
H- RMN 
spectra was obtained at 25 ºC. 
5.5 Results 
5.5.1 Conversion of OLZ in aqueous suspensions 
This study was conducted to obtain an insight into the mechanism of interaction 
between OLZ and various polymers in aqueous environments. Figure 5.1 shows the X-ray 
diffractograms of different OLZ forms. The diffractograms for the recovered samples from 180 
min suspensions are shown in Figure 5.1. The characteristic peaks of dihydrate B (higher 
proportion) and higher hydrate (lower proportion) can be observed in OLZ which was 
suspended in water (A1). Regarding OLZ recovered from PEG solution (B1), it could be 
observed that it was selectively hydrated into the higher hydrate form (Figure 5.1). This form 
showed to dehydrate into the dihydrate E in a few hours when stored at room humidity and 
temperature (25 ºC/55% RH ). OLZ showed to remain anhydrous when stirred in HPC and PVP 
solutions (Figure 5.1). The DSC analyses showed that the different OLZ hydrates recovered 
from water (A1) and PEG solution (B1 and C1) had different dehydration temperatures (Figure 
5.1). 
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Figure 5.1 – Diffractograms and thermograms of powders filtered from the different suspensions 
after 180 min. Grey bar highlights the characteristic peaks of OLZ hydrates. 
Figure 5.2  shows the FTIR spectra of all of the recovered samples within the 720 cm
-1
-
1020 cm
-1 
range. In this region, the band patterns of the OLZ hydrates and anhydrous Forms I 
can be easily distinguished. OLZ recovered from the formulations B and C after 180 min 
showed to hydrate in all of the different samples, regardless of the PEG content in the 
formulations. OLZ recovered from polymer solutions D and E showed to remain anhydrous 
when the polymer concentration was 2%, 0.2% and 0.02%.  
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Figure 5.2 – FT-Infared analyzes of OLZ recovered from the different polymeric solutions  
(A, B1-B4, C1-C4, D1-D4, E1-E4). 
Figure 5.3 shows the rates of OLZ hydration in water and PEG solutions. It was 
possible to observe that hydrate formation is faster in water and slower in PEG 40000 solution.  
In PEG 40000 solution, hydrate formation was visible only after 180 min of stirring. 
 
 
Figure 5.3 – FT-Infared analyzes of OLZ recovered from the polymeric solutions A, B1 and C1  
at different time periods. 
Figure 5.4 a) shows a SEM micrograph of OLZ raw-material, which is characterized by 
having an irregularly shape. Regarding OLZ particles which were suspended in PEG solutions 
for 180 min (Figure 5.4 b and c), one may observe that OLZ particles had their morphology 
changed due to hydrate formation. In contrast, formulations D1 and E1 showed no 
modifications on OLZ particles’ morphology over the same period (Figure 5.4 d) and e). 
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Figure 5.4 – SEM micrographs of (a) OLZ Form I (raw material)  
and formulations B1, C1, D1and E1. 
 
5.5.2 Viscosity 
Table 5.2 shows the viscosity of polymeric solutions at the highest concentrations: 2% 
and 0.2%. Results showed that HPC polymer solutions present the highest viscosity. At 0.2% all 
solutions presented low viscosity values (< 1.2 mPa.s). Polymer solutions can be ordered in 
terms of their viscosity in the following manner for both concentrations:  HPC<PEG 
40000<PVP k30< PEG 6000. 
 
Table 5.2 – Viscosity measurements of the two most concentrated polymer solutions 
 
 
 
 
 
 
 
 
 
 
 
Solutions 
Viscosity (mPa.s) of the 
polymer solutions 
Water - 
PEG 40000 (2%) 1.686 
PEG 40000 (0.2%) 1.104 
PEG 6000 (2%) 1.186 
PEG 6000 (0.2%) 1.006 
HPC (2%) 7.394 
HPC (0.2%) 1.144 
PVP (2%) 1.292 
PVP (0.2%) 1.009 
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5.5.3 Wettability of the recovered OLZ 
Table 5.3 shows the contact angle of the raw-materials and filtered OLZ particles 
(t=180 min in water or polymeric solution) with water. While the contact angle of the filtered 
OLZ particles in formulations B1, C1 and E1 showed a contribution of the contact angles of 
both polymers and OLZ raw-materials, the contact angle of OLZ particles in formulation D1 
(OLZ filtered from HPC solution) seemed to solely be due to the contribution of HPC. 
Furthermore, the contact angle observed for these particles showed a lower contact angle than 
the values measured for the polymer alone (76.4 º vs 91.84 º). This suggests that, as a result of 
changes in polymer chain conformation, this polymer was not only completely covering the 
crystalline particles of OLZ but also decreasing the number of hydrophobic groups exposed on 
the surface of the particles. OLZ recovered from the formulations D showed to have a contact 
angle inferior to the polymer in experiments D1, D2 and D3, which were the formulations 
where OLZ remained anhydrous during the 180 minutes. OLZ recovered from the formulations 
E showed to have contact angles between the drug and the polymer in formulations where 
hydrate formation of OLZ has not occurred (E1, E2 and E3). Formulations B and C showed to 
have a contact angle similar to OLZ raw-material in formulations 2, 3 and 4. 
Table 5.3 – Contact angle and standard deviation of the filtered powders (t=180 min) from different 
solutions (A, B1-B4, C1-C4, D1-D4, E1-E4) and raw materials 
 
5.5.4 Saturation solubility of OLZ 
After 36h of bath-shaking of the OLZ suspensions, the OLZ solubility in each polymer 
solution at different concentrations was evaluated and the concentration of OLZ dissolved was 
plotted against each polymer concentration (Figure 5.5). It was observed that PVP K30 and PEG 
40000 had the highest impact on the saturation solubility of OLZ. Both polymers showed to 
induce a linear increase in the solubility of OLZ, with an increase of their concentrations. 
PVPk30 at a concentration of 2.0% showed to increase at values 10 times higher than the 
solubility of OLZ in water, whereas PEG 40000 at the same concentration showed to increase 
five times the solubility of OLZ. 
 Contact angle ± SD  ( / °) of recovered samples (180 min)    
Drug:polymer 
ratio 
1:0 
1:1  
(1) 
1:10  
(2) 
1:100  
(3) 
1:1000  
(4) 
 
Raw 
Materials 
Contact angle 
± SD  ( / °) 
No polymer 104.8± 0.5 - - - -  OLZ 104.6 ± 0.6 
PEG 6000 - 100.9 ±1.0 104.8 ±1.8 105.8 ±1.1 106.2 ±1.3  PEG 6000 63.6  ± 2.0 
PEG 40000 - 100.2 ± 0.9 104.7 ± 0.9 105.2 ± 1.2 105.9 ±1.0  PEG 40000 64.3 ± 1.9 
HPC LF - 76.4 ± 2.1 81.7 ± 0.9 88.1 ± 0.8 104.9 ±1.5  HPC 91.8 ± 0.4 
PVP K30 - 97.3 ± 1.7 99.1 ± 1.8 101.1± 1.0 105.3 ±1.3  PVP 75.7 ± 2.2 
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The solubilization of the drug proved to be quite low by the HPC and PEG 6000. The 
filtration of the suspended OLZ powders after the test and their further solid-state 
characterization showed that OLZ was hydrated after being kept for 36h in all PEG 6000 and 
PEG 40000 solutions. In contrast, OLZ suspended in HPC and PVP solutions remained 
anhydrous at polymer concentrations of 2%, 0.2% and 0.02%. This suggests that the protection 
of OLZ from hydration by HPC or the absence of protection by PEG 40000 is not related to the 
drug solubilizing effect of the polymers. 
 
Figure 5.5 – OLZ saturation solubility measured in water  
and different polymeric solutions at 25ºC. 
 
5.5.5 Evaluation of molecular state of OLZ in polymer solutions by 1H-NMR studies 
1
H-NMR measurements were done to OLZ mixed with different proportions of different 
polymers. Although several attempts have been undertaken to collect these spectra in aqueous 
environments, the low solubility of OLZ in both H2O and D2O did not allow a proper OLZ 
spectrum collection. A previous 
1
H-NMR work which have studied the stabilities of hydrogen 
bonds in aprotic environments compared to water, concluded that the electronic perturbations 
due to the hydrating water molecules (which are able to form additional hydrogen bonds with 
the solute), have a low impact on the length of solute−solute hydrogen bonds (230). Other 
studies have also used aprotic organic solvents, either alone or mixed with D2O, in order to 
understand if polymers can affect the chemical environment around the drugs and, therefore, 
understand how polymers may affect the crystallization of drugs (63, 143).  
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Deuterated chloroform (CDCl3) was chosen for this study because it is an aprotic 
solvent, which means that it will not exchange the NH proton of OLZ. In addition, CDCl3 will 
not interact with the potential hydrogen bonding between OLZ and polymers (63) – therefore, 
the impact of each polymer on OLZ 
1
H-NMR spectra could be comparable.  
The increase of the signs at 3.66 ppm, 3.64 ppm, 3.5 ppm, 3.21 ppm, resulted from the 
increase of PEG 6000, PEG 40000 HPC and PVP concentrations, respectively. 
The 
1
H-NMR of OLZ in CDCl3 shows a singlet at 4.98 ppm (integration to one proton), 
which corresponds to the amino group (231). This signal shifted downfield with the increased 
addition of each polymer. A similar effect has already been observed in previous studies as a 
result of the formation of hydrogen bonds between the polymers and the drugs (143, 232). The 
chemical environment of OLZ showed also to depend on polymer concentrations.  
 
 
Figure 5.6 – OLZ molecule showing the H responsible for the peak at 4.98 ppm (a)  
and proton NMR spectra for pure OLZ and the OLZ:Polymer mixtures  
(B1-B4, C1-C4, D1-D4, E1-D4) (b). 
Figure 5.7 shows the NH proton shifts in more detail. It is noted that the downshift of 
the peak was larger for higher polymer fractions. OLZ:PEG 6000, OLZ:PEG 40000, OLZ:PVP 
and OLZ:HPC showed a downshift of  0.08, 0.10, 0.23 and 0.06 ppm, respectively, when the 
highest drug:polymer ratios were used. HPC showed to promote the lowest shift in the singlet at 
4.98 ppm of OLZ. However, this polymer showed to not completely dissolve for the highest 
polymer concentration and therefore the polymer:OLZ proportions dissolved were not the same 
as compared to the other polymers. For this reason, we could not consider this value. 
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Nevertheless, the downshift was visible for lower HPC concentrations, indicating that this 
polymer can actually interact with the drug. 
The interactions between the NH proton with the acceptor hydrogen bonding group in 
the PVP ring structure may explain the strongest shift in the singlet at 4.98 ppm of OLZ (63). 
Furthermore, the shift became larger with the increase of PVP concentration. 
  
 
Figure 5.7 – Higher magnification of proton NMR spectra for pure OLZ and the OLZ:Poymer 
mixtures within the range of 5.40-4.80 ppm (a). 
 
5.6 Discussion 
The different crystalline forms of OLZ are built through the assemblage of OLZ 
centrosymmetric racemic pairs and these pairs connect to each other through hydrogen bonds, 
either from atoms like in the OLZ structure (e.g. anhydrous form) or by water molecules (e.g. 
hydrate forms).  In an aqueous environment, anhydrous OLZ tends to hydrate in few minutes. 
The hydrate conversion is likely to occur as a solvent-mediated transformation (116, 117). In 
these transformations three steps are involved: dissolution of the metastable phase into the 
solution to reach and exceed the solubility of the stable phase; nucleation; and crystal growth of 
the stable phase coupled with the continuous dissolution of the metastable phase (6). 
In this study, the addition of soluble excipients (polymers) was analyzed in detail in 
order to understand their effect on crystallization of OLZ hydrates. 
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The results showed that, when OLZ was suspended in water, its XRPD pattern OLZ 
exhibited mixed reflections of 2 different hydrates, whereas in the presence of PEG the XRPD 
diffractograms showed a pure pattern of the higher hydrate form. In other study, a similar 
phenomenon was observed for nitrofurantoin, where the formation of hydrogen bonds with the 
polymer led to the formation of an isolated hydrate form (227). In the present work PEG 
polymers showed to also be able to retard hydrate formation, which might have affected the 
kinetics of nucleation with an impact on the final hydrate phase formed. 
The 
1
H-NMR results showed that all the different polymers have affinity to form 
hydrogen bonds with OLZ. The possible interaction between the drug and the polymers is the 
proton that is located on the nitrogen atom (amine group) of the drug. Previous studies have 
demonstrated that, besides the electrostatic and van der Waal’s forces, hydrogen bonds between 
the drug and the polymers are likely to be involved in the increase of drug’s solubility (63).  
In the present study, the saturation solubility values of crystalline OLZ at 25 °C were 
determined to be 0.059 mg/ml in water. At concentrations above 0.02% all polymers were able 
to increase the saturation solubility of OLZ by the following rank order: PVP K30>PEG 
40000>HPC LF> PEG 6000. Loftsson et al., 1994 (233) showed that the addition of 0.25% 
(w/v) PVP to water results in an average increase of 64% in the aqueous solubility of nine 
different drugs and that an addition of 0.25% (w/v) carboxymethylcellulose (also a cellulose 
derivative) resulted in an average increase of 53% in the aqueous solubility of 16 different 
drugs. PEG has also shown to increase the solubility of several drugs since it can form hydrogen 
bonds between its ether oxygens and the drug’s amino groups (143). Our results showed that 
OLZ had the highest solubility enhancement in PVP and PEG 40000 polymer solutions, which 
were the polymers that induced the strongest shift in OLZ 
1
H-NMR N-H signal.  
In another work, 
1
H-NMR studies were performed to understand the interaction between 
PVP, diphenylhydantoin and dimethylphenytoin and the relationship between these interactions 
and the solubilization efficacy of PVP on each drug. It was observed that PVP could promote 
much larger chemical shifts on the diphenylhydantoin molecule. This molecule also showed to 
have higher solubility in PVP solutions, leading the authors to conclude that the intermolecular 
interaction of PVP with diphenylhydantoin could be stronger than with dimethylphenytoin, 
resulting in increased solubilization efficiency of the former by PVP (143). As such, the 
increment of solubility seems to be related to the hydrogen bonding interactions between drug 
and polymer through the formation of a soluble complex between the drug and polymers in 
aqueous media (63). The stronger hydrogen bonding ability of PVP is likely to be associated 
with the ability of carbonyl oxygen of povidone to form stronger hydrogen bonds with drug’s 
amine groups when compared to the ether oxygen groups of PEG (194, 234). 
PEG 6000 showed to slightly increase the OLZ solubility. The lower viscosity of PEG 
6000 and its reduced capacity to increase OLZ’s solubility may explain the faster hydrate 
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conversion of OLZ in presence of this polymer when compared to PEG 40000. The increase of 
solubility by interactions with polymers has been pointed out as one of the mechanisms of 
reducing crystallization of hydrate forms, since these interactions showed to lead to a reduction 
on the amount of freely dissolved drug to undergo crystallization (143). However, although all 
polymers have shown to increase the solubility of OLZ, only PVP and HPC have showed to be 
able to inhibit the crystallization of hydrates. 
Previous studies have demonstrated that the effectiveness of a polymer as a 
crystallization inhibitor is highly dependent on the hydrogen bond ability and hydrophobicity of 
the polymer (143, 223, 224). However, it has been difficult to understand the relative 
importance of both factors. 
Polymers which are more hydrophobic are less present in the aqueous phase, having 
more ability to bind to hydrophobic crystals’ surfaces. When absorbed at relevant growth sites 
these polymers may block the growth of the forming crystals. The measured contact angles of 
the raw materials with water have shown that HPC is the most hydrophobic excipient and PEG 
is the most hydrophilic one. The recovered particles of OLZ showed that particles that were 
filtered from HPC solution presented a contact angle lower than HPC. This suggested that the 
higher hydrophobic nature of HPC may have been led to the adsorption of this polymer on the 
hydrophobic crystal surfaces of OLZ, leaving its most hydrophilic groups in contact with water 
molecules. It was only at the lowest concentration of HPC (formulation D4), when the polymer 
could not avoid the hydrate formation, that OLZ particles showed to have their contact angles 
with water similar to the OLZ raw-material. These results demonstrated that HPC could avoid 
hydrate formation due to its higher affinity towards the newly formed OLZ hydrophobic 
surfaces formed in HPC solution, stabilizing them against the crystal growth. HPC also revealed 
to be the polymer which could increase the most the viscosity of the system, which could have 
also contributed to restrain the diffusivity of the drug molecules. 
PVP exhibits moderate hydrophobicity and the surface of OLZ crystals filtered from 
most concentrated PVP solutions showed contact angles between the OLZ raw material and the 
polymer. No differences on OLZ protection were observed between PVP and HPC, since both 
polymers showed to protect OLZ hydrate formation when OLZ was suspended in solutions of 
0.02% w/v but unable to protect OLZ hydrate formation when polymers were at a concentration 
of 0.002% m/v.  
In order to explain this phenomenon the molar ratios between dissolved OLZ in each 
polymer solution and the polymer repeat units dissolved in each system (2, 0.2, 0.02 and 
0.002% m/w) in saturation stability studies were taken under consideration. The molar ratios in 
the investigated systems were calculated as presented in the following table: 
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Table 5.4 – OLZ:Polymer molar ratios of investigated systems 
Polymer 
concentration 
(% m/w) 
Polymer repeat units:OLZ dissolved  
(molar ratios)  
PVP:OLZ HPC:OLZ 
2 97.90 146.36 
0.2 42.19 20.28 
0.02 6.27 2.16 
0.002 0.70 0.23 
 
The results showed that when PVP and HPC polymers were in solution at 0.02% w/v, 
there were approximately 6 and 2 polymer monomers of PVP and HPC for each dissolved OLZ 
molecule, whereas, at polymer concentration of 0.002% m/v the number of OLZ molecules 
dissolved were higher than the number of polymer monomers in solution. It can be therefore 
concluded that up to a polymer concentration of 0.02% (w/v), the amount of polymers is 
adequate to interact with the whole amount of dissolved OLZ, resulting in OLZ hydrate 
protection. 
PEG polymers showed to be the most hydrophilic tested polymers. OLZ particles after 
being in contact for 180 min with these polymers displayed similar contact angles to the OLZ 
raw-material. This may result from the low ability of PEG to attach to the OLZ crystal surfaces 
and, therefore, the low ability to bind to surfaces of new nucleus of hydrates formed during 
stirring, leading us to conclude that the hydrophobicity of the polymers is an important factor to 
protect the drug from undergoing hydrate transformations. 
5.7 Conclusion 
This study provided an insight into the role of polymer additive on the crystallization of 
hydrates of OLZ in aqueous slurries. The results confirmed that polymers can affect 
crystallization by both hydrogen bonding with the drug and hydrophobicity. The secondary 
amine NH of OLZ has a relatively strong H-bond donor, which showed the highest potential for 
H-bonding with the oxygen atom of the polymers. The hydrogen bonding interaction between 
OLZ and polyethylene glycol showed to retard the hydrate conversion and to crystallize OLZ 
into only one hydrate form – higher hydrate. The insufficient hydrophobicity of PEG seems to 
explain the absence of hydrate protection by this polymer. PVP showed to have the ability to 
form hydrogen bonds with the drug and to increase OLZ solubility in aqueous phase but also 
sufficient hydrophobicity to adsorb into the crystals surface interface, blocking access to the 
solute molecules to the crystal terrace. Cellulose polymer, on the other hand, showed to slightly 
increase the solubility of OLZ, being its effect on the inhibition of OLZ hydrate formation 
mainly related to its strong hydrophobic nature. 
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The understanding of the interactions between OLZ and polymers, at a molecular level, 
helps to optimize the selection of excipients to be used in OLZ formulations, reducing problems 
during manufacturing of the final dosage form. 
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Chapter 6 -  Effect of RESS and RESSAS technologies on the particle 
size reduction, solid-state form and dissolution rate of 
olanzapine  
 
6.1 Abstract 
The purpose of the work was to understand the impact of rapid expansion of 
supercritical solution (RESS) and rapid expansion of supercritical solution into aqueous solution 
(RESSAS) processes on the particle size reduction, polymorphism and dissolution rate of 
olanzapine (OLZ) particles. A pilot scale unit for supercritical fluid processing was used for the 
production of RESS OLZ particles and RESSAS suspensions. Supercritical OLZ-solution 
(scCO2, 20MPa/50°C) was expanded into air (RESS) or into an aqueous solution (HPMC, PEG, 
PEG+SLS, or Polysorbate 80, RESSAS). Nanoparticles and nanosuspensions were produced 
and characterized for particle size, particle size distribution and zetapotential. After freeze-
drying nanosuspensions, nanoparticles were further evaluated for FTIR, in order to control the 
olanzapine polymorphic structure present in the nanoparticles. Their dissolution rate was also 
characterized. RESS OLZ could be produced with a mean particle size of 191.4±9.6nm, i.e., a 
200 fold size reduction compared to the original anhydrous material. The material was partially 
amorphous, as confirmed by DSC and FTIR. The particle size of RESSAS OLZ 
nanosuspensions was in the same range. The highest stability (size and solid-phase) of 
nanosuspensions before and after freeze-drying was achieved when PEG+SLS were considered. 
In conclusion, the preparation of OLZ nanoparticles with improved dissolution rate and known 
changes on the solid-state forms were achieved by RESS and RESSAS processes. 
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6.2 Introduction 
Particle size reduction is one of the oldest strategies for improving dissolution rate of 
the APIs. As the particle size becomes smaller, the surface area to volume ratio increases, thus 
increasing the surface area available for solvation (87). In the traditional RESS process, the 
supercritical fluid is used as a crystallization solvent. In fact, the solute is firstly dissolved in the 
supercritical fluid and then rapidly expanded, by sudden depressurization through a nozzle to 
ambient pressure (235-236). Due to the sudden pressure drop upon expansion, a very high rate 
of supersaturation causes the precipitation of the dissolved material as submicron or micron 
particles (237). Like most techniques that lead to the production of fine particles, particle 
harvesting is difficult in the traditional RESS process. Since the precipitated particles travel at 
high speed after expansion, they are carried with the gaseous stream and therefore recovering is 
difficult. Many studies reporting the production of micron particles and low process yields may 
do so as a consequence of losing the fine fraction of submicron particles due to insufficient 
separation from the expansion jet  (238). The typically reported micron-sized particles also 
result from particle growth processes of condensation and coagulation during the residence time 
in the expansion vessel, since theoretical modeling of the traditional RESS process predicts the 
formation of particles with initially less than 50 nm (239).  
In the case of water insoluble drugs, a viable approach is therefore spraying the RESS 
product directly into an aqueous solution containing a stabilizing agent. This technique, also 
called RESSAS (rapid expansion of supercritical solution into aqueous solutions), enables to 
form nanosuspensions of active pharmaceutical ingredients (API) in a suitable stabilizing 
medium, which can contain polymers or surfactants as steric and electrostatic stabilizers (240) 
(241) (242, 243). If the particles suspended are partially or fully crystalline, they are referred as 
nanocrystals. The formulation of nanocrystals is an important tool to enhance the bioavailability 
after oral or parenteral administration of poorly water soluble drugs with high lipophilicity 
(244). The use of a liquid at the receiving end in RESSAS technology has been thought to 
inhibit particle agglomeration and coagulation in the expansion jet (238, 245). A challenge in 
this process is however the loss of stabilizing medium due to the force of expansion into the 
liquid, which complicates the use of excipients with surface activity that stabilize foams with 
the expanding CO2. In this study, we therefore focused on using highly viscous media as 
stabilizers on the receiving end. 
The administration of nanosized OLZ is interesting because it classifies as a BCS 
(Biopharmaceutical Classification System) class II drug with low aqueous solubility. In 
addition, OLZ shows pH dependent solubility since it is a weak base (pKa = 7.4). For drugs with 
pH dependent solubility, a reduced variability of the fed-fasted bioavailability was observed in 
previous studies when formulated as nanosuspensions (246). Compared to classic bottom-up 
techniques for the formulation of nanoparticles, the risk of precipitating OLZ solvates is 
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eliminated in the RESS and RESSAS process, since no organic solvents are used (247, 248). 
The formulation of OLZ as an aqueous nanosuspension, and later freeze dried nanoparticles is 
however challenging regardless of the chosen method of production, since olanzapine may 
hydrate during the process. The choice of a stabilizer is therefore crucial to suppress 
recrystallization of the precipitated material, not only to prevent particle growth but also crystal 
conversion of the nanodispersed material. 
6.3 Purpose 
This chapter aims to study the effect of the unique expansion conditions provided by 
RESS and RESSAS on the size, solid-state form and dissolution of OLZ. For the RESSAS 
technology this study aims in particular, on finding the best stabilizer conditions to suppress 
recrystallization of the precipitated OLZ. 
6.4 Materials and methods  
Olanzapine was purchased from Vega Pharma (China), India. Polyethylenglycol (PEG) 
40000 was supplied by Serva (Amstetten, Austria), polysorbate 80 (Psb) by Croda (Nettetal, 
Germany); hydroxypropylmethylcellulose (HPMC; Pharmacoat 615) by Syntapharm (Mülheim 
a.d. Ruhr, Germay); sodium lauryl sulphate (SLS; Texapon K12 G) was purchased from Cognis 
(Düsseldorf, Germany) and carbon dioxide (CO2) from Air Liquide (Düsseldorf, Germany). 
6.4.1 Pilot unit for supercritical fluid processing 
A pilot unit designed for high-pressure extractions and RESS-technique (Sietec-
Sieber,  Zürich, Switzerland) was used for particle design (Figure 6.1). Carbon dioxide was used 
as solvent in all experiments.The equipment comprises a tank, where CO2 is present in the liquid 
state. It is conveyed via a high-pressure pump into the extraction vessel with a volume of 5 l, at 
supercritical conditions. After dissolution of the material placed inside the extraction vessel is 
completed, or an equilibrium between solid and dissolved material is reached, the supercritical 
solution is passed through a micro valve, which regulates the flux through the 150 μm nozzle. 
Upon passage of the nozzle, the supercritical solution is expanded inside the expansion 
chamber. To compensate for the cooling effect inside the expansion chamber, the mantle 
temperature was set to 70 °C for RESS experiments and to 55 °C for RESSAS experiments. The 
pressure of the expansion chamber was kept at atmospheric conditions (1 bar and room 
temperature). All RESS and RESSAS experiments were conducted during 1 h of expansion time 
with a medium CO2 flow rate between 1.5 and 3.5 kg/h.  
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Figure 6.1 – Functional sketch of the extraction equipment. 
 
6.4.2 Solubility of OLZ in supercritical carbon dioxide 
An amount of 5.0 g of OLZ powder was weighed and placed inside the extraction 
chamber, which was consequently flooded with CO2, heated to 50 °C and pressurized to 200 
bar. The solution was left to equilibrate for 24 h prior to expansion. In that time span, 236 ± 
13.1 mg of OLZ were dissolved in scCO2, corresponding to a mole fraction of y = 8.67*10
-6
.  
6.4.3 Production of OLZ nanoparticles with the RESS process 
For the collection of OLZ nanoparticles, a filter cartridge was attached to the lid of the 
expansion chamber, which contained paper filters for the collection of the nanoparticles (Figure 
6.2 a). The nozzle in this setup was placed shortly under the lid of the expansion chamber. The 
expansion chamber was allowed to reach room temperature before collecting the product to 
prevent condensation of air moisture on the products. 
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Figure 6.2 – Schematic of expansion setups for a) classic RESS process and b) RESSAS process. 
 
6.4.4 Production of OLZ nanosuspensions with the RESSAS process 
For the production of RESSAS nanosuspensions, a cylinder containing the aqueous 
stabilizer solution was placed inside the expansion chamber (Figure 6.2 b). The volume of 
stabilizer medium was 100 ml. The stabilizers were dissolved in phosphate buffer pH 7.4 in 
order to prevent a pH drift of the stabilizing medium due to dissolved CO2 and consequent 
dissolution of OLZ nanoparticles in the medium. In cases when SLS was added as co-stabilizer, 
3.3 ml of a stock solution of 10% w/w SLS were added to 30 ml of the freshly produced 
nanosuspension to yield a final concentration of 1% w/w SLS. 
6.4.5 Freeze-drying 
3 ml of the nanosuspensions were transferred to 10 ml glass vials and pre-frozen at -
18 °C for 24 h prior to freeze-drying. The nanosuspensions were freeze-dried at  
-20 °C for 12 h, followed by a secondary drying phase of 12 h at 20 °C using a Lyovac GT2 
freeze-dryer (Finn-Aqua/GEA Pharma Systems, Hildesheim, Germany). The freeze dried 
particles obtained were characterized by FTIR. For the characterization of the particle size 
distribution after freeze-drying, the cakes were reconstituted with demineralized water (3 ml). 
6.4.6 Determination of drug content in freeze-dried nanosuspensions 
The freeze-dried cakes were reconstituted with demineralized water and diluted 1:100 in 
0.1N HCl to dissolve the drug present in the cakes. The solutions were analyzed 
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spectrophotometrically at 255 nm. It was ensured that at this dilution and the given wavelength, 
the stabilizing agents did not interfere with the OLZ absorption. 
6.4.7 Measurement of particle size and zeta potential 
The particle size, particle size distribution (PSD) and zeta potential of OLZ 
nanosuspensions were measured using a Zetasizer Nano (Malvern, Herrenberg, Germany) with 
dynamic light scattering (DLS) for a 1.709 refraction index. The samples were diluted 1:4 and 
equilibrated during 120 s at a cell temperature of 20 °C. Each sample was measured 3 times for 
the size and 5 times for the zeta potential and the average values are reported. The particle sizes 
of the unprocessed material and that of freeze-dried suspensions, where particle growth to the 
micron range was observed, were measured with laser diffractometry (LD) using a Mastersizer 
2000 (Malvern, Herrenberg, Germany) equipped with a Hydro 2000S sample dispersion unit. 
The unprocessed powder was suspended in demineralized water containing 0.1% Polysorbate as 
surfactant to ensure a good dispersion of the hydrophobic OLZ particles in water. Freeze-dried 
suspensions were re-dispersed with demineralized water. Prior to the measurement cycles, 
ultrasound was applied to de-agglomerate the particles. 3 measurements were performed and the 
average values are reported. 
6.4.8 Differential scanning calorimetry (DSC) 
Measurements were performed using a DSC system (TA 8000, DSC 820, Mettler 
Toledo, Germany). The samples (1.5 – 2.0 mg) were placed in perforated 40 μl aluminum 
standard pans and crimped with punched lids. An empty aluminum sample pan was used as 
reference. The heating rate was set to 10 K/min to determine melting points (onset temperature, 
Ton) and the heat of fusion (ΔH). 
6.4.9 Scanning electron microscopy (SEM) 
The surface morphology and particle shape were examined using a scanning electron 
microscope (DSM 940 A, Zeiss, Oberkochen, Germany). Pictures were taken using the Orion 5 
frame grabber system (E.L.I. Microscopy, Charleroi, Belgium). Each sample was fixed on 
double-sided adhesive tape and coated with gold with a sputter coater (E5100, BioRad, 
München, Germany). All samples were sputtered 4 times over 60 s at 2.1 kV and 20 mA. 
6.4.10 Fourier Transform Infrared Spectroscopy (FTIR) 
Measurements were performed using a Nicolet 380 FT-IR spectrometer in absorbance 
mode (Thermo scientific, Karlsruhe, Germany). A total of 30 scans was performed over a range 
of 4000-400 cm
-1
 at a scan speed of 0.5 cm/s. The second derivative of the FTIR spectra was 
calculated. 
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6.4.11 Determination of saturation solubility 
An excess of OLZ powder (approximately 10 mg) was placed into 2 ml Eppendorf cups 
and 1 ml of the respective stabilizing medium was added. The cups were sealed and placed into 
a water bath at 37 °C shaking at 50 rpm. After 48 h, the Eppendorf cups were centrifuged at 
13,400 rpm for 20 min.  The concentrations of dissolved OLZ were determined with a UV 
microplate reader at 255 nm (Synergy HT, Biotek, Bad Friedrichshall, Germany). 
6.4.12 Dissolution studies 
Dissolution studies were conducted with a Pharmatest PT-DT 7 (Hainburg, Germany). 
A paddle apparatus (USP apparatus 2) at 37.0 °C was used. The freeze-dried cakes of OLZ 
RESSAS nanosuspensions were reconstituted with 3 ml of the dissolution medium and 
immediately added to the dissolution vessels containing 900 ml of phosphate buffer pH 6.8 
providing concentrations between 8.0 and 11.3 µg/ml. These samples were compared with 
unprocessed OLZ and with OLZ in physical mixtures with PEG, HPMC and Psb. The rotation 
speed of the paddles was set to 50 rpm. Samples were drawn at preset time intervals and filtered 
through a 5 μm sintered filter. The removed sample volume was immediately replaced by fresh 
medium. The dissolution testing was carried out under sink conditions. The concentration of the 
samples was analyzed with a UV microplate reader at 255 nm (Synergy HT, Biotek, Bad 
Friedrichshall, Germany). Results between different release profiles were compared for 
significance using an independent mathematical approach model for calculating a similarity 
factor (f2). 
6.5 Results 
6.5.1 Production of olanzapine nanoparticles with the RESS technique 
Precipitation of OLZ from supercritical solutions resulted in the production of a very 
fine powder, which complicated the separation of the product from the expansion jet. Most 
particles were likely to be removed with the air stream in the outlet, resulting in a process yield 
below 10%. SEM images of the precipitated material showed that the particle size of RESS 
OLZ was distinctly below 500 nm (Figure 6.3).  
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Figure 6.3 – SEM images of unprocessed (left) and RESS (right) OLZ. 
 
The collected particles had a round shape with a mean diameter of roughly 200 nm and 
appeared partly agglomerated merged. The particle size measurement of RESS OLZ revealed 
that they had a Di50 of 191.4 ± 9.6 nm and a span of 1.08 ± 0.15 (Figure 6.4). The unprocessed 
OLZ powder had a Dv50 of 39.3 ± 1.0 μm (Figure 6.4), showing that the size reduction via RESS 
was about 200 fold. 
 
 
Figure 6.4 – Particle size distribution of a) RESS OLZ measured in aqueous suspension with DLS; 
b) unprocessed OLZ powder measured in aqueous suspension with laser diffractometry (LD). 
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DSC analysis indicated that RESS OLZ showed a distinct reduction of the heat of fusion 
from 135.0 ± 2.7 mJ/g to 102.2 ± 6.3 mJ/g (Figure 6.5), indicating a reduced crystallinity of 
RESS OLZ. The onset temperature of the melting peak of the RESS precipitated material 
showed a reduction from 194.3 ± 0.9 °C of the unprocessed material (OLZ anhydrous form I) to 
190.7 ± 1.1 °C (Figure 6.5). Since this melting temperature does not belong to other 
polymorphic forms of OLZ, this depression maybe caused by the high ratio of surface area to 
volume for smaller OLZ particles.  
 
 
Figure 6.5 – DSC Thermograms of unprocessed OLZ (solid line) and RESS OLZ (dotted line). 
 
To confirm that OLZ remained in anhydrous Form I, but with a reduced crystallinity, 
the second derivative of the FTIR spectra of the anhydrous form, the amorphous form and RESS 
OLZ were compared in the range of 900 cm
-1
 to 1100 cm
-1
 (Figure 6.6). The amorphous form 
showed an additional band at 998 cm
-1
, which also appeared in the spectra of RESS OLZ. The 
band at 965 cm
-1 
in the amorphous form was distinctly broader than in the anhydrous form, 
which could also be observed in the spectra of RESS OLZ. In addition, the sharp peak of the 
anhydrous form at 927 cm
-1
 could also be found in spectra of RESS OLZ. This analysis 
confirmed that the material was indeed partially precipitated in the amorphous form. 
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Figure 6.6 – Second derivative of FTIR spectra of anhydrous, amorphous and RESS OLZ. 
 
6.5.2 Production of Olanzapine nanosuspensions with the RESSAS technique 
Various stabilizing media were chosen after pre-studies concerning the saturation 
solubility of OLZ in the various stabilizing media, their viscosity and tendency to foam with the 
expanding CO2. The optimized stabilizer concentrations are presented in Table 6.1. The 
solubility of the drug in the stabilizer plays an important role in the formulation of 
nanosuspensions, since an increased solubility can induce agglomeration and/or Ostwald 
ripening of the colloidal system (249). The stabilizer should thus have little effect on the 
solubility of the formulated drug. None of the tested stabilizers increased significantly the 
solubility of OLZ in comparison to the medium phosphate buffer pH 7.4. In combination with 
sodium lauryl sulfate (SLS), a distinct increase of the saturation solubility of OLZ was seen, 
especially for HPMC (1.62 ± 0.2 mg/ml). 
 
Table 6.1 – Viscosity (η) of different stabilizing media and saturation solubility (S) of OLZ 
Stabilizer 
Stabilizer 
concentratio
n (% w/w) 
S (mg/ml) S + 1% SLS (mg/ml) η (cSt) 
Foaming 
tendency 
a
 
Buffer pH 7.4 - 0.11 ± 0.06 1.82 ± 0.05 0.81 ± 0.001 - 
Psb 80 0.1 0.10 ± 0.00 n.a. 0.72 ± 0.001 + 
PEG 2 0.13 ± 0.01 0.8 ± 0.01 1.63 ± 0.001 - 
HPMC 2 0.12 ± 0.01 1.62 ± 0.20 7.27 ± 0.005 + 
All means reported are the means of 3 individual experiments 
a Assessed by visual inspection  
n.a.: not analyzed 
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The importance of the viscosity and the ability to stabilize foam for the precipitation of 
the nanoparticles into the stabilizing medium has been seen in preliminary studies (data not 
shown). Since OLZ has a rather low solubility in scCO2, the ratio of dissolved drug to fluid is 
very low and thus, a high amount of fluid needs to be processed into the stabilizing medium for 
the collection of particles in reasonable number. A low viscosity on the one hand, and a good 
ability to stabilize foams on the other, can cause loss of the medium due to the force of 
expanding gas, which can carry the medium out of the collecting cylinder and destabilize the 
process. Of the tested stabilizers, Psb and HPMC presented distinct foaming abilities when 
scCO2 was expanded into the solutions, whereas PEG did not show a high tendency to form 
foams (Table 6.2). The process conditions were therefore least subjected to variability when 
PEG was used (Table 6.2). The mean mass flow of CO2 could be adjusted to 3.01 ± 0.34 kg/h, 
which was the highest possible in the conducted experiments. Therefore, the concentration of 
OLZ in nanosuspensions stabilized with PEG was also the highest with the smallest variation 
compared to the other tested stabilizers. With this stabilizer, it was also possible to recover 
almost 100 % of the drug that was dissolved in scCO2 (Table 6.2), indicating no drug loss by the 
CO2 stream. 
 
Table 6.2 – Overview of RESSAS experiments 
Stabilizer Dissolved 
OLZ in 
scCO2 
(mg) 
Mass flow 
of CO2 
(kg/h) 
CO2 density in 
extraction 
chamber 
(kg/m
3
) 
Temperature 
in expansion 
vessel (°C) 
Volume of 
final 
suspension 
(ml) 
 
c OLZ in 
final 
suspension 
(mg/ml) 
Recovery 
of OLZ 
(% w/w)
a 
Psb 80 0.1% 221 1.55 ± 0.54 904.8 ± 19.5 40.5 ± 2.3 30 ± 11 3.3 ± 1.4 44.8 
PEG 2% 237.5 3.01 ± 0.34 877.8 ± 3.5 39.2 ± 2.2 70 ± 5 3.4 ± 0.4 98.4 
HPMC 2% 245.1 2.59 ± 0.77 886.1 ± 11.91 41.9 ± 2.2 45 ± 10 2.4 ± 1.3 44.1 
a Recovery of OLZ in nanosuspensions in relation to the dissolved mass in scCO2. 
All means reported are means of 3 individual RESSAS experiments. There is no standard deviation given for the dissolved mass of 
OLZ, since this value was calculated from the dissolved mass in the extraction chamber after 3 individual expansions.  
 
6.5.2.1 Particle size 
The smallest particle size of the colloidal OLZ suspensions after production was 
achieved with Psb as stabilizing agent giving a Di50 value of 158.7 ± 12.7 nm and a narrow size 
distribution (span = 1.15 ± 0.12; Figure 6.7). The largest particles were obtained with HPMC, 
which had a Di50 of 341.3 ± 42 nm and a broader size distribution with a span of 1.48 ± 0.37 
(Figure 6.7). The particle size of PEG stabilized nanosuspensions was between that of Psb 80 
and HPMC with a Di50 of 213.8 ± 23.7 nm and a narrow span of 0.99 ± 0.08 (Figure 6.7). 
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Figure 6.7 – Medium Di values and spans of nanosuspensions produced with different stabilizing 
agents directly after production. 
 
The Psb 80 and PEG suspensions only remained macroscopically stable for a few hours 
after production. After 12h at room humidity and temperature it was possible to observe 
flocculation of the nanosuspensions and the flocculated material was observed under FTIR 
(Figure 6.8). This recovered material showed to correspond to the dihydrate B form of OLZ. 
Therefore, freeze drying of the nanosuspensions was performed immediately after their 
production to avoid particle growth. 
 
Figure 6.8 – Infrared spectra of Flocculated material recovered from the Pbs 80 and PEG 
suspension after resting 8h at room temperature.  
After freeze-drying and reconstitution of the nanosuspensions however, the particle size 
was distinctly increased to the micron range (Dv50 of 8.5 ± 0.9 μm for PEG and 15.1 ± 2.6 μm 
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for Psb; Figure 6.9). For both stabilizers, the size distribution range was also distinctly increased 
after freeze-drying, showing particle growth during freezing. For HPMC, only a slight particle 
growth was detected (324.2.5 ± 8.7 nm before freeze-drying vs. 341.3 ± 42 nm after freeze-
drying; Figure 6.9). This shows that steric stabilization with Psb and PEG was not sufficient for 
the formulated drug. For HPMC only a slight increase of the particle size was observed.  
6.5.3 Effect of electrostatic co-stabilization with SLS 
Since the steric stabilization achieved with the polymeric agents employed in this study 
was not entirely effective for the colloidal suspensions, it was attempted to add sodium lauryl 
sulfate (SLS) as an electrostatic co-stabilizer after the actual precipitation process. The co-
stabilizer was added after the actual production of the particles and before freeze-drying, since it 
distinctly increased the foam formation of the media, destabilizing the process and resulting in 
increased loss of the stabilizer medium. At a concentration of 1 % w/w of SLS, the solubility of 
OLZ was increased to 0.8 ± 0.01 mg/ml in combination with PEG, and to 1.62 ± 0.2 mg/ml in 
combination with HPMC (Table 6.2). The increase of solubility due to surfactants is a known 
problem and can cause Ostwald ripening and agglomeration of the particles in suspension (250). 
Therefore, the attempt seemed only feasible for PEG stabilized suspensions, considering the 
drug load of approximately 3 mg/ml in the RESS suspensions. With the addition of 1% SLS, it 
was possible to suppress the drastic particle growth observed in suspensions that were only 
stabilized by PEG (Figure 6.9). With SLS, only a slight increase of the particle size was 
observed after freeze-drying and reconstitution. The addition of 1% SLS decreased the zeta 
potential of the suspensions from -1.58 mV to about -33 mV, which reflects the physical 
stability of the co-stabilized suspensions (Figure 6.9). 
 
Figure 6.9 – Comparison of D50 values and spans immediately after production and after freeze 
drying; D50 values reported for HPMC and PEG+SLS are medium Di50; values reported for Psb 
and PEG are medium Dv50. 
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6.5.4 Solid-state characterization 
Solid-state characterization of OLZ was performed via FTIR by analyzing the freeze-
dried cakes of the nanosuspensions. With the second derivative of the FTIR spectra, it was 
possible to enhance the resolution of overlapping and complex band contours in the original 
spectra. A range of the spectrum (950 - 1050 cm
-1
) was chosen, where the stabilizers did not 
interfere with the OLZ spectra (Figure 6.10). Hydration to the dihydrate B became apparent 
from two peak shifts of the anhydrous from at 965 
-1
 and 1009.6 cm
-1
 to 1003.8 cm
-1
 and 971 
cm
-1
, respectively. OLZ filtered from the flocculated nanosuspensions with PEG and 
polysorbate 80 was completely transformed in the dihydrate B (Figure 6.10). After freeze-
drying, the hydrated form was maintained by OLZ in PEG suspensions, while in Polysorbate 80 
suspensions was dehydrated during the drying process so that the solid remnant again contained 
the anhydrous Form I.  
Judging by the appearance of double bands in OLZ spectra of freeze dried HPMC 
nanosuspensions the drug was probably partially hydrated (Figure 6.10). OLZ in freeze-dried 
nanosuspensions stabilized with PEG and SLS showed no trace of hydrate formation. This 
combination of stabilizers could thus effectively suppress both particle growth of the colloidal 
system and hydrate formation. This also became apparent macroscopically, since the RESS 
OLZ suspensions only stabilized with PEG lost the yellow color and transparency after freeze-
drying and reconstitution, while suspensions stabilized with PEG and SLS showed no 
macroscopic change after freeze-drying and reconstitution compared to the freshly prepared 
samples (Figure 6.11). Particle growth and hydrate formation coincided in the insufficiently 
stabilized nanosuspensions.  
 
 
Figure 6.10 – Second derivative of FTIR spectra of Freeze-dried olanzapine (OLZ) in flocculated 
nanosuspensions (fl NS) or freeze-dried nanosuspensions (fd NS) with different stabilizing agents. 
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Figure 6.11 – Comparison of nanosuspensions (NS) before and after freeze-drying (FD) with and 
without the addition of SLS. 
 
6.5.5 In vitro drug dissolution 
All RESSAS OLZ suspensions were found to show a strongly increased dissolution rate 
when compared to the unprocessed OLZ, regardless of the drastic particle growth observed in 
Psb and PEG stabilized suspensions (Figure 6.11, Figure 6.12). Only for HPMC suspensions, a 
slower release than for the other ones was observed, which is probably related to the increased 
viscosity of these suspensions in comparison to the other stabilizing media (Table 6.2). Since 
the stabilizing agents all possess more or less pronounced surface activity, their influence on the 
dissolution of raw OLZ was also investigated (Figure 6.12 b-d). The release of the unprocessed 
drug suspended in the stabilizing media was highly accelerated in comparison to the 
unprocessed powder, which shows that the effect of these agents on the solubility of OLZ 
cannot be underestimated. The effect of the size reduction was, however, still apparent in all 
RESSAS suspensions, with HPMC showing the highest differentiation between the release 
profiles of RESSAS suspensions and suspensions of the unprocessed drug in the stabilizing 
medium (Figure 6.12 c). Significant improvements on the release rates between OLZ RESSAS 
and OLZ in physical mixtures were observed, reaching the maximum significance with 
unprocessed OLZ. 
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Figure 6.12 – Dissolution profiles in phosphate buffer pH 6.8, USP apparatus II (Paddle). 
Dissolution profile of RESSAS OLZ suspended in different stabilizers is compared to the 
dissolution profile of unprocessed OLZ. 
 
6.6 Discussion 
6.6.1 Production of RESS OLZ nanoparticles 
OLZ nanoparticles were produced by RESS technique. Polymorphic conversion during 
the RESS process has been shown before and is related to the processing conditions such as 
extraction and expansion pressure and temperature (251-253). In the present study, the original 
material was apparently not subjected to polymorphic conversion, since the RESS product was 
found to be the thermodynamically stable OLZ Form I. There are few reports about supercritical 
fluid processing of OLZ in the literature. However, US patent US20070021605 reports a RESS 
process for the production of OLZ Form II (metastable OLZ form) (254). Therein, a low 
temperature range of 30 - 50 °C at the time of depressurizing the fluid have to be used, in order 
to prevent conversion to OLZ Form I (the most stable form), which is obtained when higher 
temperatures are used. The results from this work were not in accordance with those from the 
procedure described therein, once our experiments yielded OLZ Form I nanoparticles, which 
were apparently not entirely crystalline. The particle morphology studied by SEM and DSC 
analysis suggested the formation of an amorphous layer on the nanoparticles. Due to the very 
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fast nucleation period and the rapid crystallization in RESS, the formation of an at least partially 
amorphous phase seems likely and has been shown before (255). In most RESS experiments, 
however, the formation of mostly crystalline material with particle sizes in the micron range has 
been reported, which can be ascribed to the initially colloidal (and possibly amorphous) material 
undergoing immediate recrystallization and particle growth during the residence time in the 
expansion vessel (245, 256). This is also in agreement with the Ostwald law of stages, which 
describes the conversion of initially crystallized metastable forms to more stable forms (257). 
Many researchers report a reduction in the PXRD peak intensities of RESS precipitated material 
in comparison to the unprocessed bulk powder, which is however an effect that could be related 
to the decreased particle size of RESS products and is therefore inconclusive for judging a 
possible reduction of crystallinity (251, 252, 258-262). Our results, however, confirm the 
formation of a partially amorphous product.  
Compared to usual bottom-up techniques such as liquid antisolvent precipitation, with 
the RESS process, there is no risk of precipitating a solvate or hydrate during the manufacturing 
process, since scCO2 returns to the gaseous state after expansion, resulting in a solvent residue 
free product. Solvent removal in established bottom-up techniques is critical, since solvent 
residues can cause crystal growth, physical or chemical instabilities of the formulation, and 
increase the potential toxicity of the formulation (249). Furthermore, no thermal or mechanical 
stresses are induced during RESS, which can cause degradation of the drug or crystal defects 
(249).  
6.6.2 Characterization of OLZ nanosuspensions and freeze-dried nanoparticles 
The RESSAS process for the production of nanosuspensions is comparable to bottom-
up techniques such as liquid antisolvent precipitation. A fast adsorption process and slow 
desorption of the stabilizer molecules onto the freshly created drug surface are therefore crucial 
to ensure fast and complete surface coverage of the precipitated nanoparticles and therefore a 
well stabilized system. PEG and polysorbate suspensions remained macroscopically stable for a 
couple of hours after the production process showing reduced mean Di values immediately after 
production, in comparison with the particles suspended in HPMC solution which showed an 
increased size (Figure 6.7). However, leaving the PEG nanosuspensions to rest at 20°C/ 65% 
RH for several hours, the transparent PEG and polysorbate suspensions started to turn cloudy 
and flocculation became visible. The same was reported for nanosuspensions produced with 
RESSAS, which were stabilized by PEG and PVP (258). The authors suggested that the 
RESSAS process can be divided into two related processes, the first being the actual 
precipitation step and the suppression of particle growth by the receiving medium and the 
second step being the stabilization of the particles. Our results suggest that such a division is at 
least partly reasonable, considering that the addition of SLS to PEG suspensions after the actual 
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precipitation process still results in the desired effect of preserving the colloidal particle size (no 
precipitation was visible). It is however likely to assume that by the time the co-stabilizer is 
added, the system is already undergoing a certain degree of agglomeration, since the co-
stabilizer is not present at the actual precipitation process to immediately reduce the interfacial 
tension by covering the freshly created surface (257). The larger nanoparticles and broader PSD 
obtained with HPMC, compared with Psb and PEG, where the particle size and PSD were in the 
range of the material precipitated in the classic RESS process, clearly demonstrates the 
influence of stabilizer on the primary particle formation (Figure 6.4and Figure 6.7). 
Regarding the stabilizers used, although the HPMC stabilizer showed to create 
nanosuspensions with particles larger than the ones obtained with Psb and PEG (immediately 
after the RESSAS process, Figure 6.7), the freeze-drying of the nanosuspensions and 
subsequent reconstitution of the cakes, showed just a slight particle size growth. These results 
showed that both the stabilizer used (HPMC) and the freeze-drying process applied to dry the 
nanosuspension did not lead to agglomeration or precipitation macroscopically visible (Figure 
6.9). HPMC therefore seems to at least detain the particle growth of the nanoparticles, which 
could additionally be attributed to the higher viscosity of HPMC suspensions compared to PEG 
and Psb, thus reducing the diffusivity of the drug particles in suspension (Table 6.2). 
A drastic particle growth was observed in PEG suspensions after freeze-drying. One of 
the main challenges in nanosuspension technology is prevention of particle agglomeration or 
aggregation and crystal growth (263). At the nanometer scale, attractive van der Waals and 
dispersive forces between particles come into play. These attractive forces increase dramatically 
as particles approach each other, which ultimately results in irreversible aggregation (264, 265). 
The success for the drug nanoparticle technology is the compensation of the extra free energy of 
freshly exposed surfaces (266). The tendency of the smaller particles in a suspension to dissolve 
and re-crystallize on the larger particles represents a mode of instability, termed Ostwald 
ripening. In general, the speed of Ostwald ripening is governed by molecular diffusion or 
surface reaction. Irrespective of the mechanism, particle growth can be prevented or at least 
minimized by steric hindrance and/or electrostatic repulsion. Therefore, addition of hydrophobic 
polymers during the preparation of nanosuspensions have shown to adsorb on hydrophobic 
surfaces of insoluble nanoparticles providing steric stabilization effect (266, 267) The lower 
hydrophobicity of PEG in relation to HPMC, decreases the likehood of interactions of PEG with 
OLZ crystal surface, leading to insufficient stabilization of the this polymer. Furthermore, the 
amount of polymeric excipient not only determines its adsorption onto the drug substance 
particles, but also contributes to the viscosity of the suspension medium, thereby increasing the 
diffusion barrier for particle-particle interaction (268). HPMC showed to strongly increased the 
viscosity of the medium, thus constraining the diffusivity of the drug molecules. It therefore 
seems plausible that the protective effect of HPMC is more pronounced than that of PEG.  
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The recrystallization of the drug and the hydrate formation in suspensions with mere 
steric stabilization also explain why no amorphous trace of the material could be detected after 
freeze-drying, even though the existence of amorphous material was confirmed for OLZ that 
was precipitated in the classic RESS process. It is likely that the partially amorphous material 
that is originally precipitated during RESS dissolved in the aqueous suspension medium due to 
its enhanced solubility, thus accelerating the supersaturation and recrystallization of the 
dihydrate B that was detected in the freeze-dried cakes of the OLZ RESSAS nanosuspensions 
(Figure 6.8). For PEG nanosuspensions that were co-stabilized with SLS, neither particle 
growth nor crystal conversion to the Dihydrate B was observed. This indicates that particle 
growth and hydrate formation of OLZ coincide in the insufficiently stabilized colloidal 
suspensions. Since the suppression of particle growth and hydrate formation are both 
mechanistically related to a surface interaction of the drug with the excipient in suspension, it 
seems likely to assume that these processes are also related. 
Polysorbate 80, on the other hand, as a non-polymeric small molecule prevented neither 
particle growth nor hydrate formation. OLZ in Psb nanosuspensions showed to hydrate which is 
easily explained by the classic nucleation theory, which refers that crystal nucleation increases 
with decreasing interfacial tension by the inclusion of surfactants like Psb 80 in the medium. 
After freeze-drying, OLZ showed to be anhydrous which may be due to the very low Psb 
concentration used, which was not able to prevent the dehydration phenomenon during the 
secondary drying of the freeze-drying process. Therefore, the most stable anhydrous Form I was 
always obtained in the final dried cake. 
6.7 Conclusion 
In this study, rapid expansion of supercritical solutions (RESS) and rapid expansion of 
supercritical solutions into aqueous solutions (RESSAS) was successfully employed for the 
production of nanoparticles and nanosuspensions of OLZ, a poorly soluble BCS class II 
compound. With RESSAS, OLZ nanosuspensions with an increased dissolution rate could be 
produced. As anticipated it was paramount to find a compromise between process operability 
and formulation stability when using RESSAS as a tool for the production of nanosuspension. 
This study showed that the choice of stabilizer has a critical influence on both the stability of 
nanosuspensions, particle size distribution and the expansion process itself. Polymeric 
stabilizers showed to be better choice from a processing standpoint, but steric repulsion is often 
not a sufficient stabilizing mechanism for nanosuspensions. On the other hand, it could be 
shown that retroactive electrostatic stabilization (e.g. SLS) will still lead to preservation of the 
nanosized particles. Consequently, the work shows that the combination of PEG with SLS 
provides the best stabilization system to OLZ. Both the suppression of particle growth and 
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hydrate formation showed to be mechanistically related to a surface interaction of the drug with 
the excipient used in suspension, being those processes related 
The beneficial features of the RESSAS process lie on the mild process conditions and 
the absence of organic solvents, but especially on its ability to produce particles with small sizes 
and narrow particle size distributions. It was concluded that RESSAS process may present a 
superior alternative to other bottom up techniques for the production of pharmaceutical 
nanosuspensions. 
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Chapter 7 -  Impact of extrusion process on the physical properties of 
olanzapine and pellets 
 
7.1 Abstract 
A fine control should be considered when APIs are exposed to either hydrating or 
dehydrating conditions during pharmaceutical processing. This may lead to the detection of 
polymorphic changes during processing, which may have an impact on the APIs solubility and 
bioavailability. This study focused on the ability of anhydrous olanzapine (OLZ) to hydrate 
during the manufacture of pellets by extrusion and spheronisation and the impact of hydrated 
OLZ on the pellets’ characteristics. Extrudates were made of OLZ (0, 15, 30% w/w), 
microcrystalline cellulose (MCC, 90, 75, 60% w/w), polyethylene glycol 6000 (PEG 6000, 10% 
w/w) and water (75% w/w) in a ram extruder (200 mm/min) prior to spheronisation (5 min, 
radial plate). Half of the wet mass was extruded immediately, whereas the remainder was stored 
in a hermetic container for 6 hours prior to extrusion. A placebo formulation was manufactured 
with calcium phosphate replacing olanzapine. Pellets were dried in a fluid bed drier (45 C, for 
30, 60, 90, 180 min). XRPD and FTIR analyses were performed to detect and characterize 
different solid phases of OLZ in all manufacturing steps. Physical characteristics (size, crushing 
stress and moisture) of the pellets were also evaluated. The results showed that OLZ was able to 
hydrate in a mixture of 2 hydrates (dihydrate B and a higher hydrate) when the wet mass was 
left to equilibrate for 6 h. Drying of pellets for 60 min was sufficient to remove the higher 
hydrate but not sufficient to remove the dihydrate B. The presence of the dihydrate B showed to 
have a negative impact on OLZ’s dissolution. Furthermore, the hydration of OLZ during resting 
of the wet mass was able to affect the force required for extrusion, the pellets’ sizes, the 
mechanical strength and residual moisture after drying. Overall, the study enhanced the need to 
have highly controlled processes to minimize anhydrate-hydrate conversions of OLZ. 
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7.2 Introduction 
Several particles’ agglomeration processes are well known, namely wet granulation, 
which encompasses a variety of different steps, such as wetting, mechanical stressing and 
sieving which may promote crystalline changes of a drug. The solid state transformations that 
are more likely to occur during this process are solvent-mediated transformations to a more 
stable polymorphic form or the formation of solvated forms (typically a hydrate). However, the 
kinetics of such transformations, together with the drug loading in the dosage form, the quantity 
of liquid used for granulation and the time of exposure of the solid to the liquid determine 
whether or not the changes will occur or be completed during the wet granulation process (83). 
The hydrated forms can dehydrate throughout the subsequent process of drying, depending on 
the drying conditions (e.g. water vapor, temperature, or mechanical stress) and the dehydration 
mechanisms of the crystal. The dehydration process may result in the formation of an 
amorphous form, a lower hydrate, a stable or metastable anhydrous form or even a mixture of 
different forms (105, 210). When an Active Pharmaceutical Ingredient (API) has multiple 
anhydrous or hydrated forms, the control over the final solid-form can become even more 
complex (85).
 
Extrusion and spheronisation of wet masses also involves the wetting and drying 
steps of the materials, together with mechanical stresses, which are all likely to promote solid-
state modifications of an API. Furthermore, the amount of wetting liquid used in this process is 
relatively high when compared to other processes, namely fluidized bed granulation. Therefore, 
APIs which will be included in pellets manufactured by extrusion of wet masses are more prone 
to undergo structural transformations than APIs manufactured otherwise (111). 
Olanzapine (OLZ) is practically insoluble in water and has only 60% oral 
bioavailability. Based upon individual patient characteristics, dosage adjustments may be 
required (269). The need for long term therapy of OLZ (270), can turn small variations of 
OLZ’s solubility (due to molecular structural transformations, for instance) into significant 
changes on the dissolution rates from pellets, thus affecting OLZ bioavailability. The latter can 
generate high instability on patient behavior and quality of life. 
7.3 Purpose 
This section aims to study the manufacture of pellets with OLZ form I (the most stable 
anhydrous form) and to evaluate its solid-state modifications during all of the process of 
extrusion/spheronisation, mainly the wetting and drying steps, which are the most critical ones. 
The influence of crystalline changes of OLZ on the physical characteristics of the pellets and on 
OLZ performance when dissolved into an appropriate aqueous environment is investigated in 
this chapter. 
Chapter 7 
150 
7.4 Materials and Methods 
7.4.1 API and excipients 
Olanzapine Form I (OLZ FI, Pharmorgana, India), microcrystalline cellulose (MCC, 
Avicel 101, FMC corporation, USA), polyethylene glycol 6000 (PEG, Sigma-Aldrich, 
Germany) and tricalcium phosphate (CP, Sigma-Aldrich, Germany) were used for pellets 
manufacture. MCC and PEG-6000 were chosen due to their common application on the 
production of solid dosage forms (271-273) and on the grounds of the poor crystallinity shown, 
thus their X-ray powder diffraction profiles allowed the visualization of OLZ solid-state 
transformations throughout processing. Freshly demineralized water was used as a solvent. 
7.4.2 Manufacture of pellets 
The different raw materials (50 g) were dry-mixed in a planetary mixer (Kenwood, 
Hampshire, UK) for 10 min (Table 7.1, formulations A-D) prior to the addition of water and 
mixing for another 10 min (wet massing). Half of the wet mass was extruded immediately (1) 
whereas the other half was allowed to rest for 6 h (2) in a hermetically closed polyethylene bag 
before extrusion. During the resting period, it is expected that the water is better spread over the 
components, becoming more plastic (274). The extrudates were manufactured in a ram extruder 
(Lurga, Sacavém, Portugal) adjusted to a universal testing machine (LR 50K, Lloyds 
Instruments, Leicester, UK) fitted with a load cell to allow the collection of data for the applied 
force to the ram and its displacement (200 mm/min). The wet mass was forced to pass through a 
die (L/D=6) and the extrudates placed immediately after extrusion in a spheroniser (Caleva, 
radial friction plate rotating at 500 rpm) for 5 min. The wet pellets were dried in a fluid bed 
drier (Aeromatic-Fielder AG, Switzerland) at 45 ⁰C and samples were collected after 30, 60, 90 
and 180 min of drying. 
Pellets were characterized for size and size distribution (sieving, Retsch, Haan, 
Germany) and the fraction of pellets between 1.00 and 1.40 mm was considered for physical 
and dissolution studies. The mechanical resistance of pellets for each formulation (A-D dried for 
30, 60, 90 and 180 min) was assessed by crushing them between two parallel flat plates 
approaching at a constant speed of 0.5 mm/s (n=20, Texture Analyser, XT Plus, Stable 
Microsystems, Godalming, UK).The residual water content in the pellets after drying was found 
by determination of the water loss on drying using an infrared moisture analyzer (n=6, Sartorius 
Moisture Analyzer, Germany). 
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Table 7.1 – Design of extrusion formulations 
Formulation 
OLZ:MCC 
(w/w) 
PEG-6000 
(w/w) 
CP 
(w/w) 
Water level 
(w/w dry 
powders) 
Resting time 
of the mass 
(h) 
A1 0:60 10 30 75 0 
A2 0:60 10 30 75 6 
B1 0:90 10 0 75 0 
B2 0:90 10 0 75 6 
C1 15:75 10 0 75 0 
C2 15:75 10 0 75 6 
D1 30:60 10 0 75 0 
D2 30:60 10 0 75 6 
E1 100:0 0 0 75 0 
E2 100:0 0 0 75 6 
 
7.4.3 Preparation of a wet mass without addition of excipients 
The preparation of a wet mass which only contains the API (Table 7.1, formulation E) 
was performed in a smaller scale: water (7.5 g) was added to OLZ (1 g) and the wet massing of 
OLZ was carried out in a mortar with a pestle prior to storage in a sealed vial. After 6 h the wet 
OLZ was analyzed by X-ray powder diffraction (XRPD), Fourier transform infrared 
spectroscopy (FTIR) and hot stage microscopy (HSM). For the contact angle measurements and 
scanning electron microscopy (SEM), the wet mass of OLZ was filtered and dried at 45 ºC for 
15 min and 180 min.  No extrusion was performed for this formulation. 
7.4.4 Characterization of the wet masses, wet pellets and dried pellets 
Crystalline changes of OLZ over wetting, extrusion, spheronisation and drying, and the 
impact of excipients on the changes were monitored by X-ray powder diffraction (XRPD) and 
Fourier transform infrared spectroscopy (FTIR) complemented by hot plate microscopy (HSM) 
and dissolution studies. 
X-ray powder diffraction (XRPD) 
The XRPD was performed in equipment 1 (described in chapter 2).  The X-ray powder 
diffractograms were recorded at room temperature by a diffractometer with automatic data 
acquisition software using a Cu Kα radiation source. The tube amperage was 30 mA and the 
tube voltage 40 kV. For the characterization of the OLZ crystalline structures in each process 
stage the XRPD patterns were compared with the XRPD pattern of crystalline structures of 
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anhydrous OLZ FormI, dihydrate B and higher hydrate obtained from the Cambridge Structural 
Database and visualized using the Mercury 1.4.2 software (Cambridge Crystalographic Data 
Centre, Cambridge, UK) (18). 
FT-IR Spectroscopy (FTIR) 
The wet masses and pellets were analyzed by FT-IR Spectroscopy (IR Affinity-1 
Shimadzu spectrophotometer, Japan).  Each sample was mixed with KBr at a concentration of 
0.5 w/w. The mixtures (200 mg) were compressed into a tablet of 10 mm diameter. The second-
derivative of the absorbance spectra was applied to improve the visualization of the specific 
bands of the different OLZ forms. 
Hot stage microscopy (HSM) 
HSM was used to provide a visual insight on hydrate to anhydrate OLZ transformation 
crystals obtained from the formulation E2. The dehydration of the crystals obtained from this 
wet mass were monitored under a microscope with polarized light (Olympus BX51, JP) fitted 
with a heating stage plate (Linkam THMS350V, UK). The sample was heated up to 45 °C at a 
rate of 20 °C/min and was kept at this temperature for 150 min. 
Particle size distribution (PSD) 
The PSD of the unprocessed/processed material were measured with laser 
diffractometry (LD) using a Mastersizer 2000 (Malvern, Herrenberg, Germany) equipped with a 
Hydro 2000S sample dispersion unit. The OLZ powder was suspended in demineralized water 
containing 0.1% Polysorbate as surfactant to ensure a good dispersion of the hydrophobic OLZ 
particles in water. 
7.4.5 Dissolution testing  
Dissolution studies were performed for pellets dried for 60 min and 180 min. The 
dissolution media was a phosphate buffer (pH= 6.8), used to mimic the pH of the intestinal 
fluid. The pellets were placed in each dissolution vessel in order to have 5 mg of OLZ per 
vessel. The amount of water present in the pellets was considered (Sartorius Moisture Analyzer, 
Germany), since pellets extruded immediately and pellets extruded 6 h after the wet massing 
retained different fractions of water. OLZ was quantified by UV spectrometry (λ= 254 nm, 
Hitachi U- 2000, Japan) and a comparison of dissolution profiles was possible by application of 
the similarity factor f2. 
7.4.6 Statistical analysis 
Results of the extrusion force and the fraction of pellets in the 1.00-1.40 mm range were 
considered and analysed by ANOVA (SPSS v.17, USA). This test was applied to explore 
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significant differences between the force values needed to extrudate the wet masses and the size 
of the pellets when the wet mass was left to equilibrate for 0 h or 6 h.  
7.5 Results 
7.5.1 Wet massing step 
In order to study the crystal modification of OLZ during the extrusion process, the 
XRPD diffractograms of the OLZ formulations after different steps of extrusion process were 
plotted together with the reference XRPD patterns of OLZ for a better comparison. Reference 
XRPD patterns for 3 crystalline forms of OLZ (anhydrous OLZ F I, OLZ dihydrate B and OLZ 
higher hytdrate) are shown in Figure 7.1 (a, b and c). Figure 7.1 a) shows the raw materials used 
for the pellets production. The XRPD patterns of wet mass C1 revealed that OLZ presents the 
characteristic peaks of OLZ F I (Figure 7.1 b). However, wet mass D1 presented distinct XRPD 
reflections for anhydrous OLZ FI and OLZ dihydrate B (grey bar, Figure 7.1 2b), indicating that 
in a formulation with a higher OLZ/MCC ratio, the hydration of OLZ could not be prevented 
during the wet massing. Although for formulation C1 no hydrate conversion has occurred in the 
time scale of the wet massing, the presence of OLZ hydrates in wet masses C2 revealed that 
hydration of OLZ is dependent on the time that the drug is in contact with water. Figure 7.1 c) 
shows that the diffraction pattern of OLZ in wet masses C2, D2 and E2 no longer had traces of 
OLZ F I. In these wet masses, the diffraction patterns showed characteristic peaks of 2 different 
hydrates of OLZ - OLZ higher hydrate and OLZ dihydrate B. 
In order to understand the impact of using different ratios of OLZ:MCC on the rate of 
OLZ hydration, infrared analyzes were performed for wet masses C and D at different time 
periods (Figure 7.2). The second derivate of absorbance in the 958-980 cm
-1
 region allowed the 
observation of anhydrate to hydrate conversion of OLZ in wet masses during 6 h. The 
anhydrous OLZ band at 965 cm
-1
, related to the deformation of the piperazinyl group coupled to 
the azepine and thiophene moieties (138), reduced its intensity and shifted to higher 
wavenumbers when hydration occurred. Formulation C (15 OLZ: 75 MCC) showed a slower 
reduction of the intensity of this band due to slower hydrate formation in this wet mass. 
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Figure 7.1 – The diffraction patterns for the three forms of olanzapine calculated from single-
crystal data of anhydrous olanzapine form 1 (OLZ FI), olanzapine dihydrate B (OLZ dihydr. B) 
and olanzapine higher hydrate (OLZ Higher hydr.) are followed by the XRPD pattern of  (a) raw 
materials olanzapine raw materials (OLZ RM, PEG and MCC), (b) wet mass C1, D1 and E1 and 
(c) wet mass C2, D2 and E2. The characteristic diffraction peaks of OLZ dihydrate B and OLZ 
higher hydrate are indicated with a grey bar. 
 
 
Figure 7.2 – 2nd derivative of FTIR of the region 958-972cm-1 of wet mass C (15 OLZ: 75 MCC, a) 
and D (30 OLZ: 60 MCC, b) at different time periods (0, 10, 60, 360 min). Different OLZ crystal 
forms are shown in c). 
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Formulation E was formulated without excipients in order to study the morphological 
changes of OLZ particles during the wetting process. OLZ raw-material particles (OLZ FI) 
showed to be irregularly shaped. However, after being kept for 6 h in direct contact with water 
(wet mass E2), hydrate formation has occurred (mixture of 2 hydrates), thus affecting the 
particles’ morphology, which changed to plate-like shaped crystals (Figure 7.3 a.1, a.2, b.1 and 
b.2). 
The hot stage microscopy showed that the new crystals formed were transparent and 
showed birefringence (Figure 7.3, b2). After heating for 180 min at 45 ºC, the crystals became 
darker (Figure 7.3 b.2). The optical property changes of crystals accompanying dehydration 
events have already been reported for other drugs (275, 276). Figure 7.3 shows that dehydration 
starts with a darkening of the crystal which is slowly propagated throughout the crystal’s body, 
revealing that dehydration did not occur uniformly. The XRPD pattern of this dehydrated 
sample showed that an anhydrous phase became apparent after dehydration (Figure 7.3 c) but 
with a lower crystallinity (reduction of the peak’s intensity). A higher magnification of the SEM 
microphotographs of OLZ crystals before and after dehydration showed that the crystals present 
several cracks at the surface. This change of the surface may result from the breaking up of the 
crystal into numerous small crystallites that lead to its loss of transparency as a result of light 
scattering on the surfaces of the numerous crystallites. 
Figure 7.3 d) shows the change of crystal size distribution due to the hydrate formation. 
The growth of the crystals during the resting of the wet masses led to the formation of particles 
with increased particle sizes. 
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Figure 7.3 – OLZ F I RM and Formulation E were observed by SEM (a), HSM (b) and XRPD (c) 
The particle size distribution of OLZ raw material(RM) and formulation E (t=360 min) is 
represented in d) 
a) OLZ FI RM particles (a.1); Particles from formulation E dried at 25 ºC (a.2) and 45ºC for 
180 min (a.3); after being kept 6h in direct contact with water 
b) OLZ FI RM particles (b.1) and particles from formulation E (t=360 min) subjected to an 
isothermal at 45ºC for 180 min (b.2) under the HSM 
c) Diffractograms of olanzapine RM (c.1), formulation E (wet paste, t=360 min) (c.2) and 
formulation E dried 45ºC for 180 min (c.3) 
d)  Particle size distribution (d) of OLZ FI RM and formulation E (t=360 min). 
 
7.5.2 Extrusion and drying 
During the manufacture of pellets using the extrusion-spheronisation technique, the 
steps following the wet massing of the powders is the extrusion of the moist mass, 
spheronisation and drying. Formulation C1 (containing lower content of OLZ) showed to not 
hydrate during all of the extrusion process, therefore OLZ showed to remain anhydrous after 
pelletisation (Figure 7.4). This result led to the suggestion that the time required for the 
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immediate extrusion (around 20 minutes), together with the ratio of OLZ:MCC considered in 
this experiment, were adequate in preventing hydrate formation. 
With regard to the wet pellets C2, where a concomitant crystallization of 2 hydrate 
forms have occurred, the drying process did not initiate a total retransformation of the hydrates 
to anhydrate at 45 ºC. This drying temperature is not high enough to discharge the dihydrate B 
in the first 60 minutes of drying and the dihydrate B remains within the core of the pellet. 
However, these drying conditions of 45 ºC for 60 min were sufficient to convert the OLZ higher 
hydrate into the dihydrate B (Figure 7.4). By increasing the drying time up to 180 min, 
dehydration of the dihydrate-B occurs (Figure 7.4). 
 
Figure 7.4 – Diffractograms of anhydrous OLZ form I, OLZ dihydrate-B, OLZ higher hydrate, wet 
pellets C1, wet pellets C2, and pellets C2 dried for 60 min and 180 min. The characteristic 
diffraction peaks of OLZ dihydrate B and higher hydrate are indicated with a grey bar. 
 
The process of hydration and dehydration of OLZ present in the different pellets’ 
formulations could also be monitored by IR spectroscopy. OLZ FI showed to present a distinct 
IR spectrum when compared to OLZ hydrates in the spectral regions between 1800-400 cm
-1
 
(Figure 7.5). In spite of the presence of MCC, the bands of anhydrous OLZ or hydrated OLZ 
could be clearly distinguished in the wet and dried pellets of the different formulations (Figure 
7.5 A1 and B1, b-e). The 2
nd
 derivative of the absorbance data allowed for a detailed 
observation of three distinct absorption maxima for the anhydrous OLZ FI (928, 965 and 1010 
cm
-1
), which were present in wet and dried pellets C1 and absent in wet pellets C2. For the 
formulation D, the pellets D1 showed to present bands at 928, 965 and 1010 cm
-1
, characteristic 
of OLZ FI, but also bands at 971 and 1004 cm
-1
, specific of both OLZ dihydrate B and higher 
hydrate, showing once again, a mixture of crystalline phases in pellets with a higher ratio of 
OLZ/MCC. 
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Figure 7.5 – Infrared spectra (A1) and second derivative of infrared spectra (A2) of: (a) anhydrous 
OLZ F1; (b) wet pellets C1; (c) wet pellets C2; (d) pellets C1 dried for 60 min; (e) pellets C2 dried 
for 60 min; and (f) dihydrate B. 
Infrared spectra (B1) and second derivative of: (a) infrared spectra (B2) of OLZ F1; (b) wet pellets 
D1; (c) wet pellets D2; (d) pellets D1 dried for 60 min; (e) pellets D2 dried for 60 min; and (f) 
dihydrate B. 
Grey bars show the specific bands of anhydrous OLZ FI 
 
Figure 7.6 shows the surface and the cross section of the pellets C1 produced 
immediately after wet massing (t=0) and pellets whose wet mass rested for 360 min. Although 
the pellets surfaces look similar in both processing approaches, it was possible to distinguish the 
hydrated OLZ crystals when the pellets were cross sectioned. The appearance of plate-like 
crystals of OLZ in the inner part of the pellet (t=360 min) shows that the changes in shape of 
OLZ particles due to hydrate formation are also occurring in the formulations containing 
excipients. 
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Figure 7.6 – SEM micrographs of formulation C1 t=0 min (1) and C2 A t=360 min (2). The pellet’s 
surface is shown in figure a) and the cross section of pellets is represented in b). 
 
7.5.3 Mechanical characterization of the wet mass and dried pellets 
The hydrate conversion of OLZ, together with the change of shape and size, may have a 
significant impact on several physical and mechanical characteristics of the pellets. 
7.5.3.1 Extrusion force 
The extrusion force required to obtain the extrudates depends on the rheological 
properties of the wet mass (113). For this study, formulations A and B (without OLZ) were also 
taken into consideration. 
As a result of MCC being an excipient which presents a high water retention ability, the 
wet mass B (higher MCC fraction and the same amount of wetting liquid) showed to require an 
increased force in order to be extruded due to its lower degree of water mobility (Table 7.2). 
Increasing the OLZ or calcium phosphate content (A, C, D) and therefore reducing the ratio of 
MCC/water in the wet mass, lowers the force needed for the extrusion of the masses. 
Rheological properties of the wet masses may be improved by allowing the wet mass to 
equilibrate for a few hours prior to extrusion in order to improve the water’s capability of 
hydrating the microcrystalline cellulose (MCC), making it more plastic (113). This fact was 
observed in pellets without OLZ (A and B) since the mass that rested for 6 h (2) showed to 
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require slightly less force to be extruded (Table 7.2). However, the differences between them 
were not statistically significant. Concerning the formulations containing OLZ (C and D), they 
showed the opposite result since they required lower forces to be extruded immediately after the 
wet massing as compared to extrusion after 6h. A significant increase of the force necessary for 
extrusion was verified between the pairs C1 vs C2 and D1 vs D2. 
 
Table 7.2 – The effect of formulation on the extrusion force needed to extrudate the wet masses and 
analysis of variance of the extrusion force values needed to extrudate the formulations with 
different periods of resting of wet mass (0h and 6h) 
Formulation Extrusion force at steady state (N)
a 
p- value 
b
 
A1 4233.3 ± 107.84 
0.08 
A2 3824.4 ± 286.35 
B1 7188.6 ± 226.54 
0.56 
B2 7089.1 ± 155.11 
C1 5572.6 ± 449.25 
0.02 
C2 6878.7 ± 390.50 
D1 4406.8 ± 369.65 
<0.01 
D2 6372.2 ± 108.16 
a 
Mean value of extrusion force (n=3) 
b α=0.05 
7.5.3.2 Pellet size 
Calcium phosphate pellets (A) generated pellets with similar sizes to the formulation 
D1. This excipient has low higrosocpicity and does not hydrate during the wet massing. By 
opposition to formulation D, pellets with increased sizes are observed after the resting period. 
Formulation B showed to have a higher fraction of pellets in 1.0 - 1.4 mm size range when the 
wet mass rested for 6 h. 
As opposed to the previous formulations, OLZ pellets showed to have pellets with 
reduced sizes when the wet masses rested for 6 h (C1 vs C2 and D1 vs D2, Table 7.3). This 
resulted in a higher fraction of pellets in the 1.0 and 1.4 mm size range. When the percentage of 
the pellets in the size range of 1.0-1.4 mm was compared to the formulations C1 vs C2 and D1 
vs D2 (3 different batches for each formulation) the differences showed to be significant 
(α<0.05). 
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Table 7.3 – Interquartile range and percentage of pellets within 1.0-1.4 mm (n=3 batches). The 
percentage of pellets in the 1.0-1.4 mm range was compared between batches and the statistical 
significance calculated 
Formulations Interquartil range IQR Pellets in 1.0 –1.4 mm fraction (%) p-value 
a
 
A1 0.33 68.9 ± 1.87 
0.06 
A2 0.35 65.0 ± 1.89 
B1 0.27 81.7 ± 1.64 
0.80 
B2 0.28 82.0 ± 1.09 
C1 0.28 79.3 ± 2.28 
0.03 
C2 0.23 85.9 ± 2.74 
D1 0.31 67.5 ± 2.17 
0.01 
D2 0.22 80.2 ± 3.37 
a α=0.05 
 
7.5.3.3 Pellet mechanical strength 
The values of the mechanical strength, expressed as the crushing force of the pellets 
obtained with the different preparations, are shown in Table 7.4. The strength was determined 
on pellets in the same size fraction, 1.0-1.4 mm. The value of the strength of the pellets obtained 
with the different preparations showed to increase proportionally with the increase of the drying 
time of the pellets. Considering the preparations with 15% and 30% of OLZ, the average values 
of the crushing force needed to break the pellets C2 and D2 showed to be higher than for pellets 
C1 and D1, regardless of the drying period (Table 7.4), which was not verified for pellets 
without OLZ. Comparing the mean extrusion force needed to extrudate wet masses containing 
0%, 15% and 30% of OLZ (B, C and D) and the mean crushing force needed to crush the pellets 
obtained from the same masses, one may observe that the mechanical strength changes in the 
same manner as the force needed to extrudate the wet masses. 
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Table 7.4 – Analysis of the effect of formulation on the mechanical strength of pellets 
Formulation 
Mean crushing force after different drying times (N) 
15 min 30 min 60 min 90 min 180 min 
A1 6.55 ± 0.67 7.73 ± 1.13 8.88 ± 0.94 9.64 ± 1.41 9.49 ± 1.36 
A2 6.54 ± 0.43 8.15 ± 1.02 8.64 ± 1.18 9.19 ± 1.30 9.36 ± 1.41 
B1 7.82 ± 1.62 8.82 ± 1.18 9.13 ± 0.83 9.25 ± 1.27 9.69 ± 1.68 
B2 7.51 ± 1.15 8.67 ± 1.19 9.24 ± 0.81 9.14 ± 0.82 9.44 ± 0.98 
C1 7.01 ± 0.46 7.59 ± 0.73 8.16 ± 0.60 8.48 ± 0.87 8.78 ± 1.15 
C2 7.66 ± 0.69 8.41 ± 0.94 9.07 ± 0.84 9.29 ± 0.96 9.42 ± 1.29 
D1 6.33 ± 0.51 7.01 ± 1.09 7.55 ± 0.83 7.95 ± 0.71 8.36 ± 0.81 
D2 7.47 ± 0.46 8.11 ± 0.89 8.75 ± 0.66 9.06 ± 1.18 9.33 ± 1.04 
 
Figure 7.7 shows the schematic representation of the extrusion force necessary to 
extrudate wet masses, pellet size distribution and crushing force necessary to crush the dried 
pellets of one single batch of formulations B, C and D. This figure sums up the results showed 
above, allowing for a better visualization of the differences between the formulations which 
were allowed to rest in a hermetic container and the formulations that were extruded 
immediately after their preparation. For the 3 different characterizations referred above, 
formulations B1 and B2 registered almost no differences when compared to formulations C and 
D. 
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Figure 7.7 – (1) Extrusion force necessary to extrudate wet masses; (2) pellet size distribution; and 
(3) crushing forces necessary to crush the pellets produced from the formulations (a) B, (b) C,  and 
(c) D. 
 
7.5.3.4 Water content 
Pellets A and B showed to have the same kinetics of water removal during drying, 
irrespective of the time elapsed between the wet massing and extrusion steps (Figure 7.8). 
Regarding formulations C and D, one could observe higher residual moisture for pellets C2 and 
D2 when the pellets are dried for periods inferior to 180 minutes. 
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Figure 7.8 – Moisture content (% wt/wt) of pellets: (a) A1 and A2, (b) B1 and B2, (c) C1 and C2 and 
(d) D1 and D2, dried for different periods of time. Samples measured with an Infrared dryer (n=6). 
 
7.5.4 Drug performance assessed by dissolution 
The extent of OLZ dissolution after 12 h was lower than 65% for all of the different 
formulations (Figure 7.9).  A cross section of the pellets after the dissolution test showed that 
the core of the pellets was yellow (which is the color of OLZ), proving that OLZ was retained in 
the interior of the pellet. In another approach, pellets were crushed after the end of the test, 
which enabled the release of 100% of OLZ. This demonstrated that there was no degradation of 
OLZ during the test. The release of OLZ from pellets (C2 and D2) dried for 60 or 180 minutes 
presented different behaviors. For pellets C2 and D2 dried for 60 minutes (Figure 7.9 A and B) 
the OLZ dissolution rate was decreased in relation to the pellets C1 and D1. The same was not 
verified for pellets C2/D2 dried for 180 min (Figure 7.9 C). 
The comparison of the dissolution data was possible through the calculation of f2 
values. Generally, a similarity factor f2 > 50 indicates an average difference of no more than 
10% at the sample time points. The dissolution of OLZ in formulations C1/C2 and D1/D2 (dried 
for 60 min) in the buffer with the higher pH revealed to be about 50 (f2= 49 and 51), which is 
the threshold for similarity. Moreover, formulations C2 and D2 showed to release about 10% 
less of OLZ than their counterparts (C1 and D1) after 12 h (≈ 50% of release). An increase of 
similarity of the curves was observed when OLZ in pellets C2 and D2 dehydrated again into the 
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anhydrous form I (Figure 7.9 c).Therefore, in the pellets C2 and D2 dried for 150 min, a higher 
similarity was found with their respective pair (f2=81 for the pair C1/C2 and f2=79 for the pair 
D1/D2). 
 
Figure 7.9 – Release of olanzapine from pellets: (a) C and (b) D dried for 60 min and from (c) 
pellets C and D dried for 180 minutes 
7.6 Discussion 
Hydrate formation in aqueous environments is expected to occur through solvent-
mediated transformations. These transformations start with the dissolution of the metastable 
anhydrate form (step 1) in the solvent used for the wetting process, leading to supersaturation 
with respect to the stable hydrate form and providing the thermodynamic driving force for 
nucleation (step 2) of the stable hydrate. The final growth (step 3) of the stable hydrate will 
deplete the solution concentration, resulting in further dissolution of anhydrous solid. The 
hydrate crystal will continue to grow until all of the anhydrous material has dissolved and the 
concentration of the drug in the solution reaches the solubility of the hydrate (197). 
The presence of excipients in the formulation may provide the surfaces or interfaces 
necessary to promote heterogeneous nucleation, which happens at low driving forces, and the 
favorable dissolution properties of the metastable drug may be lost due to the fast nucleation of 
the stable form (42). At the same time, water activity (aw), which has shown to affect the 
hydration kinetics (69), may be changed by certain excipients due to their dissolution on the 
Chapter 7 
166 
water used for the agglomeration of the powders, or the ability of excipients to absorb water 
(195). 
Our results showed that the rate for OLZ hydrate formation is dependent on the 
OLZ/microcrystalline cellulose ratio in the formulation. Due to the ability of MCC to absorb 
water, its addition to the formulation led to a decrease in the water activity experienced by the 
hydrate forming drug. When water interacts with MCC, new pores are formed as the cellulose 
particles swell. At low moisture contents, water molecules are adsorbed on the cellulose 
surfaces and they bind to the free hydroxylgroups of cellulose chains through hydrogen bonds. 
At high relative humidity, capillary condensation takes place and the porous cellulose can hold 
appreciable amounts of water between its fibrils and fibers (210). Thus, the formulation with 
higher MCC content (formulation C1) showed not to hydrate during all of the extrusion process, 
whereas formulation D1 showed to have features of both anhydrous and hydrated phases of 
OLZ in the wet pellets. The faster hydrate formation in formulation D1 can also be explained by 
the fact that lower content of MCC could have left OLZ molecules more exposed to shear forces 
during the wet massing, decreasing the time to supersaturation, which is a prerequisite for 
nucleation and growth. 
The time scale of the wetting process revealed to have an impact on OLZ hydrate 
formation. As nucleation is a stochastic process, and events are usually expressed as a rate or the 
number of events occurring in unit time, the probability of such an event occurring increases 
with time, and the transformations in a water environment is therefore most effective if 
continued over an extended period. Hence, both formulations whose wet mass was left to 
equilibrate during 6 h showed to be depleted of anhydrous OLZ content, showing instead a 
mixture of two different hydrate forms (dihydrate B and higher hydrate). The concomitant 
crystallization of both dihydrate B and higher hydrate may be associated with the similar 
nucleation rate of the two hydrates in these experimental conditions in which the nucleation 
takes place (29).  Although dihydrate D is the most stable hydrate form of OLZ, it was not the 
form encountered in the wet mass. These results are easily explained by the Ostwald’s rule of 
Stages (50), which states that when a given chemical system leave a metastable state it does not 
seek out the most stable state, rather the nearest metastable one that can be reached without loss 
of free energy. 
When the pellets were dried, an easier elimination of the OLZ higher hydrate as 
compared to the OLZ dihydrate B was observed. This may be related to the fact that the higher 
hydrate is only stable in wetcakes of OLZ, rapidly losing its stability when dried, as suggested 
by Reutzel-Edens et al. (18). The increase of the peak at 16.3 º (2Ɵ), which is only characteristic 
of the dihydrate B, and the reduction of the peaks’ intensity at 14.4 º and 14.6 º (2Ɵ), 
characteristic of the higher hydrate form (18), indicated that the higher hydrate form (2.5 water 
molecules) dehydrated into a lower hydrated form – the dihydrate B (2 water molecules). 
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Commonly, due to the dissolution or partial dissolution of drugs during wet massing, 
the subsequent solvent removal induces phase transformations. After the removal of the solvent, 
the solid which is regenerated from the solution may not be the same original phase (6). The 
phase obtained is therefore dependent on the rate of solvent removal, the ease of nucleation and 
crystal growth under processing conditions and the undissolved drug may act as seed during the 
dehydration (6). Therefore, prior to the dehydration into the anhydrous OLZ FI, the presence of 
the dihydrate B may have acted as a seed for the dehydration of the higher hydrate into this 
dihydrate B structure. 
The SEM pictures of OLZ in formulation E before and after hydration show that OLZ 
changes its morphology by changing from an irregular shape to a plate-like shape structure. The 
hydrate crystals revealed to form cracks over the entire surface when dehydrated. The XRPD 
analysis of the dehydrated material revealed that OLZ had a slightly lower crystallinity than the 
raw-material. Therefore, if OLZ hydrates during wetting and dehydrates during drying, even 
though the final polymorphic form is the same, the particles have a completely different shape 
and reduced crystallinity. This modification of the shape during the process seems to have an 
implication on the physical and mechanical characteristics of the extrudates/pellets. For 
instance, the forces needed for the extrusion of the wet masses containing OLZ showed to be 
affected by the OLZ hydrate formation since an increment on the force needed was observed 
when OLZ wet masses rested for 6 h. As observed previously, the hydration of OLZ was a slow 
process, being the OLZ hydrate conversion only completed in the wet masses which were kept 
in a hermetic container for 6h. The integration of part of the water available in the wet mass into 
OLZ crystal lattice may have caused its removal from the surface of the particles and, thus, a 
reduction on the liquid bridges between the particles has occurred (277). This fact, together with 
the change of the size and shape of OLZ crystals, may justify the significant increase in force 
needed for the extrusion of wet masses containing higher contents of OLZ (formulation D1 vs 
D2). 
Regarding the placebo formulations, one could observe that formulation B containing 
higher contents of MCC (90% w/w) showed to need higher forces to be extruded when 
compared to wet masses containing both MCC and calcium phosphate (60:30 % w/w, A). This 
can be related to the high water absorption of water by MCC, as opposed to calcium phosphate, 
which is not hygroscopic and has a poor solubility. Calcium phosphate may behave as a “shield” 
in the wet mass, resulting in a higher amount of free water available in the formulation. Hence, 
the wet mass becomes softer and lower forces are needed to extrudate calcium phosphate 
masses. (278). For these 2 formulations, A and B, lower forces were observed for wet masses 
which were left to equilibrate for 6 h. This shows that a better spreading of the water throughout 
the excipients was verified and a higher plasticity of the mass was achieved. 
Chapter 7 
168 
The factors that influenced the extrusion force may also be related to the pellet size 
distribution, since an increased amount of pellets within the 1-1.4 mm range was found for the 
wet masses which were extruded with increased forces. Accordingly, the reduction of the free 
water in the formulations C2 and D2 due to hydration of OLZ resulted in a reduced size and 
narrow distribution of the pellet size. 
During dehydration, the water inside the structure of OLZ molecule may have had more 
difficulty to be removed than the water just absorbed by the other components of the wet pellets. 
This explains the higher residual moisture in the pellets containing hydrated OLZ, which were 
dried for periods inferior to 180 min. The residual moisture between pellets (C1 vs C2 and D1 vs 
D2) became similar after 180 minutes of drying, when the dehydration of OLZ hydrates was 
completed. 
The increase on the pellet strength with the increase of extrusion force may be attributed 
to the fact that wet masses with a lower plasticity are squeezed with higher pressures, leading to 
a higher compaction of the mass that will generate the pellets (278). Furthermore, the 
morphological changes of OLZ crystals during the resting of the mass may cause abrupt 
modifications to particle’s surface and to interparticle bonds, affecting the strength of the 
pellets. 
Regarding the dissolution profile of the different formulations, it was visible that OLZ 
dissolved after 12 h was lower than 65% for all of the different formulations. However, the 
crushing of the pellets at the end of the test showed the total release of the OLZ from the pellet. 
The low solubility and wettability of OLZ, together with the increased amounts of cellulose 
used in the formulations, can explain the slow release of OLZ. 
Lower dissolution rates of the drug were found for pellets containing OLZ dihydrate B 
(C2 and D2, dried for 60 minutes). As it has been discussed before, the hydration of OLZ was 
also accompanied by variations in crystal morphology. Morphological/size modifications are 
able to change the dissolution rate of the drug as a result from a combination of changes to the 
size and number of crystal faces exposed to the dissolution medium, as well as the nature of 
those faces, which in turn will influence the wettability and subsequent dissolution of drug (73). 
Furthermore, dissolution rate of dihydrate B showed to be slightly lower than anhydrous Form I, 
as verified in chapter 3. Therefore, the reduction on the dissolution rate of the drug may have 
been related to the changes of both molecular and morphological properties of OLZ during the 
resting time of the drug. An increase of similarity of the curves was observed when the hydrated 
species of OLZ were dehydrated. The dehydration of OLZ is also accompanied by changes on 
its morphology since cracks appear at the surface. These cracks, resultant from dehydration, 
may increase the fragility of the crystal, resulting in the production of powder-like crystals with 
an increased surface area, as it was observed for other drugs, such as naproxen (275). 
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7.7 Conclusion 
In summary, the low water solubility of OLZ (practically insoluble in water) results in 
low wetting properties, which makes the formation of its hydrates more difficult when it is in 
contact with water for a short period of time (e.g., immediate extrusion). The higher ratio of 
MCC in the formulations showed to retard the hydrate conversion of OLZ due to a completion 
effect, as a consequence of the higher affinity of water with the amorphous regions present in 
the molecular structures of this excipient. 
The dehydration of OLZ was possible when a low temperature of drying was applied 
(45 ⁰C). However, 180 minutes were needed to complete the dehydration of the dihydrate B 
structure. In spite of the presence of excipients in the pellets’ formulations, the FTIR and XRPD 
analysis showed to be able to detect the formation of the hydrates of OLZ over the process of 
extrusion. This revealed the suitability of the utilization of these excipients (MCC and PEG-
6000) when alterations of a crystalline drug need to be studied over a pharmaceutical process. 
The presence of the dihydrate B in the dried pellets showed to affect OLZ’s dissolution 
rate. Being OLZ a drug whose absorption is dependent on the dissolution rate, the presence of 
the dihydrate B in the final dosage form may have a negative impact on the bioavailability of 
the drug.  The changes in crystalline structure of OLZ during the process showed to affect the 
rheology of the wet mass, and the pellet’s size and strength.  
Hence, the structural changes related to the hydration/dehydration process can strongly 
affect the technological performance, the bioavailability and the drug stability.  These results 
suggest that attention should be given to the pseudopolymorphism of the drugs before the 
selection of the excipients and conditions for a new pharmaceutical process. 
This study confirms the importance of monitoring the crystalline changes of a drug 
when water and temperature need to be applied during processing. 
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Chapter 8 -  Role of excipients on the stabilization of olanzapine during 
extrusion and dissolution 
 
8.1 Abstract 
Hydrate formation is a phase transition which can occur during manufacturing processes 
involving water. This work considers the prevention of olanzapine (OLZ)  hydrate conversions 
in the presence of water and polymers [polyethyleneglycol (PEG); hydroxypropylcellulose 
(HPC); polyvinylpyrrolidone (PVP)] in forming pellets by wet extrusion and spheronisation and 
during dissolution testing of dried pellets. Our previous results showed the potential that HPC 
and PVP may have on preventing hydrate formation, therefore, in this study they are going to be 
added to pellet’s formulations. Anhydrous OLZ was added to water with or without those 
polymers prior to extrusion with microcrystalline cellulose. Assessment of OLZ conversion was 
made by XRP-Diffraction; FTIR spectroscopy; calorimetry (DSC) and microscopy (SEM for 
crystal size and shape). The wettability and the surface energy of the powders before and after 
being exposed to hydrating conditions were evaluated. Both PVP and HPC prevented the 
hydrate transformations of the anhydrous drug; the latter even in the presence of hydrate seeds. 
The higher ability of HPC to spread over the OLZ particles was observed. The addition of 
microcrystalline cellulose needed for the pellets production (ﬁnal product) did not eliminate the 
protector effect of both HPC and PVP during pellets’ processing and dissolution evaluation. 
8.2 Introduction  
Active pharmaceutical ingredients (API) may undergo solvent mediated polymorphic 
transformations when they are present in certain pharmaceutical manufacturing processes e.g. 
wet granulation/wet extrusion (279) which can affect the drug’s dissolution rate which can 
ultimately result in variations in bioavailability (57, 280) . The excipients used in the 
formulation may affect the rate of hydrate conversions of the API during a wet granulation or 
wet extrusion process. It would be desirable to avoid as many phase transitions as possible by 
using inhibitors like excipients in the formulation (224, 279). 
Microcrystalline cellulose is a common excipient used in solid dosage forms and the 
effect of MCC on the reduction of the hydrate formation of the drugs during the wet massing 
step was shown to be originating from its ability to hold large amounts of water in its internal 
structure, which can retard the hydrate formation  (210, 211). However, the use of high contents 
of water (e.g., 60%–80% w/w) may reduce the protection of MCC on retarding the hydrate 
formation. The addition of other excipients to the formulation (e.g., polymers) may reduce the 
amount of water needed for the powder to agglomerate and avoid hydrate formation during the 
wet massing. (60, 281).  Therefore, depending on the API and excipients used, hydrate 
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formation may take place during the wetting step (111), which may or may not be reversible 
after the drying step. 
In the literature, one may find some examples where polymers showed to inhibit hydrate 
formation of pharmaceutical crystals in aqueous slurries (196, 282). For instance, 
polyvinylpyrrolidone (PVP) has been demonstrated to inhibit partial or completely the growth 
rate of sulfathiazole single crystals in solutions (282). The cross-linked poly(acrylic acid) (PAA) 
has been shown to completely inhibit the caffeine anhydrate to hydrate transformation in 
aqueous environments (196). Cellulose derivatives (e.g. HPC and HPMC) have been shown to 
be successful in inhibiting the hydrate conversion of carbamazepine but exhibit no effect on the 
transformation kinetics of anhydrous sulfaguanidine (196). The different inhibitory behaviors of 
different polymers, and the same polymer with different APIs, reveal that there is no single 
polymer which promotes the inhibition of hydrate conversions in all APIs. This may be a 
consequence of different specific interactions that the polymer may establish with individual 
crystal surfaces (150, 194).  
Our previous studies showed that anhydrous OLZ form is unstable under humid 
conditions or in aqueous dispersions and converts rapidly to its dihydrates/higher hydrated 
forms when exposed to water. Therefore, a rigorous process monitoring and control of the 
existing form at each step of its manufacture is necessary to ensure the quality of the final 
products. 
To the best of our knowledge, studies on the monitoring of the polymorphic transitions 
of OLZ during the entire extrusion-spheronisation process have not been reported previously. 
Furthermore, there is a lack of information about how excipients may control the OLZ 
transformations that are likely to take place during the pharmaceutical processes involving 
water. 
8.3 Purpose 
The previous section showed the impact of hydrate formation during processing on the 
physical characteristics of the pellets. Also, in chapter 5, it was observed that certain polymers 
are more prone to protect OLZ from hydration. In this study, the material is going to be wet 
massed for a short period of time and it will be evaluated how long can OLZ be kept stable 
before drying. The protector effect of polymers is also evaluated during dissolution. This study 
aims, in particular, (1) to access the time needed for OLZ to undergo hydrate conversion in wet 
masses,  (2) to study whether polymers (e.g. PEG, HPC, PVP) with different molecular weights 
can affect the hydrate conversions of OLZ during and after the wet massing step, (3) to 
characterize different hydrate crystal forms of OLZ that may be generated during processing, (4) 
to ﬁnd a formulation which allows the maintenance of the original crystal form of the API 
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throughout the entire extrusion-spheronisation process and dissolution.  For a more complete 
study, PEG and PVP with different molecular weights were taken into consideration.  
To address these goals, wet masses of OLZ with different polymers are produced and 
their characterization is carried out using different techniques such as, FTIR, XRPD, 
calorimetry and microscopy. The contact angle and surface energy of the mixtures is also 
considered. The dissolution rate of OLZ in each pellet’s formulation is assessed and fitted into 
different dissolution models.  
8.4 Materials and methods 
8.4.1 Olanzapine and polymers 
Olanzapine anhydrous Form I (OLZ FI) was purchased from Pharmorgana, India.  
The polymers considered in the study were polyethyleneglycol with different molecular 
weights (PEG, Mw = 6000 and 40000, Sigma-Aldrich, Germany), hydroxypropylcellulose 
(HPC LF Pharm grade, Mw = 95,000, Klucel™, Ashland, Germany) and polyvinylpyrrolidone 
(PVP, Kollidon 12, 2600 < Mw < 5500 and Kollidon 30, 44,000 < Mw < 54,000, BASF 
Chemicals, Germany). Other chemical were supplied by Sigma-Aldrich, Germany. The 
following OLZ forms were produced in order to identify the transformations that OLZ FI may 
undergo during processing: 
8.4.2 Conversion of OLZ FI during wet massing in the presence of polymers 
Four wet masses were prepared using anhydrous OLZ Form I (OLZ FI, 15 g, 
“formulation A”) or physical mixtures of OLZ with each one of the different polymers, 
belonging to the three groups described above, namely PEG-6000/ PEG 40000 (group I, 
“formulation B1 and B2”, 10 g), HPC-LF (group II, “formulation C”, 10 g) and PVP k12/ PVP 
k30  (group III, “formulation D1 and D2”, respectively”, 10 g) (Table 8.1).  
Formulations A-D had the same OLZ:polymer ratio as the formulations produced in the 
previous section (15:10). However, for a better understanding of the mechanism of hydrate 
protection by the polymers, we also tried different OLZ:Polymer ratios (15:5, 15:0.5 and 15:0.1) 
in this section. Moreover, seeding experiments were performed, where 5% of anhydrous OLZ 
was replaced by OLZ dihydrate, to promote crystal growth within the anhydrous OLZ 
containing formulations. These experiments were performed for better characterization of the 
mechanisms of the interaction between the polymer and OLZ. 
OLZ or physical mixtures of OLZ and polymer were blended for 5 min in a planetary 
mixer (Kenwood, Hampshire, UK). Demineralized water (75 g, 5 times the OLZ mass) was 
added for 1 min to the blends. For a homogenization of results and better comparison with the 
previous data we tried to use the same proportion OLZ: water. 
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The wet masses were mixed thoroughly for 10 min and then placed into sealed glass 
vials filled to the top. Samples were taken at different time periods (t= 0, 30, 60, 180 and 360 
min) after production. A fraction of each sample was analyzed immediately by XRPD and the 
remaining portion was dried in Petri dishes (24h at 25°C/55% RH, until constant weight) and 
analyzed by infrared spectroscopy (FTIR), thermal analysis (calorimetry, DSC) and microscopy 
(SEM).  
8.4.3 Manufacture of Pellets Containing Polymers 
Taking into consideration the same fractions of both API and excipients, 75 g MCC was 
added to the blends described previously (Table 8.1), to turn the manufacture of pellets 
possible:OLZ:MCC (AM), OLZ:MCC:PEG 6000/40000 (B1M and B2M, respectively), 
OLZ:MCC:HPC (CM) or PVP k12/k30 (D1M and D2M respectively) were dry-mixed in a 
planetary mixer (Kenwood, UK) for 5 min prior to the addition of 75 g (5 times the OLZ mass) 
of demineralized water. Each wet mass (175 g) was further mixed for another 10 min. Half of 
the wet mass was extruded immediately (#1) whereas the other half was allowed to equilibrate 
for 360 min (#2) in a sealed polyethylene bag before extrusion. The storage of wet masses to 
equilibrate for several hours is commonly considered in daily practice to ensure a uniform 
distribution of water (283) and in the present case to promote hydration of OLZ. All 
measurements were performed off-line at deﬁned time points after wet massing (t = 0, 30, 60, 
180, and 360 min) by FTIR and XRPD. Extrudates were manufactured from 2 wet masses (#1 
and #2) in a ram extruder (Lurga, Portugal) adjusted to an universal testing machine (LR 50K, 
Lloyds Instruments, UK) ﬁtted with a load cell to allow the collection of data for the applied 
force to the ram and its displacement (200 mm/min). The wet mass was forced to pass through a 
die (Length/Diameter = 6) and, after extrusion, the extrudates were immediately placed in a 
spheroniser (radial friction plate rotating at 500 rpm, Caleva, UK) for 5 min. The wet pellets 
were dried in a ﬂuid bed drier (Aeromatic-Fielder AG, Bubendorf, Switzerland) at 45 ºC for 60 
min. Dried pellets were evaluated for powder diffraction (XRPD) infrared spectroscopy (FTIR) 
and OLZ dissolution studies into an aqueous solution. 
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Table 8.1 – Formulations considered in polymer screening and pellets manufacture 
Formulation 
Components (g) 
OLZ Polymer MCC 
A 15 - - 
B1 15 10 (PEG-6000) - 
B2 15 10 (PEG-40000) - 
C 15 10 (HPC- LF) - 
D1 15 10 (PVP k12) - 
D2 15 10 (PVP k30) - 
AM 15 - 85 
B1M 15 10 (PEG-6000) 75 
B2M 15 10 (PEG-40000) 75 
CM 15 10 (HPC- LF) 75 
D1M 15 10 (PVP k12) 75 
D2M 15 10 (PVP k30) 75 
 
8.4.4 Characterization of Blends and Pellets 
X-Ray powder diffraction (XRPD) 
The X-ray powder diffractograms were recorded at room temperature on an Analytical 
X’Pert PRO apparatus (Equipment 2). X-ray diffraction characterization was performed to the 
different formulations (A, B1, B2, C, D1, D2) before and after the end of the study (360 min) in 
order to observe the hydrate conversions of OLZ in each sample. For the characterization of the 
OLZ crystalline structures in each wet mass the XRPD patterns were compared with the XRPD 
pattern of crystalline structures of anhydrous OLZ Form I(CSD refcode: UNOGIN), dihydrate B 
(CSD refcode: AQOMAU01) and higher hydrate (CSD refcode: AQOMEY) obtained from the 
Cambridge Structural Database and visualized using the software Mercury 1.4.2 (Cambridge 
Crystalographic Data Centre, Cambridge, UK) (18). 
FT-IR Spectroscopy (FTIR) 
Each OLZ formulation was mixed with KBr in a 1:1 proportion and the mixture (200 
mg) compacted (2 Tons) into compacts (12 mm diameter). The infrared spectra were collected 
in the absorption mode (IR Afﬁnity-1 Shimadzu spectrophotometer, Kyoto, Japan). 
Differential Scanning Calorimetry (DSC) 
Thermograms of different OLZ forms were obtained with a Differential Scanning 
Calorimeter after calibration with indium. Dry N2 was used as the purge gas. Dried samples (2 
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to 3 mg) were placed in pinhole crucibles and heated at 10 C/min within 0-210 C temperature 
range. 
Scanning electron microscopy (SEM)  
Different formulations were mounted on aluminum stubs and coated with gold by ion 
sputtering and observed under scanning electron microscope (JSM-5200 LV, Japan). 
8.4.5 Wettability and surface energy measurements 
In order to measure the wettability and the surface energy of the powders before and after 
being exposed to hydrating conditions, the contact angles in two liquids (bi-distilled water, 
Strom and diiodometane, Sigma, Germany) of the samples were measured (Wilhelmy plate 
technique, Krüss Tensiometer K12, Germany). Samples of powders were made to adhere on a 
rectangle shape substrate (20X20 mm) uniformly coating its surface. All measurements were 
performed at a controlled temperature 25 ± 0.5°C, by flowing water from a circulator (Haake, 
Germany). The surface energy of the polymers and OLZ was measured according to the Wu 
equation (284). 
8.4.6 Dissolution studies 
Dissolution studies were performed for OLZ (5 mg) from dried pellets (60 min / 45ºC, 
size of 1-1.4 mm). Tests were performed in a dissolution apparatus (paddle method, 50 rpm, 900 
ml of phosphate buffer at 6.8, 370.5°C, n=6, AT7, SOTAX, Switzerland) with collection of 
samples at time intervals (t= 5 to 1440 min). The residual water present in the pellets was taken 
into consideration (Sartorius Moisture Analyser, Germany). OLZ was quantified by UV 
spectrophotometry (λ= 254 nm, Hitachi U- 2000, Japan) and the analysis of OLZ release and 
dissolution profiles was possible by comparison of dissolution models. Simultaneously, 
dissolution tests were performed with pellets AM, B1M, CM and D2M for off-line FT-Infrared 
evaluation of the anhydrate to hydrate transformations occurring in non-dissolved fraction of 
OLZ present in the pellets (t=0 min, 30 min, 60 min, 180 min and 360 min). Each sample 
collected for FT-IR analysis was recovered from a different vessel. 
8.5 Results 
8.5.1 Polymer screening method to identify polymers that can stabilize OLZ FI during wet 
massing 
The different polymers used in this work may be classified into three categories 
according to their molecular structure. In group I polyethylene glycol with different molecular 
weights (PEG 6000 and 40000) were considered; this polymer has both hydrogen bond donor 
and acceptor groups at the two ends of the polymer chain. Group II is constituted by a cellulose 
derivative polymer, hydroxypropylcellulose (HPC) with both hydrogen bond donor and 
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acceptor groups in their ring structure.  Group III includes polyvinylpyrrolidone (PVP K12 and 
PVP k30) which present only one acceptor hydrogen bonding group in their ring structure.  
The X-ray powder diffraction (XRPD) patterns for OLZ, OLZ:Polymer physical 
mixtures and the respective wet/dried masses, are represented in Figure 8.1. In order to 
characterize the changes in the crystal structure of OLZ in each formulation, the XRPD patterns 
were compared to the XRPD patterns of different crystal structures of OLZ, such as, anhydrous 
form I, dihydrate B, dihydrate E and higher hydrate.  
Figure 8.1 A shows the XRPD pattern of OLZ and recovered OLZ after 360 min in 
contact with water. The XRPD diffractograms show that OLZ was able to hydrate into the 
dihydrate-B form. However, the peaks at 8.58°, 19.20°, 24.14° 2, which are characteristic of 
the higher hydrate form suggests a concomitant crystallization of both hydrates, although in 
different proportions. The subsequent resting of the wet mass at 25ºC/55% RH for 24h was 
followed by the elimination of the higher hydrate form.  
OLZ which was physically mixed with PEG 6000 /PEG 40000 was shown to hydrate 
selectively into the higher hydrate form (Figure 8.1 B).  The product from the dehydration of the 
higher hydrate (2.5 mol water per mol of OLZ) was the dihydrate E. The XRPD study of the wet 
material enabled the observation of the intermediate higher hydrate form which is generated and 
only stable in a wet environment. Similar diffraction patterns of OLZ before and after wetting 
suggests a complete inhibition of hydrate transformations of OLZ during the time of experiment 
in formulation C. However, a slight widening of the OLZ peaks was observed after drying the 
OLZ: HPC wet mass (Figure 8.1 C). Similarly OLZ: PVP mixtures also failed to show 
transformations of OLZ. No peaks due to excipients were observed after the manufacture of 
physical mixtures with PVP k12, PVP k30 and HPC LF reflecting the amorphous nature of 
these polymers. 
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Figure 8.1– Diffractograms of 6 formulations before wetting, after wetting and after drying. The 
wet samples were analyzed after storage in a sealed container for 360 min. 
A) OLZ before (a) and after wetting (b) and drying (c); (+) represents the characteristic peaks of 
the OLZ dihydrate B and (*) represents the characteristic peaks of the OLZ higher hydrate. 
B) Formulations B1 and B2 physical mixture (a.1 and a.2), after wetting (b.1 and b.2) and after 
drying (c.1 and c.2). 
C) Formulation C physical mixture (a), after wetting (b) and after drying (c). 
D) Formulation D1 and D2 physical mixture (a.1 and a.2) after wetting (b.1 and b.2) and after 
drying (c.1 and c.2). 
 
The region 720-780 cm
-1
 was selected to distinguish the different hydrate conversion 
occurrences in OLZ wet masses containing no polymer (A) or the PEGs (B1 and B2) as 
excipients. The out of plane deformation of the CH bond of the benzene group at 745 cm
-1
 was 
no longer present in both wet masses after 360 min. Wet mass A revealed a new absorption 
maximum at 767 cm
-1
 specific for the dihydrate B whereas wet masses B1 and B2 presented a 
new band at 754 cm
-1
, characteristic of the dihydrate E.  
In Figure 8.2 A, the fraction of the polymer was reduced by 1, 1.5 and 2 orders of 
magnitude in relation to formulations B, C and D. The ratio of OLZ:Polymer varied between 
15:1, 15:0.5 and 15:0.1. Figure 8.2 A displays the spectra of the wet masses collected 360 min 
after their preparation. The reduction on the polymers fraction in formulations containing PVP 
was reflected by the hydrate conversion (especially for the formulation containing PVP k12), 
which started to hydrate after 360 min in a sealed container. By opposition, no hydrate 
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transformation was observed in formulation C containing a low percentage of HPC in the wet 
mass. Hydration in OLZ:PEG formulations, was verified for all the OLZ:polymer ratios. 
Seeding experiments were carried out to determine if the HPC and PVP could still 
prevent the transformation in the presence of nuclei, and to better understand the inhibitory 
mechanism of these polymers. Five percent of the anhydrous API was thus replaced by OLZ 
dihydrate E before the wetting step. Shifts in the spectra of samples based on formulations D1 
and D2 were observed and assumed to be related to hydration of anhydrous OLZ, whereas 
samples of formulation C did not produce shifts in the characteristic bands (Figure 8.2 B). 
 
Figure 8.2– Spectra (FTIR) in the region (990-950 cm-1) for the different OLZ:polymer 
formulations. 
A) Wet masses collected 360 min after wet mass preparation. The OLZ:polymer ratio varied from 
15:1 to 15:0.1.  
B) Wet masses C, D1 and D2 with seeds (5%). The spectra were collected at 60, 180 and 360 min 
after the wet mass preparation. 
 
Figure 8.3 A1 shows that immediately after wet massing (t=0), OLZ particles were 
irregularly shaped and agglomerated. OLZ particles, alone (A) or in the presence of PEG (B1), 
after 360 min in direct contact with water, had their morphology changed to plate-like shaped 
crystals (Figure 8.3 A2) characteristic of the hydrate and the size of the latter larger than OLZ 
particles alone (Figure 8.3 B2). By opposition, formulations C and D1 showed no 
transformation of OLZ particles over the same period (Figure 8.3, C and D).  
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Figure 8.3 – Micrographs of wet masses for formulations A, B1, C and D1. 
Formulation A (t=0 min, a1 and t=360 min, a2); Formulation B1 (t=0 min, b1 and t=360 min, b2); 
Formulation C (t=360 min, c); Formulation D1 (t=360 min, d). 
 
The thermal behavior of anhydrous OLZ and physical mixtures of formulations B1, B2 
C, D1 and D2 are shown in Figure 8.4 (line 1, A to D) in which thermograms 2 and 5 
correspond to the samples recovered immediately after the wet massing (t=0 min) and the 
curves 3 and 6 correspond to the samples which were kept in a sealed container (t=360 min). 
Figure 8.4 A1 (OLZ raw-material) shows only one endotherm event at 195.29 °C due to 
the melting of OLZ. Thermograms A2 and A3 reveal a new endotherm at lower temperatures 
corresponding to the release of water in the molecular structure, as a result of the presence of 
OLZ hydrate in the samples. The small fraction of the hydrate content in OLZ samples which 
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were produced immediately after the wet massing (a mixture of anhydrous and hydrous content 
is present, Figure 8.4 resulted in a water loss endotherm with a low enthalpy. 
 
 
Figure 8.4 – Thermograms of formulations A (A), B1 (B, curves 1-3), B2 (B, 4-6), C (C), D1 (D, 1-3) 
and D2 (D, 4-6). 
Curve 1 (physical mixture of raw materials), curves 2 and 5 (wet masses at t=0 min), curves 3 and 6 
(wet masses at t=360 min).  
Tables present the melting point of OLZ and the respective enthalpy of fusion (Tmax and ΔH) for 
each formulation (grey shadow in figures). 
 
Figure 8.4 (B1 and B4) shows that the physical mixtures (PM) obtained from 
formulations B1 and B2 present 2 endothermic peaks due to the melting of both PEG and OLZ. 
The depression on OLZ melting temperature and enthalpy result from the solubilization of the 
drug within the molten PEG during heating. Figure 8.4 (B2 and B5) shows no traces of water 
evaporation allowing the assumption that no hydrate was present in the sample.  However, 
curves B3 and B6, reveal an endothermic peak due to dehydration of the dihydrate E. 
Furthermore, a reduction on the melting temperature of the PEG polymers was also registered in 
thermograms B3 and B6 (Figure 8.4), suggesting conformational changes of the polymer chains 
with an impact on its melting temperature. This is in line with the ability of the PEG chains to 
adapt its conformation when in contact with water to establishing extensive hydrogen bonds. In 
a different experiment OLZ was heated up to 120 °C with dehydration, cooled and heated again 
(Figure 8.4, B3 and B6).These samples revealed an increase of the PEG melting temperature in 
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line with its initial value (data not shown). This finding suggests reversibility of the 
conformational changes of the polymer chains occurred after removal of water in the sample. 
There was no apparent conversion to the OLZ dihydrate for the samples which were 
formulated in the presence of both PVP and HPC, however some adsorbed water created a 
broad endotherm (Figure 8.4, C and D). In thermograms C) (curves 2 and 3) and D) (curves 2, 
3, 5 and 6) the OLZ endotherm due to melting became broader, with a lower enthalpy and 
temperature than those observed in the physical mixture (curve 1). This shift towards lower 
temperatures indicates a higher miscibility of drug in the polymer after the wet massing process. 
Table 8.2 shows the surface energy and the polarity for each polymer in the formulation. 
The results show the ranking for the measured hydrophobicity as HPC>PVP>PEG. Generally, 
for the binder (polymer) to spread over the substrate (API) in a wet massing process, the work 
of cohesion of the binder must be lower than that of the substrate, allowing the spreading of the 
first on the latter. This occurred just for HPC, only. These results were in line with the results 
obtained for the contact angles (Table 8.3) which have shown the wettability of the powders, as 
measured by the contact angle (°) of the substances in water. Table 2 shows the contact angle of 
the raw-materials separately and the contact angle obtained after the wet massing. While the 
contact angle of the particles in formulations B1, B2, D1 and D2 after wet massing showed a 
contribution of the contact angles of both polymers and OLZ, the contact angle of particles in 
formulation C1 (OLZ with HPC) seemed to account only on the contribution of HPC (Table 
8.3). Furthermore, a slightly lower contact angle was observed for these particles than for the 
isolated HPC suggesting that this polymer was not only completely covering the crystalline 
particles of OLZ, but also a decreasing number of hydrophobic groups were exposed on the 
surface of the particles, as a result of polymer chain conformation. 
 
Table 8.2 – Surface energy of OLZ and polymers. 
 
γd 1 
(mN/m) 
γp  
(mN/m)
 
γ 1 
(mN/m) 
Polarity  
(%) 
Wc
2  
(mJ/m
2
)
 
Wa
2  
(mJ/m
2
)
 
Wa-Wc  
(mJ/m
2
) 
OLZ 41.31 1.19 42.50 3 85.00 
  
PEG 6000 35.71 14.62 50.33 29 100.66 81.01 -19.65 
PEG 40000 34.78 12.93 47.71 27 95.42 79.89 -15.53 
PVP k12 43.22 7.48 50.71 15 101.42 88.59 -12.83 
PVP k30 40.46 6.73 47.19 14 94.38 85.81 -8.57 
HPC LF 31.90 4.80 36.70 13 73.40 75.81 2.41 
 
1
 Surface free energy (γ) and its dispersive (γd) and polar (γp) components. 
2
 Wc and Wa are, respectively, the work cohesion and the work of adhesion (to OLZ). 
3
 Wa-Wc reflect the spreading coefficient (). 
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Table 8.3 – Contact angles of the raw materials and different formulations 
Raw-Material 
Contact angle* 
( / °) 
 
Formulations after 
massing t=0 
Contact angle* 
( / °) 
OLZ 104.65 ± 0.64  A 104.87 ± 0.74 
PEG 6000 63.60 ± 2.05  B1 81.24 ± 2.98 
PEG 40000 64.30 ± 1.95  B2 79.52 ± 1.07 
HPC-LF 91.84 ± 0.47  C 87.41 ± 1.72 
PVP k12 56.46 ± 1.36  D1 79.73 ± 1.54 
PVP K30 75.77 ± 2.17  D2 89.14 ± 3.40 
*Contact angle measured in water (n=6) 
 
8.5.2 Characterization of OLZ wet masses and pellets containing microcrystalline cellulose 
For the formulations containing MCC, the ratio OLZ:polymer was maintained, as well 
as the amount of liquid used for the wet massing. The examination of the diffractograms 
acquired off-line after the wet massing (t=360 min) (Figure 8.5) revealed that the contact with 
the liquid binder triggered the hydrate formation in formulations AM, B1M and B2M (Figure 8.5, 
A and B). In all these formulations, both OLZ dihydrate B and OLZ higher hydrate were 
observed in the wet mass. For formulations B1M and B2M, the conversion of the anhydrous OLZ 
into 2 hydrates, instead of only one hydrate (B1 and B2), suggests that PEG was not interacting 
with the drug at the same extent as occurring without the MCC. Drying the pellets (Figure 8.5, 
A c and B c1 and c2) at 45ºC for 60 min was not sufficient to remove the dihydrate B, which 
was visible in both OLZ formulations (Figure 8.5, A c and B c1 and C2).  
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Figure 8.5 – Diffractograms of formulations as physical mixtures (a),  
as wet masses (t=360 min, b) and dried pellets (c).  
A) Formulation AM;  
B) Formulation B1M (a.1-c.1) and B2M (a.2-c.2); 
C) Formulation CM;  
D) Formulation D1M (a.1-c.1) and D2M (a.2-c.2). 
 
Figure 8.6 (A) shows the dissolution curves of OLZ released from pellets prepared 
immediately before the test. For each formulation, dissolution profiles were obtained from AM, 
B1M (PEG 6000), CM (HPC) and D2M (PVP k30) pellets made from non-stored (#1, i.e., t=0) 
and stored (#2, i.e., t=360 min) wet masses. A significant change on OLZ dissolution rate (p< 
0.05) was observed between #1 and #2 pellets for AM and B1M formulations. On contrary, no 
significant differences on the OLZ dissolution rate from pellets #1 and #2 from formulations CM 
(HPC) and D2M (PVP), although a slight increase on OLZ dissolution rate was verified for 
pellets #2. 
During dissolution it was possible to characterize the OLZ solid-state form remaining in 
the pellets. The 2
nd
 derivative from FTIR absorbance spectra of the pellets taken from the 
dissolution media, have shown that PVP and HPC can also have a suppressing effect on the 
OLZ hydrate conversion in the dissolution media, by opposition to pellets AM  (no polymer) and 
B1M (PEG) in which OLZ suffered hydration. This observation strongly suggests that HPC and 
PVP, which had shown a strong protection of OLZ over the production of wet masses, also 
stabilize the anhydrous OLZ over the release from pellets into the dissolution medium. 
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Figure 8.6 – Dissolution profiles of OLZ from pellets (top) and Spectra (FTIR) analysis made from 
different formulations (AM, B1M, CM and D2M).  
A) Dissolution profiles of OLZ from pellets #1 (t=0 min) and #2 (t=360 min);   
B) Formulations and the time periods (a-e) in which pellets were collected for FTIR chacterization;  
C) Second derivative of FTIR absorbance spectra from collected samples (times a-e for 
formulations AM and B1M and times c-d for formulations CM and D2M). 
 
Table 8.4 summarizes the results of OLZ release modelling for the pellets under 
investigation. The goodness of fit for the various models ranked in the order: Korsmeyer-Peppas 
> Higuchi > First-order for the formulations AM, B1M and CM. For formulation D2M, the 
goodness of fit for first-order model was better than for Higuchi model. The fact that drug 
release from pellets follows Korsmeyer-Peppas model and the values of the exponent n are 
lower than 0.5 (0.383–0.441) indicate that the OLZ, independently of the polymorphic form 
present in the pellets follows a diffusion controlled release. 
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Table 8.4 – Fitting of dissolution models to OLZ release data for pellets 
Formulation 
First-order Model Higuchi Model Korsmeyer-Peppas Model 
Adj 
R
2
 
MSE 
root 
K1 
Adj 
R
2
 
MSE 
root 
kH 
Adj 
R
2
 
MSE 
root 
kKP n 
AM 
#
#1 
0.669 9.946 0.001 0.952 3.797 1.648 0.997 0.958 3.585 0.383 
#
#2 
0.706 8.624 0.001 0.970 2.728 1.441 0.995 1.127 2.676 0.407 
B1M 
#
#1 
0.820 10.15 0.002 0.962 4.674 2.218 0.994 1.794 4.442 0.395 
#
#2 
0.839 8.466 0.001 0.986 2.464 1.821 0.995 1.554 2.703 0.441 
CM 
#
#1 
0.951 6.910 0.002 0.986 3.810 2.696 0.995 2.226 4.450 0.431 
#
#2 
0.926 8.408 0.003 0.973 5.044 2.755 0.995 2.353 4.966 0.411 
DM 
#
#1 
0.972 5.697 0.003 0.958 6.991 2.995 0.980 4.801 5.510 0.408 
#
#2 
0.978 5.115 0.003 0.956 7.321 3.069 0.981 4.658 5.494 0.410 
#1 and #2 represent pellets manufactured at t=0 min and t=360 min of wet masses, respectively. 
8.6 Discussion 
The different crystalline forms of OLZ are built through the assemblage of (OLZ) 
centrosymmetric racemic pairs and then connected to each other through hydrogen bonds, either 
from atoms like in the OLZ structure (e.g. anhydrous form) or by water molecules (e.g. hydrate 
forms). In form I the hydrogen bond interactions between the amine and imine (NH-N) are 
responsible for the connection of two different OLZ pairs (18). When the hydrate formation 
occurs the NH-N interactions are disrupted and replaced by water bridging molecules between 
the dimmers. The presence of water balances the hydrogen bond donor/acceptor ratio of OLZ, 
thus making 2 acceptors able to participate in hydrogen-bonding, which was not possible in the 
anhydrates. Therefore, in OLZ hydrates, a single hydrogen-bond donor (NH) and two good 
acceptors (imine and piperidine) may participate in hydrogen bonding with water.  In 
manufacturing processes in which water is added (e.g. wet extrusion) OLZ is exposed to 
conditions in which the hydrate forms are expected to be the most stable due to high water 
activity (224). Consequently, starting from the addition of water until the final drying, the API 
may undergo an anhydrate to hydrate transformation which may or, may not, be completed by 
the end of the process. The API transformations in an aqueous environment are expected to 
occur via a solvent-mediated transformation (SMT) (224) which encompasses a three stage 
process. Firstly, the metastable phase starts to dissolve, in this work the anhydrous OLZ. Since 
the dissolution of the metastable phase is a prerequisite for the transformation to take place, the 
solubility of the metastable form will initially provide the thermodynamic driving force for the 
phase transformation. Dissolution under non-sink conditions will lead to a supersaturation with 
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respect to the stable hydrate phase and provide a thermodynamic driving force for nucleation of 
the stable phase (hydrate).  The next stage involves nucleation of the stable hydrate once 
supersaturation has been reached. During wet massing of powders, which can be regarded as a 
suspension, there is an abundance of particles in the form of the anhydrate phase, which might 
aid heterogeneous nucleation (285). By opposition to homogeneous nucleation, heterogeneous 
nucleation lowers the thermodynamic free energy barrier. Thus, heterogeneous nucleation can 
occur at lower driving forces (44). Finally, once nuclei of the stable form are present in the 
solution, growth of that form continues until all the metastable phase has dissolved. Therefore, 
the growth of the stable phase (hydrate) is maintained by the supersaturation created by the 
dissolution of the metastable phase (286). The kinetics of solvent-mediated transformations is 
therefore governed by dissolution of the unstable phase and nucleation and growth of the stable 
phase. It follows that, if nucleation of the hydrate phase could not be inhibited by polymers, 
then crystal growth could occur, i.e., inhibition of crystal growth only became important if 
seeding crystals were present.  
When observing the XRPD data obtained from the masses without the presence of  
excipients, one could observe that hydration of all of the material was not finished in the time 
scale of the wet massing step and that a concomitant crystallization of both dihydrate B and 
higher hydrate took place on the OLZ wet mass A. This phenomenon may be associated with 
the similar nucleation rates of both forms, favoring the concomitant crystallization of both 
hydrates (44). The kinetics of this process was controlled by the dissolution rate of the unstable 
form, the rate of crystallization of the more stable form and their relative solubilities. It means 
that in wet massing, the extent of hydrate formation is proportional to the solubility of the 
anhydrate and the volume of the wetting liquid used (82). Furthermore, since that wetting of 
powders is a factor governing hydrate formation kinetics (287), it is clear that the APIs with 
poor wettability will require an excessive amount of moisture and/or prolonged contact with wet 
massing liquid for the hydrate to form. Thus, the short wet massing period together with the low 
wettability of OLZ (≈104°) led to the incomplete hydrate conversion of OLZ during wet 
massing. Furthermore its low solubility (288) (a small quantity of OLZ can be dissolved in the 
liquid at any time) resulted in a slower hydrate rate conversion, which contrasts with other drugs 
such as theophylline (solubility in water of 12 mg/mL) (224) or sulfaguanidine (solubility in 
water of 1.38 mg/mL) that showed to hydrate in less than 5 minutes during wet granulation 
processes (224). 
The presence of the polymers in the wet mass can cause stabilization of OLZ anhydrous 
phase by increasing the local viscosity, impeding diffusion of drug molecules, and increasing 
thermodynamic and kinetic barriers for nucleation.  Furthermore, polymers can kinetically 
stabilize the supersaturated state by forming intermolecular interactions with the drug via 
hydrogen bonding or hydrophobic interactions. They can also promote steric hindrance to the 
Chapter 8 
 
189 
crystallization process (224). The addition of PEG 6000 and 40000 to the formulations, 
respectively B1 and B2, has retarded the hydrate conversion without no concomitant 
crystallization into two different hydrates. The disappearance of the XRPD pattern of the PEG 
(semi-crystalline nature, which facilitates its distinction when compared with other amorphous 
polymers) was observed in the PEG wet masses (B1 and B2), which was indicative of its 
dissolution into the wet massing medium. Therefore, an increase on the viscosity of the binding 
liquid is expected due to the high network associations of these polymers. This change on the 
reological properties of solvent, contributes to restraints the diffusivity of the API. A reduction 
on the drug’s diffusivity,  reduces the degree of supersaturation (118), affecting both nucleation 
and crystal growth rates (44) (118) .  
The effect of the viscosity of the medium on the nucleation rate has been described by 
Turnbull and Fisher (289) The frequency of atomic or molecular transport at the nucleus-liquid 
interface (ν) is inversely related to the bulk viscosity, ɳ, with the Stokes-Einstein relation: 
𝐯 =
𝐤𝐓
𝟑𝛑𝐚𝐨
𝟑ɳ(𝐓)
                                                                                  Eq.8.1 
Where a0 is the mean effective diameter of the diffusing species, k, is a constant and T is 
temperature. If the viscosity dependence on temperature is described by Arrhenius behavior, 
then: 
𝐉 =
𝐊
ɳ𝟎
𝐞𝐱𝐩 (
−∆𝐆∗−∆𝐆𝐚
𝐊𝐁𝐓
)          Eq. 8.2 
J is the number of nuclei formed per unit time per unit volume, ∆G* is the maximum in 
Gibbs free energy change for the formation of clusters, at a certain size. ∆Ga is the activation 
energy for transport across the nucleus-liquid interface.  
Therefore, the addition of PEG may have changed the nucleation kinetics, favoring the 
appearance of a single form – higher hydrate- which is never obtained as an isolated form in 
water environments without any additive. 
On the other hand, a complete inhibition of OLZ hydration was achieved by addition of 
both HPC and PVP. According to the literature,  there are two major factors that lead to an 
efficient hindrance of the hydrate formation by the polymeric excipients: the capacity to form 
hydrogen bonds with the drug and a sufficient hydrophobicity (194). Both these features prevent 
the drug from binding with water and force it to bind with the polymer instead (194, 224, 290), 
which are important factors affecting the nucleation and growth rates of crystals.  
The capacity to form hydrogen bonds can affect the nucleation rates. For nucleation to 
occur, drug–polymer hydrogen bonds have to be broken so that drug molecules may diffuse and 
form a nucleus. The strength of the drug–polymer association determines the time required for 
the nucleation to take place (194). Furthermore, the ability of polymers to adsorb to the crystal 
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surface interface (also by formation of hydrogen bonding between the polymer and the drug) are 
able to block the crystal growth by preventing the access of the solute molecules to the crystal 
terrace (39). In the wet masses with HPC (C) and PVP (D) OLZ molecules may interact with the 
polymer molecules to form OLZ–polymer hydrogen bonds in the aqueous environment. These 
interactions may, then, inhibit or retard the formation of nuclei due to collisions or/and block the 
growth of the crystals.  
When the content of HPC, PVP k30 and PVP k12 was reduced by two orders of 
magnitude in formulations C, D1 and D2, respectively, only HPC has shown to continue to 
inhibit hydrate conversion which can easily be explained by both the hydrogen’s bond ability of 
the involved polymers and spreading over OLZ particles. In a different experiment, where 
hydrate seeds were added to the wet masses, transformation times decreased for PVPs. When 
hydrate seeds were added to the HPC formulation the hydrate transformation continued to be 
inhibited during the 6 h of the test, indicating that HPC can effectively inhibit the crystal 
growth. Although PVP was not successful on preventing transformations, polymer Mw had an 
impact (formulations D1 and D2). In both cases the nucleation step was no longer a limiting 
factor but nuclei grew at different rates: faster for PVP k12 (more hydrophilic) than for PVP 
k30. This was also observed by other authors (194) for which the inhibition effect of polymers 
on carbamazepine was also related to their hydrophobicity, since polymers with a higher 
hydrophobicity had a stronger interaction with the carbamazepine crystal surface. Also, the 
slower hydration rate of OLZ in presence of PVP k30 can be attributed to an increase in the 
number of available functional groups on the polymer chains (39).  
Data has shown that HPC had a lower polarity (higher hydrophobicity), and a lower 
work of cohesion than the work of adhesion to the OLZ molecules. This showed the ability of 
this polymer to spread over the OLZ crystal surfaces. The other more hydrophilic polymers 
were not so successful on spreading on OLZ surfaces. These results indicate affinity of this 
polymer to OLZ surfaces, which when absorbed at relevant growth sites may have led to a 
blockage of the growth of the nuclei.  
 The addition of cellulose (MCC) to the wet masses as an excipient did not have an 
effect on the inhibition of hydrate conversion, and the respective formulations AM, B1M and 
B2M, OLZ were shown to hydrate in the same manner as had occurred in formulations without 
HPC or PVP. However, while in formulation B1 and B2 only one hydrate was obtained (higher 
hydrate), in formulations with cellulose (B1M and B2M), two hydrates were visible in the wet 
mass (dihydrate B and higher hydrate). This loss of selectively of hydrate conversion indicates a 
reduction of the close contact between the polymer (PEG) and the drug. 
A better understanding of the dissolution process can be accomplished by analyzing not 
only the drug in the liquid dissolution medium but also in the solid state of the dissolving 
sample, which provides a more complete understanding of the dissolution behavior. 
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The fast and similar dissolution rate of OLZ present in all the different pellets 
formulations at the very beginning can be partly explained by the dissolution of OLZ anhydrate 
before the hydrates began to crystallize. Moreover, the dissolution of OLZ particles on the 
surface of the pellet can promote the burst effect during the ﬁrst few minutes. 
The mechanism by which OLZ hydrates in the dissolution vessel is expected to be the 
same as the one that occurs when OLZ is subjected to the wet massing process, since in this 
situation the drug is also exposed to a solvent. Aaltonen et al. (291) reported hydration by 
solvent-mediated phase transformation of theophylline and nitrofurantoin during dissolution in 
puriﬁed water. The FTIR absorbance spectra of OLZ present in the pellets after being for 
different periods in the dissolution medium (not dissolved OLZ fraction) showed that both PVP 
and HPC had a suppressing effect on the OLZ hydrate formation during the dissolution test, 
which coincides with the best performance of OLZ. 
During the dissolution process of the pellets, several processes competing with each 
other may take place simultaneously, such as: dissolution of OLZ, recrystallization of anhydrous 
OLZ to OLZ hydrated, swelling of the polymer and dissolution of the polymer. The polymers 
that were shown to strongly interact with the drug during the wet massing of OLZ may also 
stabilize the anhydrous OLZ during the dissolution by inhibiting aggregation due to a stronger 
interaction between the drug and polymer in the dissolution media. Therefore, the interaction 
with the polymers prevents the formation of the hydrate crystals, thus rendering the drug 
dispersed in the matrix of the polymer easier to dissolve. 
8.7 Conclusion 
In an attempt to clarify the mechanisms underlying the effect of polymeric excipients on 
the hydrate conversion of anhydrous OLZ in aqueous environments, the impact of various 
polymers on the hydration of OLZ in wet masses was investigated. The polymer screening 
methodology used to identify polymers that could stabilize OLZ during wet massing proved to 
be useful to identify which polymers may have the strongest effect of inhibition of OLZ. In 
general all polymers promoted the inhibition of the transformation with different degrees of 
success, provided the contact time of OLZ anhydrous with water was low (e.g., less than 30 
min). PEGs delayed the conversion of OLZ, but after 360 min of storage in a moist 
environment, conversion was observed. The HPC had the strongest effect on protecting the 
hydrate conversion of OLZ. The major reduction of the wettability of the OLZ powders in a 
blend with HPC revealed that this polymer can adsorb to OLZ’s surface inhibiting the water 
attack and, therefore, causing a hydrate formation. 
The presence of microcrystalline cellulose in formulations, needed for the pellets 
production, neither improves the protection against water nor did it eliminate the protector effect 
of both PVP and HPC. Conversion of the anhydrous form into hydrate was partially reversible 
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and occurred during the wetting, and dissolution test in which the anhydrous form was 
converted into a hydrate. The combination of data retrieved from the different analytical 
techniques (FTIR spectroscopy, XRPD, calorimetry and microscopy) was successfully used to 
investigate the hydrate conversion of OLZ in various excipients allowing visualizing the 
different hydrate conversions that OLZ may undergo in the presence of excipients. 
The results of this work are relevant to industrial practice as they can orient choice 
towards the most appropriate excipients for industrial production of OLZ and support the 
preparation of extrudates at lower cost, with lower risks of lot-to-lot variability and with 
improvements in biopharmaceutical properties. 
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Chapter 9 -  Conclusions and suggestions for future work 
 
9.1 Concluding Remarks 
The research of polymorphism and pseudopolymorphism of APIs provides important 
information about the stability of the drugs during pharmaceutical processing. Health 
Authorities require manufacturers to provide evidence of the polymorphic form of the drug and 
its stability. When different excipients are combined with the API to allow the manufacturing of 
a medicine they can contribute to changes on the molecular organization of a drug molecule. It 
is therefore in the interest of regulators and industry that the polymorphic changes of an API are 
well characterized and documented in order to prevent problems in the process and final 
products. 
The work presented in this Thesis was focused on the characterization of different 
molecular organizations of OLZ. The impact of polymorphism/pseudopolymorphism on OLZ’s 
technological performance and dissolution was evaluated.  
Overall, this work has highlighted the importance of studying OLZ when it is exposed 
to different environmental conditions (e.g. temperature, humidity and pressure) and processing 
techniques, such as tableting (a dry process run at room temperature), extrusion (a wet process 
requiring drying) and RESS/RESSAS (a supercritical fluid is used as a solvent) to evaluate their 
stability and rate of conversion into a different polymorph. During the processing of the 
polymorphic drugs, special attention was paid to the excipients used in the formulations, namely 
polymers. This strategy was important to understand how some excipients may stabilize the 
drug, inhibiting polymorphic conversions during pharmaceutical processing.  
Therefore, the characterization of the different polymorphic transformations was 
performed by using several techniques, such as calorimetry (DSC, TGA, DMA), powder 
diffractometry (XRPD), infrared spectroscopy (FTIR, Raman), microscopy (optical, electronic, 
hot stage and atomic force) and surface free energy analyses.  
In the chapter 3 of this Thesis one has focused on the environmental conditions that can 
affect the stability of anhydrous forms of OLZ. In this study we aimed to predict if high relative 
humidity could induce hydrate transformations and the impact of those conversions on the 
dissolution of the drug. Our results showed that anhydrous forms could not hydrate at RH below 
75% (anhydrous Form I) and 53 % (anhydrous Form II) at room temperature. At 93% RH and 
75% RH, pseudopolymorphic transitions can occur for form I and II, respectively. The dihydrate 
conversion of the anhydrous forms revealed to decrease their rate of dissolution. This revealed 
to be significant for OLZ Form I, which proved to hydrate into the most stable dihydrate form – 
Dihydrate D. These results clarified the negative impact that the appearance of these hydrated 
forms may have if the RH during the storage of the raw materials is not controlled.  
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During the same study it was possible to develop a method to measure the hydration of 
anhydrous Form I and II during storage through DRIFT analysis. This method was achieved due 
to visible differences between the IR spectra of both anhydrous forms and dihydrates. 
In chapter 4 the interplay between Form I, humidity and excipients was analyzed.  The 
effect of compaction on water sorption of OLZ in presence of excipients was also characterized. 
The kinetics of hydrate formation showed to be highly affected if polymeric excipients are 
physically mixed with the drug. Polymeric excipients, such as PEG and HPC showed to induce 
hydrate transformation at 75% RH, which was a RH where OLZ was not able to hydrate when 
stored by itself. PVP showed to avoid hydrate conversions at 93% relative humidity, whereas 
PEG accelerated hydrate conversion at the same humidity. The OLZ dihydrate formed during 
storage was always the same, the dihydrate D form, which is the dihydrate form of OLZ with 
the lowest dissolution rate. Storing the physical mixtures as powders or tablets proved to have 
an impact on hydrate formation rates. Tableting showed to accelerate the hydrate formation 
during the first week of storage due to a reduction of crystallinity of the OLZ material when 
subjected to pressure. Also, the higher contact interaction between OLZ and the polymers 
enabled PEG to induce the complete dihydrate conversion of OLZ material in only 7 days of 
storage at 93% RH. In tablets, however, the lower surface area exposed to humidity retarded the 
hydration of OLZ during the further days of storage in comparison to the powders. This study 
emphasized the importance of the right choice of polymers in order to maintain the drug stable 
both during formulation and shelf life. 
In chapter 5 the process of OLZ hydrate transformations in an aqueous medium and the 
mechanism of interaction between OLZ and various polymers in aqueous suspension was 
explored. The results showed that polymers were able to affect OLZ hydration by both 
hydrogen bonding with OLZ and sufficient hydrophobicity to adsorb into the crystals surface 
interface, blocking access of the solute molecules to the crystal terrace. 
Chapter 6 showed that SCF technology produces OLZ particles with submicron size and 
increased dissolution rate. Production and stabilization of OLZ nanoparticles and 
nanosuspensions was achieved by using RESS and RESSAS technologies. RESSAS enabled to 
decrease the particle size of OLZ with a final recovery of almost 100% of the drug that was 
dissolved in scCO2, thus indicating no drug loss by the CO2 stream. However, when RESSAS 
approach was used as a tool to obtain particles in the nanoscale, it was paramount to find a 
compromise between process operability and formulation stability. This study showed that the 
choice of stabilizer had a critical influence on the stability of nanosuspensions, particle size 
distribution and the expansion process itself. The particle growth and hydrate formation of OLZ 
showed to coincide with the insufficiently stabilized colloidal suspensions. The suppression of 
particle growth and hydrate formation showed to be mechanistically related to a surface 
interaction of the drug with the excipient used in suspension, being those processes related 
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Extrusion and spheronisation of wet masses involves both wetting and drying, which are 
steps that could promote solid-state modifications of OLZ. In Chapter 7 it was possible to 
observe that anhydrous OLZ Form I hydrated into 2 different hydrates (dihydrate B and higher 
hydrate) when exposed to aqueous environments involved in wet extrusion process. Higher 
ratios of MCC in the formulations showed to retard the hydrate conversion of OLZ, as a 
consequence of the higher affinity of water to the amorphous regions present in the molecular 
structures of this excipient. PEG proved to be an excipient which could not protect hydrate 
formation during extrusion. Applying low temperatures of drying (45⁰C) for less than 60 
minutes proved to be ineffective in eliminating the dihydrate B. The presence of this hydrate 
showed to reduce OLZ’s dissolution rate. The changes in crystalline structure of OLZ during the 
process showed to affect the rheology of the wet mass and the size and strength of the dried 
pellets. These results suggested that attention should be given to the pseudopolymorphism of the 
drugs before the selection of the excipients and process conditions for a new pharmaceutical 
process. Thus, in chapter 8, attention was payed to the ability of polymeric excipients to avoid 
the crystalline changes of OLZ when wetting of the OLZ is required during the pharmaceutical 
processing. Chapter 8 also aimed to determine whether the protector effect by excipients was 
also present during the dissolution of OLZ from the formulated pellets or not. The results 
showed that when using PVP and HPC polymers in extrusion process the hydrate formation in 
wet masses is avoided, even in the presence of other excipients (eg. MCC). Hydrophobicity and 
surface energy calculations helped to elucidate why HPC was the best polymer to be used in a 
wet extrusion process. The inhibition of the conversion of OLZ into lower soluble dihydrate 
forms during both wet extrusion and dissolution testing showed to have a favorable impact on 
the dissolution profile of the drug. Since OLZ is a drug used in mental disorders (e.g. 
schizophrenic and bipolar disorders) and very often used in prolonged therapies, small 
variations on its solubility may delay the fraction of API dissolved from the dosage form. 
Therefore, absorption may be compromised with a negative impact on the patients’ behavior. 
Overall, one could conclude that polymorphic/pseudopolymorphic changes of OLZ can 
occur during storage and pharmaceutical processing, with an impact on the drug’s performance. 
Furthermore, these solid-phase transformations of OLZ could be easily monitored by infrared 
techniques (FTIR/DRIFT), even in the presence of excipients. On the other hand, interaction 
between the drug and excipients could be studied at the molecular level using nuclear magnetic 
resonance. The prevention of  hydration of OLZ, showed to be easily avoided by the right 
choice of excipients.  
In-depth knowledge of hydrated forms of OLZ and their stability under different 
experimental conditions is essential to the development of successful drug products. From an 
industrial point of view, changes in process variables (process parameters, equipment used, 
excipient characteristics and their amount) should be carefully studied in order to validate the 
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processes in use and reduce the risks of variability between batches. The results of this work are 
relevant to the industrial practice as they can orient choice towards the most appropriate 
excipients for industrial production of OLZ and support the preparation of tablets/extrudates at 
lower cost and with improvements in their biopharmaceutical properties, for example. 
 
9.2 Recommendations for Future Work  
The work developed, regardless of the findings described in this Thesis, can be 
considered as a starting point for new projects as it only addresses a part of the challenges 
facing the polymorphism study during pharmaceutical development. This work aimed to 
understand the main challenges when processing olanzapine, however, the results showed us 
that there were some results that need to be studied in more detail.  
In order to continue this research path it would be very important to explore the 
following areas: 
 
1- Control and characterization of the conversion kinetics of olanzapine polymorphs to the 
hydrate forms in aqueous suspensions using RAMAN (online) technology. 
The conversions of olanzapine could be monitored and the kinetics of transformation 
characterized in more detail. RAMAN technology can be used in the presence of solvents 
(e.g. wet granulation). Furthermore, it does not need any sample preparation, is non-
destructive and avoids water interference; 
2- Using a combination of molecular dynamics (MD) simulations and docking calculations to 
model and predict polymer-drug interactions and therefore understand the subtle structural 
features that can significantly affect the effectiveness of the protection of hydration by 
polymers. The computational calculations of polymer-drug pairs hold the potential of 
becoming a powerful pre-screening tool in the excipients selection process for a new solid-
dosage form, with an impact on the stabilization of the drug; 
3- Determine adsorption isotherms to quantify the amount of polymer adsorbed onto the API 
crystals. Different experimental techniques can probe the interactions between drug and 
polymers. For example, NMR relaxation time measurements can determine the fraction of 
stabilizer molecule “bound” to the interface. This method distinguishes adsorbed polymer 
chains from those in bulk solution. NMR can discriminate between highly mobile (liquid-
like) and immobile (solid-like) protons on the basis of magnetic relaxation times. Other 
analytical techniques have been developed for monitoring polymer solution concentrations. 
Some are specific to a given polymer or group of polymers (e.g., complex formation to 
give species which adsorb in the visible/uv part of the electromagnetic spectrum). Other 
techniques, such as solution depletion method are used to quantify adsorption of polymers 
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to drug seed crystals using size exclusion chromatography (SEC-HPLC) to measure 
polymer concentrations adsorbed per crystal unit surface area; 
4- Preparation of solid dispersions of olanzapine with the same polymers used in this study. 
The preparation of these solid dispersions has shown a considerable potential for the 
solubility enhancement of various active pharmaceutical ingredients belonging to BCS 
class II. 
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Appendices 
 
 
Table A.1– Values for axis length a, b and c and angles α, β and γ of the unit cell  of both forms I 
and II of olanzapine. Standard errors are represented in the second line. 
 a b c α β γ 
F
o
rm
 I
 
10.436 14.902 10.605 90 100.630 90 
0.039 0.013 0.033 0 0.729 0 
F
o
rm
 I
I 
9.8448 16.340 9.983 90 98.280 90 
0.0289 0.0187 0.0201 0 0.368 0 
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Table A.2– Integer Miller indices (h, k, l) of both forms I and II of olanzapine 
 h k l 2 (obs) 2 (Calc) diff. 
F
o
rm
 I
 
1 0 0 8.6145 8.6203 -0.0058 
0 1 1 10.3515 10.3566 -0.0051 
-1 1 1 12.4325 12.4429 -0.0104 
0 2 1 14.5455 14.6129 -0.0674 
0 0 2 16.9906 17.0129 -0.0223 
2 0 0 17.3087 17.2899 0.0188 
1 2 1 17.7287 17.7763 -0.0476 
-1 1 2 18.602 18.596 0.006 
-2 1 1 18.784 18.7872 -0.0032 
0 3 1 19.7972 19.7978 -0.0006 
-1 3 1 20.9595 20.9814 -0.0219 
-2 2 1 21.4366 21.4612 -0.0246 
1 3 1 22.2487 22.2566 -0.0079 
0 4 0 23.8707 23.8834 -0.0127 
2 3 0 24.9511 24.954 -0.0029 
-1 3 2 25.1814 25.1799 0.0015 
0 1 3 26.3205 26.3388 -0.0183 
1 4 1 27.3922 27.3727 0.0195 
-3 1 2 29.1066 29.0947 0.0119 
2 4 0 29.6388 29.636 0.0028 
1 4 2 31.7919 31.667 0.1249 
1 3 3 33.8474 33.9244 -0.077 
0 0 4 34.4653 34.4159 0.0494 
F
o
rm
 I
I 
0 0 1 8.9400 8.9510 -0.011 
0 1 1 10.4222 10.4635 -0.0413 
0 2 0 10.8337 10.828 0.0057 
-1 1 1 12.9082 12.9908 -0.0826 
0 1 2 18.8031 18.7667 0.0364 
-1 1 2 19.6433 19.7068 -0.0635 
0 2 2 20.9526 21.0156 -0.063 
0 4 0 21.715 21.7543 -0.0393 
2 1 1 22.1463 22.1562 -0.0099 
1 4 0 23.65 23.615 0.035 
2 2 1 24.0757 24.104 -0.0283 
-1 4 1 24.8946 24.8189 0.0757 
2 0 2 27.5207 27.5066 0.0141 
2 1 2 28.0913 28.0538 0.0375 
0 5 1 28.7343 28.7719 -0.0376 
0 2 3 29.3155 29.2387 0.0768 
1 1 3 30.3208 30.3738 -0.053 
-2 1 3 30.9986 30.9958 0.0028 
-2 2 3 32.4926 32.4509 0.0417 
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